piperidones - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	piperidones	go back to main search page
Accession:	CHEBI:48589	browse the term
Synonyms:	related_synonym:	piperidone
	xref_mesh:	MESH:D010881

show annotations for term's descendants Sort by:
Rat (1528 ) Mouse (1568 ) Human (1540 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (5 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (1528)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

heat shock transcription factor 1

increases activity

ISO

Piperidones results in increased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

4-ethyl-4-methylpiperidine-2,6-dione

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

gamma-aminobutyric acid type A receptor subunit alpha 1

multiple interactions

ISO

Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,595,151...26,650,611
Ensembl chr10:27,096,740...27,152,442

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

ISO

Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:27,438,238...27,655,171

G

gamma-aminobutyric acid type A receptor subunit gamma 2

multiple interactions

ISO

Bemegride inhibits the reaction [Carisoprodol results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]]

NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,876,926...26,965,523

aminoglutethimide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acid phosphatase 1

decreases expression

ISO

Aminoglutethimide results in decreased expression of ACP1 protein

NCBI chr 6:53,233,937...53,249,576
Ensembl chr 6:53,233,948...53,251,959

G

acidic nuclear phosphoprotein 32 family member B

decreases expression

ISO

Aminoglutethimide results in decreased expression of ANP32B protein

NCBI chr 5:65,538,872...65,561,305
Ensembl chr 5:65,538,535...65,561,437

G

brain abundant, membrane attached signal protein 1

decreases expression

ISO

Aminoglutethimide results in decreased expression of BASP1 protein

NCBI chr 2:77,546,628...77,594,297
Ensembl chr 2:77,546,092...77,597,178

G

B-cell receptor-associated protein 31

decreases expression

ISO

Aminoglutethimide results in decreased expression of BCAP31 protein

NCBI chr X:156,548,911...156,581,002
Ensembl chr X:156,548,911...156,579,371

G

chaperonin containing TCP1 subunit 4

increases expression

ISO

Aminoglutethimide results in increased expression of CCT4 protein

NCBI chr14:101,193,057...101,205,935
Ensembl chr14:101,192,772...101,205,770

G

chaperonin containing TCP1 subunit 6A

decreases expression

ISO

Aminoglutethimide results in decreased expression of CCT6A protein

NCBI chr12:32,508,842...32,519,072
Ensembl chr12:32,508,675...32,519,119

G

chaperonin containing TCP1 subunit 7

decreases expression

ISO

Aminoglutethimide results in decreased expression of CCT7 protein

NCBI chr 4:119,546,730...119,563,973
Ensembl chr 4:119,546,730...119,563,973

G

catechol-O-methyltransferase

increases expression

ISO

Aminoglutethimide results in increased expression of COMT protein

NCBI chr11:96,072,371...96,091,956
Ensembl chr11:96,072,489...96,092,533

G

cutA divalent cation tolerance homolog

decreases expression

ISO

Aminoglutethimide results in decreased expression of CUTA protein

NCBI chr20:5,022,956...5,024,580
Ensembl chr20:5,024,816...5,026,631

G

cytochrome P450, family 11, subfamily a, polypeptide 1

multiple interactions

ISO

Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP11A1 mRNA]

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

ISO

Aminoglutethimide results in decreased expression of CYP17A1 mRNA

NCBI chr 1:255,476,861...255,484,547
Ensembl chr 1:255,476,861...255,482,974

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions
increases activity
decreases activity

ISO

Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA]; Aminoglutethimide inhibits the reaction [CYP19A1 protein affects the chemical synthesis of 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine]; Aminoglutethimide inhibits the reaction [CYP19A1 protein affects the metabolism of Methadone]
Aminoglutethimide results in increased activity of CYP19A1 protein
Aminoglutethimide results in decreased activity of CYP19A1 protein

PMID:15242824 PMID:15968818 PMID:16935330 PMID:17910019 PMID:20087668

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

follicle stimulating hormone subunit beta

decreases expression
multiple interactions

ISO

Aminoglutethimide results in decreased expression of FSHB protein
Aminoglutethimide inhibits the reaction [[FSHB protein co-treated with LHB protein co-treated with Testosterone] results in increased abundance of Acetaldehyde]

PMID:9208491 PMID:22285649

NCBI chr 3:114,003,262...114,007,072
Ensembl chr 3:114,003,262...114,007,072

G

glutamine amidotransferase class 1 domain containing 3A

increases expression

ISO

Aminoglutethimide results in increased expression of GATD3 protein

NCBI chr20:10,514,459...10,522,556
Ensembl chr20:10,514,443...10,522,555

G

glucosamine (N-acetyl)-6-sulfatase

decreases expression

ISO

Aminoglutethimide results in decreased expression of GNS protein

NCBI chr 7:56,889,148...56,923,173
Ensembl chr 7:58,774,625...58,808,650

G

glutathione peroxidase 1

increases expression

ISO

Aminoglutethimide results in increased expression of GPX1 protein

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

gelsolin

decreases expression

ISO

Aminoglutethimide results in decreased expression of GSN protein

NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850

G

H1.2 linker histone, cluster member

increases expression

ISO

Aminoglutethimide results in increased expression of H1-2 protein

NCBI chr17:41,818,962...41,820,453
Ensembl chr17:41,779,051...41,822,317

G

H2A clustered histone 12

increases expression

ISO

Aminoglutethimide results in increased expression of H2AC12 protein

NCBI chr17:42,486,415...42,486,880

G

H2A.Z variant histone 1

increases expression

ISO

Aminoglutethimide results in increased expression of H2AZ1 protein

NCBI chr 2:229,026,464...229,031,411
Ensembl chr 2:229,028,843...229,031,411

G

H2B clustered histone 12

increases expression

ISO

Aminoglutethimide results in increased expression of H2BC12 protein

NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816

G

H3 clustered histone 13

increases expression

ISO

Aminoglutethimide results in increased expression of H3C13 protein

NCBI chr17:41,531,502...41,531,971
Ensembl chr17:41,958,965...41,960,099

G

high mobility group box 2

decreases expression

ISO

Aminoglutethimide results in decreased expression of HMGB2 protein

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860

G

heterogeneous nuclear ribonucleoprotein H1

decreases expression

ISO

Aminoglutethimide results in decreased expression of HNRNPH1 protein

NCBI chr10:35,187,412...35,203,909
Ensembl chr10:35,193,890...35,203,906

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

ISO

[Colforsin co-treated with Aminoglutethimide] results in decreased expression of HSD17B1 mRNA

NCBI chr10:86,510,011...86,512,211
Ensembl chr10:86,510,011...86,512,210

G

hydroxysteroid (17-beta) dehydrogenase 10

decreases expression

ISO

Aminoglutethimide results in decreased expression of HSD17B10 protein

NCBI chr X:24,568,551...24,571,012
Ensembl chr X:24,568,551...24,574,681

G

hydroxysteroid (17-beta) dehydrogenase 4

multiple interactions
decreases expression

ISO

Aminoglutethimide inhibits the reaction [Colforsin results in increased expression of HSD17B4 mRNA]
Aminoglutethimide results in decreased expression of HSD17B4 mRNA

NCBI chr18:43,328,903...43,417,950
Ensembl chr18:45,515,373...45,604,467

G

hydroxysteroid (17-beta) dehydrogenase 7

decreases expression

EXP

Aminoglutethimide results in decreased expression of HSD17B7 mRNA

NCBI chr13:84,702,875...84,722,810
Ensembl chr13:84,705,631...84,722,754

G

heat shock protein family A (Hsp70) member 1A

increases expression

ISO

Aminoglutethimide results in increased expression of HSPA1A protein

NCBI chr20:3,875,411...3,877,866
Ensembl chr20:3,855,780...3,877,979

G

hypoxia up-regulated 1

increases expression

ISO

Aminoglutethimide results in increased expression of HYOU1 protein

NCBI chr 8:53,602,882...53,614,998
Ensembl chr 8:53,602,604...53,614,997

G

inosine monophosphate dehydrogenase 2

decreases expression

ISO

Aminoglutethimide results in decreased expression of IMPDH2 protein

NCBI chr 8:118,135,204...118,139,892
Ensembl chr 8:118,135,262...118,139,873

G

luteinizing hormone subunit beta

decreases expression
multiple interactions

ISO

Aminoglutethimide results in decreased expression of LHB protein
Aminoglutethimide inhibits the reaction [[FSHB protein co-treated with LHB protein co-treated with Testosterone] results in increased abundance of Acetaldehyde]

PMID:9208491 PMID:22285649

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

lamin A/C

decreases expression

ISO

Aminoglutethimide results in decreased expression of LMNA protein

NCBI chr 2:176,237,564...176,265,301
Ensembl chr 2:176,237,564...176,288,072

G

lamin B2

decreases expression

ISO

Aminoglutethimide results in decreased expression of LMNB2 protein

NCBI chr 7:9,443,308...9,459,468
Ensembl chr 7:9,440,128...9,459,342

G

minichromosome maintenance complex component 3

decreases expression

ISO

Aminoglutethimide results in decreased expression of MCM3 protein

NCBI chr 9:30,715,602...30,733,746
Ensembl chr 9:30,715,602...30,733,746

G

myeloperoxidase

multiple interactions

ISO

[[MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide] which results in increased expression of MPO protein modified form; [Aminoglutethimide co-treated with Hydrogen Peroxide] results in increased oxidation of MPO protein; [MPO protein co-treated with Hydrogen Peroxide co-treated with 5,5-dimethyl-1-pyrroline-1-oxide] results in increased metabolism of Aminoglutethimide

PMID:20199096 PMID:26102013

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

myosin XVIIIa

decreases expression

ISO

Aminoglutethimide results in decreased expression of MYO18A protein

NCBI chr10:63,152,303...63,253,543
Ensembl chr10:63,152,103...63,253,543

G

nucleophosmin/nucleoplasmin, 3

decreases expression

ISO

Aminoglutethimide results in decreased expression of NPM3 protein

NCBI chr 1:254,544,664...254,546,649
Ensembl chr 1:254,544,664...254,546,649

G

nuclear receptor subfamily 1, group I, member 2

increases activity

ISO

Aminoglutethimide results in increased activity of NR1I2 protein

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nucleoporin 210

decreases expression

ISO

Aminoglutethimide results in decreased expression of NUP210 protein

NCBI chr 4:125,068,736...125,167,238
Ensembl chr 4:125,068,736...125,167,047

G

progesterone receptor

multiple interactions
decreases expression

ISO

[Aminoglutethimide co-treated with 17 alpha-Hydroxyprogesterone Caproate] results in decreased expression of PGR protein
Aminoglutethimide results in decreased expression of PGR protein

PMID:8565696 PMID:9208491

NCBI chr 8:14,354,398...14,413,271
Ensembl chr 8:14,354,398...14,413,271

G

phosphatidylinositol transfer protein, beta

increases expression

ISO

Aminoglutethimide results in increased expression of PITPNB protein

NCBI chr12:50,909,140...50,958,193
Ensembl chr12:50,909,143...50,958,140

G

protein phosphatase 1 catalytic subunit alpha

decreases expression

ISO

Aminoglutethimide results in decreased expression of PPP1CA protein

NCBI chr 1:210,914,576...210,918,193
Ensembl chr 1:210,914,567...210,918,193

G

peroxiredoxin 3

increases expression

ISO

Aminoglutethimide results in increased expression of PRDX3 protein

NCBI chr 1:269,987,691...270,000,111
Ensembl chr 1:269,987,685...270,000,300

G

proteasome 20S subunit beta 4

decreases expression

ISO

Aminoglutethimide results in decreased expression of PSMB4 protein

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

RNA transcription, translation and transport factor

decreases expression

ISO

Aminoglutethimide results in decreased expression of RTRAF protein

NCBI chr15:4,447,243...4,457,973
Ensembl chr15:4,480,966...4,507,115

G

secreted phosphoprotein 1

decreases expression

EXP

Aminoglutethimide results in decreased expression of SPP1 mRNA

NCBI chr14:5,613,569...5,620,695
Ensembl chr14:5,613,576...5,619,820

G

small RNA binding exonuclease protection factor La

decreases expression

ISO

Aminoglutethimide results in decreased expression of SSB protein

NCBI chr 3:75,024,385...75,034,016
Ensembl chr 3:75,024,474...75,034,031

G

steroidogenic acute regulatory protein

decreases expression
increases expression

ISO

Aminoglutethimide results in decreased expression of STAR mRNA
Aminoglutethimide results in increased expression of STAR mRNA

PMID:10960482 PMID:16935330

NCBI chr16:72,969,824...72,974,447
Ensembl chr16:72,961,518...72,974,447

G

tumor protein, translationally-controlled 1

decreases expression

ISO

Aminoglutethimide results in decreased expression of TPT1 protein

NCBI chr15:57,562,217...57,568,968
Ensembl chr15:57,566,067...57,569,554

G

ubiquitin C

increases expression

ISO

Aminoglutethimide results in increased expression of UBC protein

NCBI chr12:31,239,149...31,243,924
Ensembl chr12:36,900,127...36,905,275

G

ubiquitin-conjugating enzyme E2K

decreases expression

ISO

Aminoglutethimide results in decreased expression of UBE2K protein

NCBI chr14:43,011,681...43,077,825
Ensembl chr14:43,011,681...43,072,462

G

WD repeat domain 1

increases expression

ISO

Aminoglutethimide results in increased expression of WDR1 protein

NCBI chr14:72,258,032...72,291,768
Ensembl chr14:76,470,176...76,504,080

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta

increases expression

ISO

Aminoglutethimide results in increased expression of YWHAQ protein

NCBI chr 6:46,664,358...46,694,875
Ensembl chr 6:46,664,358...46,694,875

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate-semialdehyde synthase

increases expression

EXP

Buspirone results in increased expression of AASS mRNA

NCBI chr 4:52,572,146...52,628,811
Ensembl chr 4:52,572,147...52,657,600

G

ATP binding cassette subfamily A member 1

increases expression

EXP

Buspirone results in increased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP-binding cassette, subfamily A (ABC1), member 8a

decreases expression

EXP

Buspirone results in decreased expression of ABCA8A mRNA

NCBI chr10:95,501,798...95,571,770
Ensembl chr10:95,501,798...95,571,873

G

ATP binding cassette subfamily C member 2

decreases expression

EXP

Buspirone results in decreased expression of ABCC2 mRNA

NCBI chr 1:252,613,875...252,672,459
Ensembl chr 1:252,614,017...252,673,471

G

ATP binding cassette subfamily F member 1

decreases expression

EXP

Buspirone results in decreased expression of ABCF1 mRNA

NCBI chr20:2,807,315...2,820,240
Ensembl chr20:2,807,106...2,820,240

G

ATP binding cassette subfamily G member 2

decreases expression

EXP

Buspirone results in decreased expression of ABCG2 mRNA

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

abhydrolase domain containing 14b

increases expression

EXP

Buspirone results in increased expression of ABHD14B mRNA

NCBI chr 8:115,966,792...115,970,829
Ensembl chr 8:115,965,932...115,970,833

G

ankyrin repeat and BTB domain containing 1

increases expression

EXP

Buspirone results in increased expression of ABTB1 mRNA

NCBI chr 4:122,856,558...122,862,895
Ensembl chr 4:122,856,564...122,862,789

G

acetyl-CoA acyltransferase 2

increases expression

EXP

Buspirone results in increased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acetyl-CoA carboxylase alpha

decreases expression

EXP

Buspirone results in decreased expression of ACACA mRNA

NCBI chr10:69,511,627...69,773,888
Ensembl chr10:69,511,857...69,773,888

G

acyl-CoA binding domain containing 4

increases expression

EXP

Buspirone results in increased expression of ACBD4 mRNA

NCBI chr10:88,548,146...88,558,588
Ensembl chr10:88,548,158...88,558,587

G

ATP citrate lyase

decreases expression

EXP

Buspirone results in decreased expression of ACLY mRNA

NCBI chr10:85,912,402...85,964,605
Ensembl chr10:85,912,402...85,963,631

G

acyl-CoA synthetase family member 2

decreases expression

EXP

Buspirone results in decreased expression of ACSF2 mRNA

NCBI chr10:80,001,389...80,043,796
Ensembl chr10:80,001,389...80,045,050

G

acyl-CoA synthetase long-chain family member 3

decreases expression

EXP

Buspirone results in decreased expression of ACSL3 mRNA

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097

G

acyl-CoA synthetase long-chain family member 4

increases expression

EXP

Buspirone results in increased expression of ACSL4 mRNA

NCBI chr X:110,739,633...110,803,416
Ensembl chr X:110,739,648...110,803,261

G

acyl-CoA synthetase long-chain family member 5

decreases expression

EXP

Buspirone results in decreased expression of ACSL5 mRNA

NCBI chr 1:264,294,851...264,341,943
Ensembl chr 1:264,294,864...264,341,943

G

actin, beta

decreases expression

EXP

Buspirone results in decreased expression of ACTB mRNA

NCBI chr12:16,776,664...16,779,634
Ensembl chr12:16,776,661...16,780,242

G

actin, gamma 1

decreases expression

EXP

Buspirone results in decreased expression of ACTG1 mRNA

NCBI chr10:106,118,106...106,120,951
Ensembl chr10:106,118,108...106,120,951

G

actinin, alpha 1

decreases expression

EXP

Buspirone results in decreased expression of ACTN1 mRNA

NCBI chr 6:104,731,485...104,826,312
Ensembl chr 6:104,731,485...104,826,172

G

aminoacylase 1

decreases expression

EXP

Buspirone results in decreased expression of ACY1 mRNA

NCBI chr 8:115,951,068...115,956,471
Ensembl chr 8:115,951,068...115,956,405

G

ADAMTS-like 4

increases expression

EXP

Buspirone results in increased expression of ADAMTSL4 mRNA

NCBI chr 2:185,924,582...185,936,039
Ensembl chr 2:185,924,594...185,935,796

G

adenylate cyclase 6

increases expression

EXP

Buspirone results in increased expression of ADCY6 mRNA

NCBI chr 7:131,621,860...131,642,923
Ensembl chr 7:131,621,860...131,642,770

G

adiponectin receptor 2

decreases expression

EXP

Buspirone results in decreased expression of ADIPOR2 mRNA

NCBI chr 4:154,195,440...154,261,141
Ensembl chr 4:154,172,567...154,231,666

G

adrenoceptor alpha 1A

multiple interactions

EXP

Buspirone binds to and results in decreased activity of ADRA1A protein

NCBI chr15:45,005,648...45,111,416
Ensembl chr15:45,005,799...45,102,534

G

adrenoceptor alpha 1D

multiple interactions

EXP

Buspirone binds to and results in increased activity of ADRA1D protein

NCBI chr 3:139,246,333...139,262,331
Ensembl chr 3:139,246,323...139,262,331

G

agmatinase

increases expression

EXP

Buspirone results in increased expression of AGMAT mRNA

NCBI chr 5:159,326,680...159,357,300
Ensembl chr 5:159,343,160...159,357,299

G

adenosylhomocysteinase

increases expression

EXP

Buspirone results in increased expression of AHCY mRNA

NCBI chr 3:164,029,338...164,044,562
Ensembl chr 3:164,029,338...164,044,587

G

allograft inflammatory factor 1

decreases expression

EXP

Buspirone results in decreased expression of AIF1 mRNA

NCBI chr20:3,651,435...3,657,341
Ensembl chr20:3,652,243...3,657,339

G

androgen-induced 1

increases expression

EXP

Buspirone results in increased expression of AIG1 mRNA

NCBI chr 1:9,866,546...10,089,454
Ensembl chr 1:9,866,548...10,089,155

G

adenylate kinase 4

decreases expression

EXP

Buspirone results in decreased expression of AK4 mRNA

NCBI chr 5:121,154,565...121,214,403
Ensembl chr 5:121,154,572...121,214,401

G

A-kinase anchoring protein 8 like

increases expression

EXP

Buspirone results in increased expression of AKAP8L mRNA

NCBI chr 7:11,983,215...12,012,843
Ensembl chr 7:11,982,721...12,012,811

G

aldo-keto reductase family 1, member C14

increases expression

EXP

Buspirone results in increased expression of AKR1C14 mRNA

NCBI chr17:71,066,197...71,083,184
Ensembl chr17:71,066,200...71,083,157

G

aldo-keto reductase family 7 member A3

decreases expression

EXP

Buspirone results in decreased expression of AKR7A3 mRNA

NCBI chr 5:156,876,721...156,884,599
Ensembl chr 5:156,874,086...156,885,153

G

aldehyde dehydrogenase 1 family, member B1

decreases expression

EXP

Buspirone results in decreased expression of ALDH1B1 mRNA

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

alkB homolog 7

increases expression

EXP

Buspirone results in increased expression of ALKBH7 mRNA

NCBI chr 9:1,925,896...1,928,048
Ensembl chr 9:1,925,743...1,928,048

G

ANKH inorganic pyrophosphate transport regulator

decreases expression

EXP

Buspirone results in decreased expression of ANKH mRNA

NCBI chr 2:79,883,350...80,011,222
Ensembl chr 2:79,883,544...80,011,699

G

ankyrin repeat and KH domain containing 1

increases expression

EXP

Buspirone results in increased expression of ANKHD1-EIF4EBP3 mRNA

NCBI chr18:28,436,296...28,534,954
Ensembl chr18:28,436,394...28,534,954

G

ankyrin repeat domain 46

increases expression

EXP

Buspirone results in increased expression of ANKRD46 mRNA

NCBI chr 7:69,532,303...69,553,311
Ensembl chr 7:69,532,304...69,545,421

G

ANTXR cell adhesion molecule 2

increases expression

EXP

Buspirone results in increased expression of ANTXR2 mRNA

NCBI chr14:11,845,774...11,986,166
Ensembl chr14:11,845,700...11,986,168

G

annexin A3

decreases expression

EXP

Buspirone results in decreased expression of ANXA3 mRNA

NCBI chr14:13,031,675...13,085,678
Ensembl chr14:13,023,762...13,085,849

G

annexin A5

decreases expression

EXP

Buspirone results in decreased expression of ANXA5 mRNA

NCBI chr 2:121,242,133...121,272,935
Ensembl chr 2:121,242,136...121,281,400

G

apolipoprotein B

decreases expression

EXP

Buspirone results in decreased expression of APOB mRNA

NCBI chr 6:36,563,704...36,603,300
Ensembl chr 6:36,563,704...36,611,814

G

Apol9a-Apol7a readthrough

decreases expression

EXP

Buspirone results in decreased expression of APOL7B mRNA

NCBI chr 7:111,011,645...111,019,326
Ensembl chr 7:111,011,645...111,017,084

G

apolipoprotein N

increases expression

EXP

Buspirone results in increased expression of APON mRNA

NCBI chr 7:1,271,514...1,272,917
Ensembl chr 7:1,271,515...1,272,917

G

apolipoprotein O

decreases expression

EXP

Buspirone results in decreased expression of APOO mRNA

NCBI chr X:63,151,736...63,256,696
Ensembl chr X:63,151,814...63,256,690

G

apolipoprotein O-like

decreases expression

EXP

Buspirone results in decreased expression of APOOL mRNA

NCBI chr X:81,569,960...81,635,906
Ensembl chr X:81,570,053...81,640,036

G

amyloid beta precursor protein

decreases expression

EXP

Buspirone results in decreased expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

Rho GTPase activating protein 24

decreases expression

EXP

Buspirone results in decreased expression of ARHGAP24 mRNA

NCBI chr14:7,105,200...7,488,437
Ensembl chr14:7,105,200...7,528,950

G

Rho GDP dissociation inhibitor beta

decreases expression

EXP

Buspirone results in decreased expression of ARHGDIB mRNA

NCBI chr 4:171,554,139...171,573,057
Ensembl chr 4:171,554,140...171,573,068

G

ARF like GTPase 1

decreases expression

EXP

Buspirone results in decreased expression of ARL1 mRNA

NCBI chr 7:25,007,401...25,018,572
Ensembl chr 7:25,006,981...25,019,319

G

ARF like GTPase 4A

increases expression

EXP

Buspirone results in increased expression of ARL4A mRNA

NCBI chr 6:62,809,287...62,811,297
Ensembl chr 6:62,804,548...62,820,760

G

ARL6 interacting reticulophagy regulator 1

decreases expression

EXP

Buspirone results in decreased expression of ARL6IP1 mRNA

NCBI chr 1:181,864,717...181,874,232
Ensembl chr 1:181,864,746...181,874,232

G

acidic residue methyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of DCPH1 mRNA

NCBI chr 1:43,299,916...43,323,675
Ensembl chr 1:43,299,826...43,323,670

G

arylsulfatase B

decreases expression

EXP

Buspirone results in decreased expression of ARSB mRNA

NCBI chr 2:26,736,395...26,895,682
Ensembl chr 2:26,736,957...26,897,611

G

arsenite methyltransferase

increases expression

EXP

Buspirone results in increased expression of AS3MT mRNA

NCBI chr 1:255,536,879...255,569,245
Ensembl chr 1:255,537,109...255,569,249

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 2

decreases expression

EXP

Buspirone results in decreased expression of ASAP2 mRNA

NCBI chr 6:46,386,605...46,549,669
Ensembl chr 6:46,386,605...46,549,669

G

asialoglycoprotein receptor 1

increases expression

EXP

Buspirone results in increased expression of ASGR1 mRNA

NCBI chr10:55,274,299...55,278,323
Ensembl chr10:55,274,706...55,278,322

G

asparaginase

increases expression

EXP

Buspirone results in increased expression of ASPG mRNA

NCBI chr 6:136,997,832...137,017,417
Ensembl chr 6:136,998,023...137,017,417

G

activating transcription factor 5

increases expression

EXP

Buspirone results in increased expression of ATF5 mRNA

NCBI chr 1:104,432,094...104,437,611
Ensembl chr 1:104,432,094...104,436,183

G

autophagy related 2B

increases expression

EXP

Buspirone results in increased expression of ATG2B mRNA

NCBI chr 6:130,286,979...130,357,109
Ensembl chr 6:130,286,986...130,357,109

G

atlastin GTPase 2

increases expression

EXP

Buspirone results in increased expression of ATL2 mRNA

NCBI chr 6:20,891,220...20,932,644
Ensembl chr 6:20,891,227...20,933,320

G

ATPase phospholipid transporting 11C

increases expression

EXP

Buspirone results in increased expression of ATP11C mRNA

NCBI chr X:143,600,763...143,788,407
Ensembl chr X:143,600,767...143,788,432

G

ATPase H+ transporting V0 subunit B

increases expression

EXP

Buspirone results in increased expression of ATP6V0B mRNA

NCBI chr 5:136,708,823...136,710,339
Ensembl chr 5:136,708,823...136,716,828

G

ATPase H+ transporting V0 subunit e1

increases expression

EXP

Buspirone results in increased expression of ATP6V0E1 mRNA

NCBI chr10:16,984,084...17,007,156
Ensembl chr10:16,984,084...17,028,858

G

ATPase H+ transporting V1 subunit G1

increases expression

EXP

Buspirone results in increased expression of ATP6V1G1 mRNA

NCBI chr 5:81,976,959...81,983,139
Ensembl chr 5:81,977,015...81,985,930

G

Axl receptor tyrosine kinase

decreases expression

EXP

Buspirone results in decreased expression of AXL mRNA

NCBI chr 1:90,392,864...90,424,123
Ensembl chr 1:90,392,864...90,424,009

G

antizyme inhibitor 1

decreases expression

EXP

Buspirone results in decreased expression of AZIN1 mRNA

NCBI chr 7:71,539,711...71,566,515
Ensembl chr 7:71,539,711...71,566,515

G

beta-1,4-N-acetyl-galactosaminyl transferase 1

increases expression

EXP

Buspirone results in increased expression of B4GALNT1 mRNA

NCBI chr 7:64,873,909...64,881,512
Ensembl chr 7:64,874,022...64,881,516

G

BAR/IMD domain containing adaptor protein 2 like 1

increases expression

EXP

Buspirone results in increased expression of BAIAP2L1 mRNA

NCBI chr12:15,364,090...15,453,602
Ensembl chr12:15,364,109...15,453,605

G

biglycan

decreases expression

EXP

Buspirone results in decreased expression of BGN mRNA

NCBI chr X:156,348,633...156,360,797
Ensembl chr X:156,348,615...156,360,799

G

basic helix-loop-helix family, member e40

decreases expression

EXP

Buspirone results in decreased expression of BHLHE40 mRNA

NCBI chr 4:143,174,450...143,180,150
Ensembl chr 4:143,174,048...143,180,783

G

biliverdin reductase B

increases expression

EXP

Buspirone results in increased expression of BLVRB mRNA

NCBI chr 1:91,866,258...91,883,921
Ensembl chr 1:91,866,258...91,884,225

G

BCL2 interacting protein 3

increases expression

EXP

Buspirone results in increased expression of BNIP3 mRNA

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

bolA family member 1

increases expression

EXP

Buspirone results in increased expression of BOLA1 mRNA

NCBI chr 2:186,447,386...186,448,402
Ensembl chr 2:186,443,583...186,501,358

G

bisphosphoglycerate mutase

decreases expression

EXP

Buspirone results in decreased expression of BPGM mRNA

NCBI chr 4:64,106,809...64,135,749
Ensembl chr 4:64,106,804...64,135,627

G

BTG anti-proliferation factor 2

decreases expression

EXP

Buspirone results in decreased expression of BTG2 mRNA

NCBI chr13:48,083,931...48,087,690
Ensembl chr13:48,083,931...48,087,690

G

similar to human chromosome 17 open reading frame 58

increases expression

EXP

Buspirone results in increased expression of C10H17ORF58 mRNA

NCBI chr10:92,472,779...92,477,330
Ensembl chr10:92,471,934...92,477,330

G

complement C1q B chain

decreases expression

EXP

Buspirone results in decreased expression of C1QB mRNA

NCBI chr 5:154,402,276...154,407,827
Ensembl chr 5:154,402,279...154,407,840

G

similar to human chromosome 1 open reading frame 50

increases expression

EXP

Buspirone results in increased expression of C5H1ORF50 mRNA

NCBI chr 5:138,122,595...138,126,973
Ensembl chr 5:138,122,236...138,127,240

G

complement C5 like 1

increases expression

EXP

Buspirone results in increased expression of C5L1 mRNA

NCBI chr 3:38,799,165...38,818,443
Ensembl chr 3:38,799,731...38,817,527

G

complement C6

decreases expression

EXP

Buspirone results in decreased expression of C6 mRNA

NCBI chr 2:55,573,596...55,648,857
Ensembl chr 2:55,573,653...55,649,120

G

complement C8 gamma chain

increases expression

EXP

Buspirone results in increased expression of C8G mRNA

NCBI chr 3:28,718,648...28,720,232

G

similar to human chromosome 11 open reading frame 54

decreases expression

EXP

Buspirone results in decreased expression of C8H11ORF54 mRNA

NCBI chr 8:20,405,240...20,427,811
Ensembl chr 8:20,405,241...20,427,811

G

similar to human chromosome 11 open reading frame 65

increases expression

EXP

Buspirone results in increased expression of C8H11ORF65 mRNA

NCBI chr 8:62,692,123...62,720,951
Ensembl chr 8:62,692,568...62,720,946

G

similar to human chromosome 11 open reading frame 71

increases expression

EXP

Buspirone results in increased expression of C8H11ORF71 mRNA

NCBI chr 8:57,735,075...57,735,489
Ensembl chr 8:57,734,900...57,738,597

G

similar to human chromosome 15 open reading frame 61

increases expression

EXP

Buspirone results in increased expression of C8H15ORF61 mRNA

NCBI chr 8:72,763,513...72,768,248
Ensembl chr 8:72,757,256...72,768,748

G

carbonic anhydrase 3

decreases expression

EXP

Buspirone results in decreased expression of CAR3 mRNA

NCBI chr 2:88,491,666...88,501,299
Ensembl chr 2:88,491,670...88,500,524

G

carbonic anhydrase 5A

increases expression

EXP

Buspirone results in increased expression of CAR5A mRNA

NCBI chr19:66,881,678...66,911,486
Ensembl chr19:66,881,693...66,911,486

G

caldesmon 1

decreases expression

EXP

Buspirone results in decreased expression of CALD1 mRNA

NCBI chr 4:64,232,906...64,414,085
Ensembl chr 4:64,233,171...64,414,085

G

calmodulin 1

decreases expression

EXP

Buspirone results in decreased expression of CALM1 mRNA

NCBI chr 6:125,217,191...125,227,855
Ensembl chr 6:125,217,246...125,225,381

G

calmodulin 2

decreases expression

EXP

Buspirone results in decreased expression of CALM2 mRNA

NCBI chr 6:12,845,170...12,857,830
Ensembl chr15:64,519,554...64,520,657
Ensembl chr 6:64,519,554...64,520,657

G

calreticulin

decreases expression

EXP

Buspirone results in decreased expression of CALR mRNA

NCBI chr19:40,213,367...40,218,262
Ensembl chr19:40,213,239...40,219,236

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

EXP

Buspirone results in decreased expression of CAP1 mRNA

NCBI chr 5:140,427,265...140,507,678
Ensembl chr 5:140,427,269...140,453,470

G

caspase 1

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased cleavage of CASP1 protein]

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

decreases expression

EXP

Buspirone results in decreased expression of CASP3 mRNA

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 6

increases expression

EXP

Buspirone results in increased expression of CASP6 mRNA

NCBI chr 2:221,140,287...221,152,727
Ensembl chr 2:221,140,256...221,152,726

G

caspase 7

decreases expression

EXP

Buspirone results in decreased expression of CASP7 mRNA

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

catalase

increases expression

EXP

Buspirone results in increased expression of CAT protein

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 4

increases expression

EXP

Buspirone results in increased expression of CBR4 mRNA

NCBI chr16:33,625,734...33,695,067
Ensembl chr16:33,617,399...33,656,832

G

coiled-coil domain containing 6

increases expression

EXP

Buspirone results in increased expression of CCDC6 mRNA

NCBI chr20:18,431,243...18,527,227
Ensembl chr20:18,431,243...18,527,227

G

coiled-coil domain containing 80

decreases expression

EXP

Buspirone results in decreased expression of CCDC80 mRNA

NCBI chr11:69,191,188...69,224,844
Ensembl chr11:69,191,189...69,224,844

G

C-C motif chemokine ligand 9

decreases expression

EXP

Buspirone results in decreased expression of CCL6 mRNA

NCBI chr10:68,863,994...68,868,928
Ensembl chr10:68,863,995...68,868,877

G

cyclin B2

decreases expression

EXP

Buspirone results in decreased expression of CCNB2 mRNA

NCBI chr 8:79,968,459...79,981,717
Ensembl chr 8:79,968,465...79,981,682

G

cyclin D1

decreases expression

EXP

Buspirone results in decreased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

CD164 molecule

decreases expression

EXP

Buspirone results in decreased expression of CD164 mRNA

NCBI chr20:46,606,439...46,618,015
Ensembl chr20:46,606,107...46,638,649

G

Cd5 molecule-like

decreases expression

EXP

Buspirone results in decreased expression of CD5L mRNA

NCBI chr 2:175,088,915...175,099,928
Ensembl chr 2:175,088,884...175,099,926

G

Cd68 molecule

decreases expression

EXP

Buspirone results in decreased expression of CD68 mRNA

NCBI chr10:54,880,562...54,882,441
Ensembl chr10:54,880,563...54,882,540

G

CD74 molecule

decreases expression

EXP

Buspirone results in decreased expression of CD74 mRNA

NCBI chr18:56,527,071...56,536,406
Ensembl chr18:56,527,132...56,536,410

G

cell division cycle 20

decreases expression

EXP

Buspirone results in decreased expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

cyclin-dependent kinase 1

decreases expression

EXP

Buspirone results in decreased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase inhibitor 2C

decreases expression

EXP

Buspirone results in decreased expression of CDKN2C mRNA

NCBI chr 5:129,639,736...129,645,564
Ensembl chr 5:129,639,736...129,644,891

G

cyclin-dependent kinase inhibitor 3

decreases expression

EXP

Buspirone results in decreased expression of CDKN3 mRNA

NCBI chr15:22,502,299...22,513,725
Ensembl chr15:22,502,382...22,513,722

G

CEA cell adhesion molecule 1

decreases expression

EXP

Buspirone results in decreased expression of CEACAM1 mRNA

NCBI chr 1:90,171,401...90,187,810
Ensembl chr 1:90,171,401...90,187,798

G

CEA cell adhesion molecule 4

decreases expression

EXP

Buspirone results in decreased expression of CEACAM10 mRNA

NCBI chr 1:89,504,555...89,510,831
Ensembl chr 1:89,504,555...89,510,831

G

centrosomal protein 20

decreases expression

EXP

Buspirone results in decreased expression of CEP20 mRNA

NCBI chr10:1,221,294...1,243,144
Ensembl chr10:1,221,371...1,245,241

G

cofilin 1

decreases expression

EXP

Buspirone results in decreased expression of CFL1 mRNA

NCBI chr 1:212,227,124...212,230,656
Ensembl chr 1:212,226,121...212,231,353

G

cingulin

decreases expression

EXP

Buspirone results in decreased expression of CGN mRNA

NCBI chr 2:184,997,425...185,024,785
Ensembl chr 2:184,997,425...185,023,635

G

choline phosphotransferase 1

increases expression

EXP

Buspirone results in increased expression of CHPT1 mRNA

NCBI chr 7:24,753,880...24,802,529
Ensembl chr 7:24,750,343...24,802,521

G

churchill domain containing 1

increases expression

EXP

Buspirone results in increased expression of CHURC1 mRNA

NCBI chr 6:101,203,778...101,218,364
Ensembl chr 6:101,203,841...101,237,748

G

CDC28 protein kinase regulatory subunit 2

decreases expression

EXP

Buspirone results in decreased expression of CKS2 mRNA

NCBI chr17:13,722,360...13,727,519
Ensembl chr17:13,722,361...13,727,519

G

C-type lectin domain family 4, member F

decreases expression

EXP

Buspirone results in decreased expression of CLEC4F mRNA

NCBI chr 4:117,686,686...117,696,407
Ensembl chr 4:117,686,686...117,696,438

G

chloride intracellular channel 1

decreases expression

EXP

Buspirone results in decreased expression of CLIC1 mRNA

NCBI chr20:3,769,522...3,778,367
Ensembl chr20:3,769,527...3,778,367

G

ClpB family mitochondrial disaggregase

decreases expression

EXP

Buspirone results in decreased expression of CLPB mRNA

NCBI chr 1:165,440,705...165,563,514
Ensembl chr 1:165,440,861...165,583,815

G

clathrin, light chain B

increases expression

EXP

Buspirone results in increased expression of CLTB mRNA

NCBI chr17:10,006,416...10,024,278
Ensembl chr17:10,006,656...10,024,915

G

CKLF-like MARVEL transmembrane domain containing 6

decreases expression

EXP

Buspirone results in decreased expression of CMTM6 mRNA

NCBI chr 8:123,301,131...123,319,230
Ensembl chr 8:123,300,918...123,319,230

G

cyclin Pas1/PHO80 domain containing 1

increases expression

EXP

Buspirone results in increased expression of CNPPD1 mRNA

NCBI chr 9:84,082,148...84,088,888
Ensembl chr 9:84,082,149...84,089,788

G

cannabinoid receptor 1

affects response to substance

ISO

CNR1 affects the susceptibility to Buspirone

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

cordon-bleu WH2 repeat protein-like 1

increases expression

EXP

Buspirone results in increased expression of COBLL1 mRNA

NCBI chr 3:70,161,369...70,324,844
Ensembl chr 3:70,161,372...70,323,460

G

collagen type XIV alpha 1 chain

decreases expression

EXP

Buspirone results in decreased expression of COL14A1 mRNA

NCBI chr 7:88,611,827...88,826,939
Ensembl chr 7:88,611,828...88,826,938

G

collagen type I alpha 2 chain

decreases expression

EXP

Buspirone results in decreased expression of COL1A2 mRNA

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

collagen type III alpha 1 chain

decreases expression

EXP

Buspirone results in decreased expression of COL3A1 mRNA

NCBI chr 9:54,866,646...54,902,578
Ensembl chr 9:54,866,632...54,903,232

G

COMM domain containing 5

increases expression

EXP

Buspirone results in increased expression of COMMD5 mRNA

NCBI chr 7:110,502,492...110,503,916
Ensembl chr 7:110,479,403...110,505,897

G

COPI coat complex subunit gamma 1

decreases expression

EXP

Buspirone results in decreased expression of COPG1 mRNA

NCBI chr 4:121,923,644...121,949,819
Ensembl chr 4:121,923,873...121,949,812

G

coronin 1C

decreases expression

EXP

Buspirone results in decreased expression of CORO1C mRNA

NCBI chr12:48,373,573...48,445,718
Ensembl chr12:48,373,597...48,445,716

G

cytochrome c oxidase assembly factor COX14

increases expression

EXP

Buspirone results in increased expression of COX14 mRNA

NCBI chr 7:132,731,069...132,733,159
Ensembl chr 7:132,731,069...132,733,159

G

cytochrome c oxidase subunit 7A2 like

increases expression

EXP

Buspirone results in increased expression of COX7A2L mRNA

NCBI chr 6:16,936,574...16,950,797
Ensembl chr 6:16,936,795...16,950,798

G

carnitine palmitoyltransferase 1A

increases expression

EXP

Buspirone results in increased expression of CPT1A mRNA

NCBI chr 1:209,993,881...210,056,329
Ensembl chr 1:209,993,875...210,056,326

G

carnitine palmitoyltransferase 2

increases expression

EXP

Buspirone results in increased expression of CPT2 mRNA

NCBI chr 5:127,893,450...127,911,347
Ensembl chr 5:127,893,207...127,910,818

G

cAMP responsive element modulator

decreases expression

EXP

Buspirone results in decreased expression of CREM mRNA

NCBI chr17:58,932,011...59,001,160
Ensembl chr17:58,934,147...59,001,160

G

cryptochrome circadian regulator 1

decreases expression

EXP

Buspirone results in decreased expression of CRY1 mRNA

NCBI chr 7:20,417,526...20,481,791
Ensembl chr 7:20,417,107...20,481,822

G

chromosome segregation 1 like

decreases expression

EXP

Buspirone results in decreased expression of CSE1L mRNA

NCBI chr 3:176,060,183...176,097,909
Ensembl chr 3:176,060,215...176,108,734

G

colony stimulating factor 1 receptor

decreases expression

EXP

Buspirone results in decreased expression of CSF1R mRNA

NCBI chr18:56,834,152...56,860,804
Ensembl chr18:56,817,049...56,860,806

G

casein kinase 2 alpha 2

increases expression

EXP

Buspirone results in increased expression of CSNK2A2 mRNA

NCBI chr19:9,562,340...9,602,136
Ensembl chr19:9,562,321...9,602,136

G

cysteine and glycine-rich protein 1

decreases expression

EXP

Buspirone results in decreased expression of CSRP1 mRNA

NCBI chr13:49,709,928...49,731,141
Ensembl chr13:49,709,914...49,731,139

G

cathepsin D

increases expression

EXP

Buspirone results in increased expression of CTSD mRNA

NCBI chr 1:206,956,945...206,968,821
Ensembl chr 1:206,956,944...206,968,821

G

cathepsin L

increases expression

EXP

Buspirone results in increased expression of CTSL mRNA

NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113

G

cathepsin S

decreases expression

EXP

Buspirone results in decreased expression of CTSS mRNA

NCBI chr 2:185,775,316...185,803,440
Ensembl chr 2:185,775,296...185,803,440

G

cathepsin Z

decreases expression

EXP

Buspirone results in decreased expression of CTSZ mRNA

NCBI chr 3:183,643,077...183,653,847
Ensembl chr 3:183,643,077...183,657,012

G

C-X-C motif chemokine ligand 11

increases expression

EXP

Buspirone results in increased expression of CXCL11 mRNA

NCBI chr14:15,973,728...15,976,503
Ensembl chr14:15,973,720...15,976,567

G

cytochrome b-245 beta chain

decreases expression

EXP

Buspirone results in decreased expression of CYBB mRNA

NCBI chr X:16,030,596...16,065,065
Ensembl chr X:16,030,596...16,065,065

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

EXP

Buspirone results in increased expression of CYP27A1 mRNA

NCBI chr 9:83,712,402...83,743,222
Ensembl chr 9:83,713,293...83,743,215

G

cytochrome P450, family 2, subfamily c, polypeptide 22

decreases expression

EXP

Buspirone results in decreased expression of CYP2C22 mRNA

NCBI chr 1:248,941,143...248,980,767
Ensembl chr 1:248,904,062...248,971,182

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases oxidation
increases expression

ISO
EXP

CYP2D6 protein results in increased oxidation of Buspirone
Buspirone results in increased expression of CYP2D4 mRNA

PMID:15640381 PMID:24136188

NCBI chr 7:115,762,662...115,771,832
Ensembl chr 7:115,761,696...115,771,837

G

cytochrome P450, family 2, subfamily j, polypeptide 3

increases expression

EXP

Buspirone results in increased expression of CYP2J3 mRNA

NCBI chr 5:116,335,755...116,360,677
Ensembl chr 5:116,335,755...116,360,499

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases oxidation
increases metabolic processing
multiple interactions

ISO

CYP3A4 protein results in increased oxidation of Buspirone
CYP3A4 protein results in increased metabolism of Buspirone
Resveratrol inhibits the reaction [CYP3A4 protein results in increased metabolism of Buspirone]

PMID:15640381 PMID:20716633

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases oxidation
increases expression

ISO
EXP

CYP3A5 protein results in increased oxidation of Buspirone
Buspirone results in increased expression of CYP3A9 mRNA

PMID:15640381 PMID:24136188

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 4, subfamily a, polypeptide 1

increases expression

EXP

Buspirone results in increased expression of CYP4A1 mRNA

NCBI chr 5:134,360,096...134,374,233
Ensembl chr 5:134,360,111...134,374,231

G

cytochrome P450, family 4, subfamily b, polypeptide 1

increases expression

EXP

Buspirone results in increased expression of CYP4B1 mRNA

NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:134,375,807...134,393,116

G

cytochrome P450, family 4, subfamily f, polypeptide 1

decreases expression

EXP

Buspirone results in decreased expression of CYP4F1 mRNA

NCBI chr 7:12,661,357...12,672,952
Ensembl chr 7:12,661,359...12,672,612

G

cytochrome P450, family 4, subfamily f, polypeptide 4

increases expression

EXP

Buspirone results in increased expression of CYP4F4 mRNA

NCBI chr 7:12,367,711...12,384,010
Ensembl chr 7:12,367,660...12,384,010

G

cytochrome P450 family 8 subfamily B member 1

increases expression

EXP

Buspirone results in increased expression of CYP8B1 mRNA

NCBI chr 8:130,455,622...130,457,592
Ensembl chr 8:130,442,503...130,457,689

G

dishevelled associated activator of morphogenesis 1

decreases expression

EXP

Buspirone results in decreased expression of DAAM1 mRNA

NCBI chr 6:96,125,521...96,286,049
Ensembl chr 6:96,125,621...96,286,049

G

DAB adaptor protein 2

decreases expression

EXP

Buspirone results in decreased expression of DAB2 mRNA

NCBI chr 2:57,241,947...57,294,893
Ensembl chr 2:57,242,064...57,294,888

G

death associated protein kinase 1

decreases expression

EXP

Buspirone results in decreased expression of DAPK1 mRNA

NCBI chr17:3,935,826...4,096,858
Ensembl chr17:3,935,625...4,096,581

G

diazepam binding inhibitor

decreases expression

EXP

Buspirone results in decreased expression of DBI mRNA

NCBI chr13:33,794,231...33,802,632
Ensembl chr13:33,759,845...33,821,450

G

dopa decarboxylase

decreases expression

EXP

Buspirone results in decreased expression of DDC mRNA

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DDHD domain containing 1

decreases expression

EXP

Buspirone results in decreased expression of DDHD1 mRNA

NCBI chr15:21,304,053...21,370,608
Ensembl chr15:21,303,826...21,370,608

G

DEAD-box helicase 1

decreases expression

EXP

Buspirone results in decreased expression of DDX1 mRNA

NCBI chr 6:41,725,365...41,756,236
Ensembl chr 6:41,725,367...41,758,302

G

2,4-dienoyl-CoA reductase 1

increases expression

EXP

Buspirone results in increased expression of DECR1 mRNA

NCBI chr 5:34,208,195...34,236,074
Ensembl chr 5:34,208,195...34,236,033

G

DEK proto-oncogene

decreases expression

EXP

Buspirone results in decreased expression of DEK mRNA

NCBI chr17:17,786,989...17,809,096
Ensembl chr17:17,787,139...17,810,122

G

DEP domain containing MTOR-interacting protein

increases expression

EXP

Buspirone results in increased expression of DEPTOR mRNA

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

dehydrogenase/reductase 7

increases expression

EXP

Buspirone results in increased expression of DHRS7 mRNA

NCBI chr 6:97,068,149...97,083,744
Ensembl chr 6:97,068,149...97,083,744

G

dihydrolipoamide dehydrogenase

decreases expression

EXP

Buspirone results in decreased expression of DLD mRNA

NCBI chr 6:53,631,686...53,655,059
Ensembl chr 6:53,619,631...53,652,354

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

EXP

Buspirone results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

DnaJ heat shock protein family (Hsp40) member C9

decreases expression

EXP

Buspirone results in decreased expression of DNAJC9 mRNA

NCBI chr15:3,970,843...4,003,009
Ensembl chr15:3,970,114...3,977,304

G

dolichyl-phosphate mannosyltransferase subunit 1, catalytic

increases expression

EXP

Buspirone results in increased expression of DPM1 mRNA

NCBI chr 3:177,338,855...177,358,398
Ensembl chr 3:177,338,855...177,358,412

G

dolichyl-phosphate mannosyltransferase subunit 3, regulatory

increases expression

EXP

Buspirone results in increased expression of DPM3 mRNA

NCBI chr 2:176,974,290...176,974,805
Ensembl chr15:52,612,418...52,612,696

G

dihydropyrimidinase-like 2

decreases expression

EXP

Buspirone results in decreased expression of DPYSL2 mRNA

NCBI chr15:45,181,041...45,287,065
Ensembl chr15:45,181,041...45,287,065

G

deoxythymidylate kinase

decreases expression

EXP

Buspirone results in decreased expression of DTYMK mRNA

NCBI chr 9:101,762,899...101,771,733
Ensembl chr 9:101,762,899...101,774,504

G

deoxyuridine triphosphatase

decreases expression

EXP

Buspirone results in decreased expression of DUT mRNA

NCBI chr 3:132,952,258...132,963,433
Ensembl chr 3:132,952,394...132,964,956

G

dynein light chain LC8-type 1

decreases expression

EXP

Buspirone results in decreased expression of DYNLL1 mRNA

NCBI chr12:46,945,291...46,976,867
Ensembl chr12:46,973,050...46,976,861

G

dynein light chain Tctex-type 3

decreases expression

EXP

Buspirone results in decreased expression of DYNLT3 mRNA

NCBI chr X:16,000,425...16,009,632
Ensembl chr X:16,000,395...16,009,627

G

enoyl-CoA hydratase 1

increases expression

EXP

Buspirone results in increased expression of ECH1 mRNA

NCBI chr 1:93,241,076...93,248,314
Ensembl chr 1:93,241,734...93,248,440

G

ethylmalonyl-CoA decarboxylase 1

decreases expression

EXP

Buspirone results in decreased expression of ECHDC1 mRNA

NCBI chr 1:30,304,968...30,355,957
Ensembl chr 1:30,304,971...30,337,208

G

enoyl CoA hydratase domain containing 3

increases expression

EXP

Buspirone results in increased expression of ECHDC3 mRNA

NCBI chr17:76,980,112...77,002,934
Ensembl chr17:76,980,083...77,002,934

G

enoyl-CoA delta isomerase 1

increases expression

EXP

Buspirone results in increased expression of ECI1 mRNA

NCBI chr10:13,961,250...13,974,595
Ensembl chr10:13,961,218...13,974,773

G

ER degradation enhancing alpha-mannosidase like protein 1

increases expression

EXP

Buspirone results in increased expression of EDEM1 mRNA

NCBI chr 4:143,350,989...143,385,693
Ensembl chr 4:143,353,624...143,388,060

G

elongation factor Tu GTP binding domain containing 2

decreases expression

EXP

Buspirone results in decreased expression of EFTUD2 mRNA

NCBI chr10:88,304,992...88,352,229
Ensembl chr10:88,304,992...88,346,299

G

EH domain binding protein 1

decreases expression

EXP

Buspirone results in decreased expression of EHBP1 mRNA

NCBI chr14:100,294,585...100,581,764
Ensembl chr14:100,294,585...100,546,579

G

EI24, autophagy associated transmembrane protein

increases expression

EXP

Buspirone results in increased expression of EI24 mRNA

NCBI chr 8:44,683,138...44,699,502
Ensembl chr 8:44,683,144...44,695,214

G

eukaryotic translation initiation factor 3, subunit C

decreases expression

EXP

Buspirone results in decreased expression of EIF3C mRNA

NCBI chr 1:190,565,183...190,583,067
Ensembl chr 1:190,565,184...190,583,067

G

eukaryotic translation initiation factor 3, subunit L

decreases expression

EXP

Buspirone results in decreased expression of EIF3L mRNA

NCBI chr 7:112,522,222...112,544,063
Ensembl chr 7:112,507,831...112,544,062

G

eukaryotic translation initiation factor 4A2

increases expression

EXP

Buspirone results in increased expression of EIF4A2 mRNA

NCBI chr11:91,268,730...91,276,738
Ensembl chr11:91,268,731...91,275,323

G

eukaryotic translation initiation factor 4B

increases expression

EXP

Buspirone results in increased expression of EIF4B mRNA

NCBI chr 7:135,085,259...135,107,054
Ensembl chr 7:135,085,066...135,107,064

G

ELOVL fatty acid elongase 5

decreases expression

EXP

Buspirone results in decreased expression of ELOVL5 mRNA

NCBI chr 8:87,671,164...87,737,618
Ensembl chr 8:87,671,159...87,737,616

G

ELOVL fatty acid elongase 6

decreases expression

EXP

Buspirone results in decreased expression of ELOVL6 mRNA

NCBI chr 2:220,738,095...220,845,528
Ensembl chr 2:220,738,064...220,845,549

G

glutamyl aminopeptidase

decreases expression

EXP

Buspirone results in decreased expression of ENPEP mRNA

NCBI chr 2:220,456,258...220,526,218
Ensembl chr 2:220,456,278...220,526,218

G

epoxide hydrolase 1

decreases expression

EXP

Buspirone results in decreased expression of EPHX1 mRNA

NCBI chr13:95,246,079...95,275,852
Ensembl chr13:95,246,080...95,321,981

G

ergosterol biosynthesis 28 homolog

increases expression

EXP

Buspirone results in increased expression of ERG28 mRNA

NCBI chr 6:111,205,102...111,214,068
Ensembl chr 6:111,205,103...111,214,068

G

endoplasmic reticulum-golgi intermediate compartment 1

decreases expression

EXP

Buspirone results in decreased expression of ERGIC1 mRNA

NCBI chr10:17,035,615...17,131,411
Ensembl chr10:17,035,615...17,131,376

G

endoplasmic reticulum protein 29

decreases expression

EXP

Buspirone results in decreased expression of ERP29 mRNA

NCBI chr12:40,750,177...40,756,607
Ensembl chr12:40,750,314...40,757,010

G

ethanolamine kinase 2

increases expression

EXP

Buspirone results in increased expression of ETNK2 mRNA

NCBI chr13:47,362,964...47,381,100
Ensembl chr13:47,363,060...47,381,100

G

EWS RNA-binding protein 1

decreases expression

EXP

Buspirone results in decreased expression of EWSR1 mRNA

NCBI chr14:84,179,413...84,208,149
Ensembl chr14:84,179,618...84,208,095

G

exosome component 5

increases expression

EXP

Buspirone results in increased expression of EXOSC5 mRNA

NCBI chr 1:90,295,495...90,305,047
Ensembl chr 1:90,293,797...90,305,046

G

fatty acid binding protein 5

decreases expression

EXP

Buspirone results in decreased expression of FABP5 mRNA

NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127

G

fatty acid desaturase 1

decreases expression

EXP

Buspirone results in decreased expression of FADS1 mRNA

NCBI chr 1:216,252,605...216,267,618
Ensembl chr 1:216,252,602...216,267,615

G

fatty acid desaturase 2

decreases expression

EXP

Buspirone results in decreased expression of FADS2 mRNA

NCBI chr 1:216,132,277...216,172,190
Ensembl chr 1:216,133,676...216,172,066

G

FAM111 trypsin like peptidase A

decreases expression

EXP

Buspirone results in decreased expression of FAM111A mRNA

NCBI chr 1:219,065,542...219,081,213
Ensembl chr 1:219,065,601...219,081,211

G

family with sequence similarity 98, member A

decreases expression

EXP

Buspirone results in decreased expression of FAM98A mRNA

NCBI chr 6:25,626,108...25,640,767
Ensembl chr 6:25,625,984...25,640,767

G

fatty acid synthase

decreases expression

EXP

Buspirone results in decreased expression of FASN mRNA

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

FAT atypical cadherin 1

decreases expression

EXP

Buspirone results in decreased expression of FAT1 mRNA

NCBI chr16:53,909,759...54,029,175
Ensembl chr16:53,909,556...54,028,609

G

F-box protein 31

increases expression

EXP

Buspirone results in increased expression of FBXO31 mRNA

NCBI chr19:66,533,437...66,564,674
Ensembl chr19:66,533,437...66,564,674

G

F-box and WD repeat domain containing 2

increases expression

EXP

Buspirone results in increased expression of FBXW2 mRNA

NCBI chr 3:38,486,358...38,511,683
Ensembl chr 3:38,486,362...38,511,667

G

Fc gamma receptor 2A

decreases expression

EXP

Buspirone results in decreased expression of FCGR2A mRNA

NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394

G

ficolin A

decreases expression

EXP

Buspirone results in decreased expression of FCNA mRNA

NCBI chr 3:28,844,036...28,847,441
Ensembl chr 3:28,844,039...28,847,237

G

fasciculation and elongation protein zeta 2

decreases expression

EXP

Buspirone results in decreased expression of FEZ2 mRNA

NCBI chr 6:22,406,685...22,446,745
Ensembl chr 6:22,406,632...22,447,041

G

fibrinogen alpha chain

decreases expression

EXP

Buspirone results in decreased expression of FGA mRNA

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

fibroblast growth factor receptor 2

decreases expression

EXP

Buspirone results in decreased expression of FGFR2 mRNA

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

folliculin

increases expression

EXP

Buspirone results in increased expression of FLCN mRNA

NCBI chr10:45,088,164...45,107,581
Ensembl chr10:45,088,167...45,107,309

G

flavin containing dimethylaniline monoxygenase 3

increases expression

EXP

Buspirone results in increased expression of FMO3 mRNA

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256

G

flavin containing dimethylaniline monoxygenase 5

increases expression

EXP

Buspirone results in increased expression of FMO5 mRNA

NCBI chr 2:187,885,741...187,938,468
Ensembl chr 2:187,910,964...187,938,464

G

forkhead box A3

increases expression

EXP

Buspirone results in increased expression of FOXA3 mRNA

NCBI chr 1:87,790,111...87,800,259
Ensembl chr 1:87,790,012...87,800,953

G

forkhead box O1

increases expression

EXP

Buspirone results in increased expression of FOXO1 mRNA

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

follistatin-like 1

decreases expression

EXP

Buspirone results in decreased expression of FSTL1 mRNA

NCBI chr11:76,400,870...76,454,053
Ensembl chr11:76,391,315...76,455,126

G

formimidoyltransferase cyclodeaminase

increases expression

EXP

Buspirone results in increased expression of FTCD mRNA

NCBI chr20:12,054,710...12,068,219
Ensembl chr20:12,054,711...12,068,237

G

Fus RNA binding protein

decreases expression

EXP

Buspirone results in decreased expression of FUS mRNA

NCBI chr 1:192,007,011...192,020,887
Ensembl chr 1:192,007,006...192,020,884

G

FXYD domain-containing ion transport regulator 1

increases expression

EXP

Buspirone results in increased expression of FXYD1 mRNA

NCBI chr 1:95,414,556...95,418,645
Ensembl chr 1:95,414,557...95,418,591

G

G0/G1switch 2

increases expression

EXP

Buspirone results in increased expression of G0S2 mRNA

NCBI chr13:107,335,036...107,335,948
Ensembl chr13:107,335,036...107,336,293

G

glucose-6-phosphate dehydrogenase

decreases expression

EXP

Buspirone results in decreased expression of G6PD mRNA

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

growth arrest and DNA-damage-inducible, gamma

decreases expression

EXP

Buspirone results in decreased expression of GADD45G mRNA

NCBI chr17:13,528,606...13,530,351
Ensembl chr17:13,528,610...13,530,369

G

polypeptide N-acetylgalactosaminyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588

G

glycyl-tRNA synthetase 1

decreases expression

EXP

Buspirone results in decreased expression of GARS1 mRNA

NCBI chr 4:85,484,939...85,542,876
Ensembl chr 4:85,493,753...85,542,876

G

growth arrest specific 5

increases expression

EXP

Buspirone results in increased expression of GAS5 mRNA

NCBI chr13:75,836,963...75,840,284

G

1,4-alpha-glucan branching enzyme 1

decreases expression

EXP

Buspirone results in decreased expression of GBE1 mRNA

NCBI chr11:22,181,194...22,446,640
Ensembl chr11:22,181,103...22,446,638

G

glutaryl-CoA dehydrogenase

increases expression

EXP

Buspirone results in increased expression of GCDH mRNA

NCBI chr19:40,168,038...40,174,536
Ensembl chr19:40,168,141...40,175,686

G

GTP cyclohydrolase I feedback regulator

increases expression

EXP

Buspirone results in increased expression of GCHFR mRNA

NCBI chr 3:126,611,892...126,615,926
Ensembl chr 3:126,613,240...126,615,926

G

glutamate-cysteine ligase, catalytic subunit

decreases expression

EXP

Buspirone results in decreased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glycerophosphodiester phosphodiesterase 1

increases expression

EXP

Buspirone results in increased expression of GDE1 mRNA

NCBI chr 1:182,451,182...182,466,569
Ensembl chr 1:182,451,184...182,466,772

G

GDP dissociation inhibitor 2

decreases expression

EXP

Buspirone results in decreased expression of GDI2 mRNA

NCBI chr17:71,559,460...71,586,147
Ensembl chr17:71,559,461...71,586,147

G

G elongation factor, mitochondrial 1

decreases expression

EXP

Buspirone results in decreased expression of GFM1 mRNA

NCBI chr 2:154,010,601...154,055,523
Ensembl chr 2:154,010,614...154,065,805

G

gamma-glutamyl carboxylase

decreases expression

EXP

Buspirone results in decreased expression of GGCX mRNA

NCBI chr 4:106,027,918...106,043,653
Ensembl chr 4:106,027,912...106,043,923

G

growth hormone receptor

decreases expression

EXP

Buspirone results in decreased expression of GHR mRNA

NCBI chr 2:54,269,066...54,532,595
Ensembl chr 2:54,270,206...54,532,331

G

glycine decarboxylase

decreases expression

EXP

Buspirone results in decreased expression of GLDC mRNA

NCBI chr 1:237,296,753...237,375,620
Ensembl chr 1:237,296,753...237,375,604

G

glutaredoxin

increases expression

EXP

Buspirone results in increased expression of GLRX mRNA

NCBI chr 2:7,073,737...7,083,548
Ensembl chr 2:7,073,759...7,083,543

G

glycine-N-acyltransferase

increases expression

EXP

Buspirone results in increased expression of GLYAT mRNA

NCBI chr 1:219,128,798...219,149,615
Ensembl chr 1:219,128,811...219,150,774

G

glycine-N-acyltransferase-like 2

increases expression

EXP

Buspirone results in increased expression of GLYATL2 mRNA

NCBI chr 1:219,232,154...219,265,142
Ensembl chr 1:219,232,103...219,266,322

G

glucosamine-phosphate N-acetyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of GNPNAT1 mRNA

NCBI chr15:21,076,129...21,088,526
Ensembl chr15:21,076,130...21,088,423

G

glycerol-3-phosphate acyltransferase, mitochondrial

decreases expression

EXP

Buspirone results in decreased expression of GPAM mRNA

NCBI chr 1:264,111,599...264,176,112
Ensembl chr 1:264,113,813...264,175,911

G

glycerol-3-phosphate dehydrogenase 1

decreases expression

EXP

Buspirone results in decreased expression of GPD1 mRNA

NCBI chr 7:132,722,982...132,730,373
Ensembl chr 7:132,721,915...132,730,368

G

glutamic--pyruvic transaminase

increases expression

EXP

Buspirone results in increased expression of GPT mRNA

NCBI chr 7:110,295,599...110,300,134
Ensembl chr 7:110,296,206...110,300,160

G

G1 to S phase transition 1

decreases expression

EXP

Buspirone results in decreased expression of GSPT1 mRNA

NCBI chr10:4,867,687...4,904,186
Ensembl chr10:4,869,465...4,908,040

G

glutathione S-transferase pi 1

increases expression

EXP

Buspirone results in increased expression of GSTP1 mRNA

NCBI chr 1:210,767,237...210,770,242
Ensembl chr 1:210,767,237...210,769,705

G

glutathione S-transferase theta 2

increases expression

EXP

Buspirone results in increased expression of GSTT2 mRNA

NCBI chr20:12,819,053...12,822,724
Ensembl chr20:12,818,540...12,822,718

G

gulonolactone (L-) oxidase

decreases expression

EXP

Buspirone results in decreased expression of GULO mRNA

NCBI chr15:44,381,226...44,403,314
Ensembl chr15:44,381,214...44,403,422

G

H1.0 linker histone

decreases expression

EXP

Buspirone results in decreased expression of H1F0 mRNA

NCBI chr 7:112,473,280...112,475,140
Ensembl chr 7:112,473,222...112,475,006

G

H2A.Z variant histone 1

decreases expression

EXP

Buspirone results in decreased expression of H2AZ1 mRNA

NCBI chr 2:229,026,464...229,031,411
Ensembl chr 2:229,028,843...229,031,411

G

3-hydroxyacyl-CoA dehydratase 2

decreases expression

EXP

Buspirone results in decreased expression of HACD2 mRNA

NCBI chr11:79,175,470...79,268,975
Ensembl chr11:79,175,482...79,268,126

G

3-hydroxyacyl-CoA dehydratase 3

decreases expression

EXP

Buspirone results in decreased expression of HACD3 mRNA

NCBI chr 8:74,396,441...74,433,700
Ensembl chr 8:74,396,442...74,433,700

G

2-hydroxyacyl-CoA lyase 1

increases expression

EXP

Buspirone results in increased expression of HACL1 mRNA

NCBI chr16:6,831,293...6,869,410
Ensembl chr16:6,833,268...6,869,410

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

increases expression

EXP

Buspirone results in increased expression of HADHB mRNA

NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:31,873,404...31,907,835

G

hydroxyacid oxidase 1

decreases expression

EXP

Buspirone results in decreased expression of HAO1 mRNA

NCBI chr 3:142,102,873...142,281,527
Ensembl chr 3:142,224,612...142,281,494

G

histone acetyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of HAT1 mRNA

NCBI chr 3:76,624,442...76,672,701
Ensembl chr 3:76,624,869...76,672,696

G

HAUS augmin-like complex, subunit 4

decreases expression

EXP

Buspirone results in decreased expression of HAUS4 mRNA

NCBI chr15:31,964,555...31,976,853
Ensembl chr15:31,964,556...31,975,941

G

hemoglobin alpha, adult chain 1

decreases expression

EXP

Buspirone results in decreased expression of HBA-A1 mRNA

NCBI chr10:15,841,724...15,842,580
Ensembl chr10:15,841,763...15,842,603

G

hemoglobin alpha, adult chain 2

decreases expression

EXP

Buspirone results in decreased expression of HBA1 mRNA

NCBI chr10:15,828,291...15,829,138
Ensembl chr10:15,828,377...15,829,141

G

HECT domain E3 ubiquitin protein ligase 1

increases expression

EXP

Buspirone results in increased expression of HECTD1 mRNA

NCBI chr 6:74,916,803...75,003,408
Ensembl chr 6:74,916,803...75,003,408

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

EXP

Buspirone results in increased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

hes family bHLH transcription factor 1

increases expression

EXP

Buspirone results in increased expression of HES1 mRNA

NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061

G

hes family bHLH transcription factor 6

decreases expression

EXP

Buspirone results in decreased expression of HES6 mRNA

NCBI chr 9:99,449,375...99,451,343
Ensembl chr 9:99,449,371...99,451,096

G

hexosaminidase subunit beta

increases expression

EXP

Buspirone results in increased expression of HEXB mRNA

NCBI chr 2:30,218,608...30,238,771
Ensembl chr 2:30,218,608...30,238,771

G

hematopoietically expressed homeobox

decreases expression

EXP

Buspirone results in decreased expression of HHEX mRNA

NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604

G

3-hydroxyisobutyryl-CoA hydrolase

increases expression

EXP

Buspirone results in increased expression of HIBCH mRNA

NCBI chr 9:56,082,082...56,161,796
Ensembl chr 9:56,082,091...56,161,886

G

HIG1 hypoxia inducible domain family, member 2A

increases expression

EXP

Buspirone results in increased expression of HIGD2A mRNA

NCBI chr17:10,026,961...10,027,885
Ensembl chr17:10,026,961...10,027,874

G

high mobility group box 2

decreases expression

EXP

Buspirone results in decreased expression of HMGB2 mRNA

NCBI chr16:37,721,374...37,723,950
Ensembl chr16:37,721,379...37,723,860

G

high mobility group nucleosomal binding domain 2

decreases expression

EXP

Buspirone results in decreased expression of HMGN2 mRNA

NCBI chr 5:151,475,907...151,479,361
Ensembl chr 5:151,475,909...151,479,397

G

high mobility group nucleosomal binding domain 3

decreases expression

EXP

Buspirone results in decreased expression of HMGN3 mRNA

NCBI chr 8:92,902,555...92,939,980

G

heme oxygenase 1

multiple interactions
increases expression

EXP

Buspirone inhibits the reaction [Methotrexate results in decreased expression of HMOX1 mRNA]
Buspirone results in increased expression of HMOX1 mRNA

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein A1

decreases expression

EXP

Buspirone results in decreased expression of HNRNPA1 mRNA

NCBI chr 7:136,253,633...136,260,085
Ensembl chr 7:136,253,278...136,260,085

G

heterogeneous nuclear ribonucleoprotein A2/B1

decreases expression

EXP

Buspirone results in decreased expression of HNRNPA2B1 mRNA

NCBI chr 4:81,867,354...81,875,886
Ensembl chr 4:81,869,661...81,877,572

G

heterogeneous nuclear ribonucleoprotein M

decreases expression

EXP

Buspirone results in decreased expression of HNRNPM mRNA

NCBI chr 7:15,140,877...15,178,871
Ensembl chr 7:15,129,287...15,178,871

G

heterogeneous nuclear ribonucleoprotein R

decreases expression

EXP

Buspirone results in decreased expression of HNRNPR mRNA

NCBI chr 5:153,826,482...153,872,272
Ensembl chr 5:153,826,692...153,858,344

G

hypoxanthine phosphoribosyltransferase 1

increases expression

EXP

Buspirone results in increased expression of HPRT1 mRNA

NCBI chr X:137,655,744...137,687,718
Ensembl chr X:137,655,680...137,687,712

G

hydroxysteroid dehydrogenase like 2

increases expression

EXP

Buspirone results in increased expression of HSDL2 mRNA

NCBI chr 5:79,238,881...79,274,051
Ensembl chr 5:79,212,525...79,274,798

G

heat shock protein family A (Hsp70) member 13

decreases expression

EXP

Buspirone results in decreased expression of HSPA13 mRNA

NCBI chr11:27,862,717...27,876,898
Ensembl chr11:27,862,593...27,876,898

G

heat shock protein family A (Hsp70) member 5

decreases expression

EXP

Buspirone results in decreased expression of HSPA5 mRNA

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

HIV-1 Tat specific factor 1

decreases expression

EXP

Buspirone results in decreased expression of HTATSF1 mRNA

NCBI chr X:139,972,742...139,986,923
Ensembl chr X:139,972,742...139,986,923

G

5-hydroxytryptamine receptor 1A

multiple interactions

ISO
EXP

Buspirone binds to and affects the activity of HTR1A protein
Buspirone binds to and results in decreased activity of HTR1A protein

PMID:2207497 PMID:15482641

NCBI chr 2:38,427,169...38,431,733
Ensembl chr 2:38,427,083...38,540,760

G

5-hydroxytryptamine receptor 2A

decreases expression

EXP

Buspirone results in decreased expression of HTR2A protein

NCBI chr15:56,360,647...56,428,703
Ensembl chr15:56,359,596...56,431,619

G

hyaluronidase 3

decreases expression

EXP

Buspirone results in decreased expression of HYAL3 mRNA

NCBI chr 8:117,133,028...117,138,663
Ensembl chr 8:117,132,649...117,139,289

G

hyccin PI4KA lipid kinase complex subunit 2

increases expression

EXP

Buspirone results in increased expression of HYCC2 mRNA

NCBI chr 9:67,551,064...67,623,353
Ensembl chr 9:67,551,064...67,587,186

G

isoleucyl-tRNA synthetase 1

decreases expression

EXP

Buspirone results in decreased expression of IARS1 mRNA

NCBI chr17:15,147,357...15,193,716
Ensembl chr17:15,147,357...15,193,652

G

intercellular adhesion molecule 1

decreases expression

EXP

Buspirone results in decreased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

interferon-induced protein with tetratricopeptide repeats 2

decreases expression

EXP

Buspirone results in decreased expression of IFIT2 mRNA

NCBI chr 1:241,515,735...241,521,799
Ensembl chr 1:241,515,709...241,521,798

G

interferon induced transmembrane protein 1

decreases expression

EXP

Buspirone results in decreased expression of IFITM1 mRNA

NCBI chr 1:205,496,757...205,498,796
Ensembl chr 1:205,496,807...205,498,776

G

insulin-like growth factor 1

decreases expression

EXP

Buspirone results in decreased expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor binding protein 7

decreases expression

EXP

Buspirone results in decreased expression of IGFBP7 mRNA

NCBI chr14:31,091,681...31,151,623
Ensembl chr14:31,091,347...31,151,620

G

IK cytokine

decreases expression

EXP

Buspirone results in decreased expression of IK mRNA

NCBI chr18:28,632,025...28,646,829
Ensembl chr18:28,631,616...28,653,463

G

interleukin 1 beta

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of IL1B protein]

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 6

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of IL6 protein]

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 receptor

increases expression

EXP

Buspirone results in increased expression of IL6R mRNA

NCBI chr 2:177,582,020...177,646,705
Ensembl chr 2:177,582,164...177,645,221

G

IMP U3 small nucleolar ribonucleoprotein 3

increases expression

EXP

Buspirone results in increased expression of IMP3 mRNA

NCBI chr 8:66,235,498...66,236,386

G

inhibin subunit beta A

decreases expression

EXP

Buspirone results in decreased expression of INHBA mRNA

NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508

G

inositol hexakisphosphate kinase 1

increases expression

EXP

Buspirone results in increased expression of IP6K1 mRNA

NCBI chr 8:117,594,177...117,613,266
Ensembl chr 8:117,594,317...117,613,274

G

importin 9

decreases expression

EXP

Buspirone results in decreased expression of IPO9 mRNA

NCBI chr13:49,362,244...49,414,477
Ensembl chr13:49,365,716...49,414,477

G

interferon regulatory factor 1

decreases expression

EXP

Buspirone results in decreased expression of IRF1 mRNA

NCBI chr10:38,417,935...38,424,946
Ensembl chr10:38,417,148...38,424,947

G

interferon regulatory factor 7

decreases expression

EXP

Buspirone results in decreased expression of IRF7 mRNA

NCBI chr 1:205,796,956...205,800,543
Ensembl chr 1:205,796,959...205,800,023

G

immunity-related GTPase M

decreases expression

EXP

Buspirone results in decreased expression of IRGM mRNA

NCBI chr10:33,734,640...33,742,720
Ensembl chr10:33,732,961...33,743,228

G

integrin subunit alpha 6

decreases expression

EXP

Buspirone results in decreased expression of ITGA6 mRNA

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

integrin subunit beta 2

decreases expression

EXP

Buspirone results in decreased expression of ITGB2 mRNA

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182

G

Janus kinase 1

decreases expression

EXP

Buspirone results in decreased expression of JAK1 mRNA

NCBI chr 5:120,895,606...121,004,207
Ensembl chr 5:120,896,046...120,996,758

G

junctional adhesion molecule 2

decreases expression

EXP

Buspirone results in decreased expression of JAM2 mRNA

NCBI chr11:37,316,287...37,366,517
Ensembl chr11:37,317,511...37,367,510

G

Jupiter microtubule associated homolog 2

decreases expression

EXP

Buspirone results in decreased expression of JPT2 mRNA

NCBI chr10:14,467,652...14,487,769
Ensembl chr10:14,467,661...14,535,664

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases expression

EXP

Buspirone results in decreased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

junction plakoglobin

decreases expression

EXP

Buspirone results in decreased expression of JUP mRNA

NCBI chr10:85,800,812...85,827,881
Ensembl chr10:85,800,814...85,827,429

G

potassium channel tetramerization domain containing 5

increases expression

EXP

Buspirone results in increased expression of KCTD5 mRNA

NCBI chr10:13,583,781...13,609,762
Ensembl chr10:13,583,781...13,610,062

G

Kelch-like ECH-associated protein 1

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of KEAP1 mRNA]

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KH RNA binding domain containing, signal transduction associated 1

decreases expression

EXP

Buspirone results in decreased expression of KHDRBS1 mRNA

NCBI chr 5:147,337,048...147,374,604
Ensembl chr 5:147,347,904...147,373,448

G

KLF transcription factor 15

increases expression

EXP

Buspirone results in increased expression of KLF15 mRNA

NCBI chr 4:124,522,652...124,535,613
Ensembl chr 4:124,522,909...124,542,373

G

KLF transcription factor 9

increases expression

EXP

Buspirone results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

kelch-like family member 24

increases expression

EXP

Buspirone results in increased expression of KLHL24 mRNA

NCBI chr11:94,348,024...94,382,085
Ensembl chr11:94,351,157...94,382,050

G

karyopherin subunit alpha 2

decreases expression

EXP

Buspirone results in decreased expression of KPNA2 mRNA

NCBI chr10:92,433,678...92,445,841
Ensembl chr10:92,433,679...92,445,937

G

karyopherin subunit beta 1

decreases expression

EXP

Buspirone results in decreased expression of KPNB1 mRNA

NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856

G

keratin 18

decreases expression

EXP

Buspirone results in decreased expression of KRT18 mRNA

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848

G

kynurenine aminotransferase 1

increases expression

EXP

Buspirone results in increased expression of KYAT1 mRNA

NCBI chr 3:33,857,407...33,891,153
Ensembl chr 3:33,857,743...33,890,642

G

kynurenine aminotransferase 3

increases expression

EXP

Buspirone results in increased expression of KYAT3 mRNA

NCBI chr 2:234,362,306...234,407,646
Ensembl chr 2:234,362,322...234,407,878

G

lactamase, beta

decreases expression

EXP

Buspirone results in decreased expression of LACTB mRNA

NCBI chr 8:76,452,679...76,469,986
Ensembl chr 8:76,452,349...76,468,716

G

late endosomal/lysosomal adaptor, MAPK and MTOR activator 2

increases expression

EXP

Buspirone results in increased expression of LAMTOR2 mRNA

NCBI chr 2:176,306,353...176,310,617
Ensembl chr 2:176,306,280...176,310,730

G

lipopolysaccharide binding protein

increases expression

EXP

Buspirone results in increased expression of LBP mRNA

NCBI chr 3:167,373,786...167,400,941
Ensembl chr 3:167,373,924...167,401,518

G

leucine carboxyl methyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of LCMT1 mRNA

NCBI chr 1:187,335,173...187,391,195
Ensembl chr 1:187,327,706...187,391,516

G

lymphocyte cytosolic protein 1

decreases expression

EXP

Buspirone results in decreased expression of LCP1 mRNA

NCBI chr15:56,846,375...56,954,090
Ensembl chr15:56,847,433...56,954,092

G

leptin receptor overlapping transcript-like 1

increases expression

EXP

Buspirone results in increased expression of LEPROTL1 mRNA

NCBI chr16:64,744,148...64,756,776
Ensembl chr16:64,743,717...64,756,776

G

leucine zipper and EF-hand containing transmembrane protein 1

decreases expression

EXP

Buspirone results in decreased expression of LETM1 mRNA

NCBI chr14:81,167,268...81,206,776
Ensembl chr14:81,162,309...81,209,459

G

galectin 3

decreases expression

EXP

Buspirone results in decreased expression of LGALS3 mRNA

NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737

G

galectin 5

decreases expression

EXP

Buspirone results in decreased expression of LGALS5 mRNA

NCBI chr10:64,351,976...64,355,137
Ensembl chr10:64,351,964...64,355,180

G

galectin 9

decreases expression

EXP

Buspirone results in decreased expression of LGALS9 mRNA

NCBI chr10:64,405,044...64,428,249
Ensembl chr10:64,405,044...64,428,070

G

galectin-like

decreases expression

EXP

Buspirone results in decreased expression of LGALSL mRNA

NCBI chr14:99,198,340...99,205,846
Ensembl chr14:99,198,339...99,206,487

G

legumain

decreases expression

EXP

Buspirone results in decreased expression of LGMN mRNA

NCBI chr 6:127,308,913...127,347,355
Ensembl chr 6:127,308,913...127,347,328

G

lipase C, hepatic type

decreases expression

EXP

Buspirone results in decreased expression of LIPC mRNA

NCBI chr 8:80,390,470...80,516,463
Ensembl chr 8:80,390,471...80,516,285

G

lectin, mannose-binding, 1

decreases expression

EXP

Buspirone results in decreased expression of LMAN1 mRNA

NCBI chr18:61,778,971...61,800,960
Ensembl chr18:61,772,917...61,800,820

G

lecithin retinol acyltransferase

decreases expression

EXP

Buspirone results in decreased expression of LRAT mRNA

NCBI chr 2:170,562,148...170,571,212
Ensembl chr 2:170,565,543...170,571,148

G

LDL receptor related protein 11

increases expression

EXP

Buspirone results in increased expression of LRP11 mRNA

NCBI chr 1:3,868,665...3,928,513
Ensembl chr 1:3,899,985...3,928,507

G

leucine rich repeat containing 59

decreases expression

EXP

Buspirone results in decreased expression of LRRC59 mRNA

NCBI chr10:80,069,162...80,083,820
Ensembl chr10:80,069,120...80,084,079

G

LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

EXP

Buspirone results in decreased expression of LSM6 mRNA

NCBI chr19:46,002,592...46,017,152

G

leukotriene A4 hydrolase

decreases expression

EXP

Buspirone results in decreased expression of LTA4H mRNA

NCBI chr 7:29,856,846...29,888,642
Ensembl chr 7:29,856,802...29,888,641

G

lymphocyte antigen 6 family member E

decreases expression

EXP

Buspirone results in decreased expression of LY6E mRNA

NCBI chr 7:108,815,970...108,820,444
Ensembl chr 7:108,816,887...108,820,443

G

lymphatic vessel endothelial hyaluronan receptor 1

decreases expression

EXP

Buspirone results in decreased expression of LYVE1 mRNA

NCBI chr 1:174,393,387...174,410,977

G

lysozyme 2

decreases expression

EXP

Buspirone results in decreased expression of LYZ2 mRNA

NCBI chr 7:54,792,715...54,798,060
Ensembl chr 7:54,792,716...54,798,011

G

microtubule-associated protein 1 light chain 3 beta

increases expression

EXP

Buspirone results in increased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase 9

decreases expression

EXP

Buspirone results in decreased expression of MAPK9 mRNA

NCBI chr10:34,670,750...34,711,972
Ensembl chr10:34,670,756...34,712,228

G

microtubule-associated protein, RP/EB family, member 1

decreases expression

EXP

Buspirone results in decreased expression of MAPRE1 mRNA

NCBI chr 3:162,679,020...162,707,167
Ensembl chr 3:162,673,195...162,711,210

G

membrane associated ring-CH-type finger 2

increases expression

EXP

Buspirone results in increased expression of MARCHF2 mRNA

NCBI chr 7:15,183,931...15,209,988
Ensembl chr 7:15,183,925...15,202,002

G

membrane associated ring-CH-type finger 6

increases expression

EXP

Buspirone results in increased expression of MARCHF6 mRNA

NCBI chr 2:84,166,570...84,243,817
Ensembl chr 2:84,166,570...84,243,792

G

MARCKS-like 1

decreases expression

EXP

Buspirone results in decreased expression of MARCKSL1 mRNA

NCBI chr 5:147,135,827...147,138,150
Ensembl chr 5:147,134,514...147,138,417

G

meiosis regulator and mRNA stability factor 1

increases expression

EXP

Buspirone results in increased expression of MARF1 mRNA

NCBI chr10:1,395,271...1,439,974
Ensembl chr10:1,395,282...1,439,974

G

methionine adenosyltransferase 1A

increases expression

EXP

Buspirone results in increased expression of MAT1A mRNA

NCBI chr16:17,017,168...17,035,368
Ensembl chr16:17,016,030...17,035,367

G

mannose binding lectin 2

decreases expression

EXP

Buspirone results in decreased expression of MBL2 mRNA

NCBI chr 1:237,429,873...237,465,567
Ensembl chr 1:237,429,973...237,437,546

G

minichromosome maintenance complex component 7

decreases expression

EXP

Buspirone results in decreased expression of MCM7 mRNA

NCBI chr12:22,155,921...22,163,320
Ensembl chr12:22,155,921...22,163,771

G

malic enzyme 1

decreases expression

EXP

Buspirone results in decreased expression of ME1 mRNA

NCBI chr 8:96,429,057...96,540,244
Ensembl chr 8:96,429,057...96,540,275

G

methyltransferase 23, arginine

increases expression

EXP

Buspirone results in increased expression of METTL23 mRNA

NCBI chr10:102,546,102...102,550,782
Ensembl chr10:102,545,430...102,553,909

G

MFSD2 lysolipid transporter A, lysophospholipid

increases expression

EXP

Buspirone results in increased expression of MFSD2A mRNA

NCBI chr 5:140,510,933...140,525,828
Ensembl chr 5:140,510,953...140,525,916

G

monoglyceride lipase

decreases expression

EXP

Buspirone results in decreased expression of MGLL mRNA

NCBI chr 4:122,749,436...122,851,440
Ensembl chr 4:122,749,436...122,851,440

G

MID1 interacting protein 1

decreases expression

EXP

Buspirone results in decreased expression of MID1IP1 mRNA

NCBI chr X:14,733,539...14,735,859
Ensembl chr X:14,732,830...14,739,079

G

macrophage migration inhibitory factor

decreases expression

EXP

Buspirone results in decreased expression of MIF mRNA

NCBI chr20:12,767,138...12,791,222
Ensembl chr 4:134,041,774...134,042,121
Ensembl chr20:134,041,774...134,042,121

G

mortality factor 4 like 2

decreases expression

EXP

Buspirone results in decreased expression of MORF4L2 mRNA

NCBI chr X:104,874,850...104,885,946
Ensembl chr X:104,852,693...104,892,855

G

mitochondrial ribosomal protein L1

decreases expression

EXP

Buspirone results in decreased expression of MRPL1 mRNA

NCBI chr14:13,604,498...13,663,633
Ensembl chr14:13,604,499...13,663,602

G

mitochondrial ribosomal protein L15

decreases expression

EXP

Buspirone results in decreased expression of MRPL15 mRNA

NCBI chr 5:19,527,745...19,539,061
Ensembl chr 5:19,524,588...19,538,004

G

mitochondrial ribosomal protein L34

increases expression

EXP

Buspirone results in increased expression of MRPL34 mRNA

NCBI chr16:18,186,447...18,187,182
Ensembl chr16:18,185,306...18,187,181

G

mitochondrial ribosomal protein S22

decreases expression

EXP

Buspirone results in decreased expression of MRPS22 mRNA

NCBI chr 8:108,063,468...108,076,638
Ensembl chr 8:108,063,471...108,076,638

G

metallothionein 1A

increases expression

EXP

Buspirone results in increased expression of MT1A mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

mitochondrial amidoxime reducing component 2

increases expression

EXP

Buspirone results in increased expression of MTARC2 mRNA

NCBI chr13:98,894,347...98,928,754
Ensembl chr13:98,897,108...98,928,781

G

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1

decreases expression

EXP

Buspirone results in decreased expression of MTHFD1 mRNA

NCBI chr 6:100,713,510...100,781,013
Ensembl chr 6:100,713,681...100,781,957

G

MTSS I-BAR domain containing 1

increases expression

EXP

Buspirone results in increased expression of MTSS1 mRNA

NCBI chr 7:92,378,228...92,517,444
Ensembl chr 7:92,378,238...92,517,303

G

microsomal triglyceride transfer protein

decreases expression

EXP

Buspirone results in decreased expression of MTTP mRNA

NCBI chr 2:229,286,501...229,327,650
Ensembl chr 2:229,286,501...229,327,650

G

murinoglobulin 1

decreases expression

EXP

Buspirone results in decreased expression of MUG1 mRNA

NCBI chr 4:156,748,351...156,802,132

G

MYD88, innate immune signal transduction adaptor

increases expression

EXP

Buspirone results in increased expression of MYD88 mRNA

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin, heavy chain 9

decreases expression

EXP

Buspirone results in decreased expression of MYH9 mRNA

NCBI chr 7:111,224,291...111,304,963
Ensembl chr 7:111,224,291...111,304,963

G

N(alpha)-acetyltransferase 15, NatA auxiliary subunit

decreases expression

EXP

Buspirone results in decreased expression of NAA15 mRNA

NCBI chr 2:137,608,883...137,671,618
Ensembl chr 2:137,608,797...137,671,619

G

N-acetylneuraminate synthase

decreases expression

EXP

Buspirone results in decreased expression of NANS mRNA

NCBI chr 5:65,575,970...65,593,164
Ensembl chr 5:65,576,015...65,610,547

G

Nedd4 family interacting protein 1

increases expression

EXP

Buspirone results in increased expression of NDFIP1 mRNA

NCBI chr18:30,516,931...30,567,199
Ensembl chr18:30,516,981...30,568,471

G

NADH:ubiquinone oxidoreductase subunit A6

increases expression

EXP

Buspirone results in increased expression of NDUFA6 mRNA

NCBI chr 7:115,746,460...115,750,317
Ensembl chr 7:115,746,460...115,750,317

G

NADH:ubiquinone oxidoreductase subunit A7

increases expression

EXP

Buspirone results in increased expression of NDUFA7 mRNA

NCBI chr 7:15,311,446...15,324,226
Ensembl chr 7:15,311,286...15,334,138

G

NADH:ubiquinone oxidoreductase subunit B2

increases expression

EXP

Buspirone results in increased expression of NDUFB2 mRNA

NCBI chr 4:69,334,307...69,341,394
Ensembl chr 4:69,334,307...69,340,136
Ensembl chr15:69,334,307...69,340,136

G

nectin cell adhesion molecule 3

decreases expression

EXP

Buspirone results in decreased expression of NECTIN3 mRNA

NCBI chr11:67,825,296...67,931,999
Ensembl chr11:67,827,137...67,871,383

G

NFE2 like bZIP transcription factor 2

decreases expression
multiple interactions
increases expression

EXP

Buspirone results in decreased expression of NFE2L2 mRNA
Buspirone inhibits the reaction [Methotrexate results in decreased expression of NFE2L2 mRNA]
Buspirone results in increased expression of NFE2L2 mRNA

PMID:24136188 PMID:37341015

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

NHP2 ribonucleoprotein

decreases expression

EXP

Buspirone results in decreased expression of NHP2 mRNA

NCBI chr10:36,378,020...36,381,362
Ensembl chr10:36,377,997...36,381,354

G

nidogen 1

decreases expression

EXP

Buspirone results in decreased expression of NID1 mRNA

NCBI chr17:93,069,013...93,142,416
Ensembl chr17:93,069,278...93,142,386

G

nitrilase 1

increases expression

EXP

Buspirone results in increased expression of NIT1 mRNA

NCBI chr13:86,302,334...86,305,770
Ensembl chr13:86,298,387...86,305,770

G

neurolysin

decreases expression

EXP

Buspirone results in decreased expression of NLN mRNA

NCBI chr 2:36,867,436...36,966,749
Ensembl chr 2:36,853,551...36,966,680

G

NLR family, pyrin domain containing 3

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of NLRP3 protein]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

NME/NM23 nucleoside diphosphate kinase 1

decreases expression

EXP

Buspirone results in decreased expression of NME1 mRNA

NCBI chr10:79,403,939...79,426,620
Ensembl chr10:79,403,940...79,413,310

G

NME/NM23 nucleoside diphosphate kinase 3

increases expression

EXP

Buspirone results in increased expression of NME3 mRNA

NCBI chr10:14,421,922...14,422,878
Ensembl chr10:14,421,702...14,422,907

G

NOP53 ribosome biogenesis factor

increases expression

EXP

Buspirone results in increased expression of NOP53 mRNA

NCBI chr 1:85,757,271...85,765,089
Ensembl chr 1:85,756,586...85,765,089

G

NOP58 ribonucleoprotein

decreases expression

EXP

Buspirone results in decreased expression of NOL5 mRNA

NCBI chr 9:68,614,992...68,638,911
Ensembl chr 9:68,615,010...68,638,909

G

nitric oxide synthase 1

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of NOS1 mRNA]

NCBI chr12:44,276,011...44,456,371
Ensembl chr12:44,287,614...44,371,837

G

notch receptor 2

decreases expression

EXP

Buspirone results in decreased expression of NOTCH2 mRNA

NCBI chr 2:188,299,336...188,432,823
Ensembl chr 2:188,299,336...188,432,823

G

nuclear receptor subfamily 1, group D, member 2

increases expression

EXP

Buspirone results in increased expression of NR1D2 mRNA

NCBI chr15:9,955,034...9,981,329
Ensembl chr15:9,954,906...9,981,330

G

nuclear receptor subfamily 1, group I, member 2

increases expression

EXP

Buspirone results in increased expression of NR1I2 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor binding protein 2

increases expression

EXP

Buspirone results in increased expression of NRBP2 mRNA

NCBI chr 7:109,679,330...109,685,656
Ensembl chr 7:109,679,330...109,685,588

G

neuronal regeneration related protein

decreases expression

EXP

Buspirone results in decreased expression of NREP mRNA

NCBI chr18:25,291,219...25,320,742
Ensembl chr18:25,291,219...25,320,742

G

NAD(P) dependent 3-beta-hydroxysteroid dehydrogenase NSDHL

decreases expression

EXP

Buspirone results in decreased expression of NSDHL mRNA

NCBI chr X:155,817,301...155,848,224
Ensembl chr X:155,817,340...155,848,220

G

5' nucleotidase, ecto

decreases expression

EXP

Buspirone results in decreased expression of NT5E mRNA

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

nucleoside-triphosphatase, cancer-related

increases expression

EXP

Buspirone results in increased expression of NTPCR mRNA

NCBI chr19:70,598,816...70,612,580
Ensembl chr19:70,593,274...70,613,197

G

nucleobindin 2

decreases expression

EXP

Buspirone results in decreased expression of NUCB2 mRNA

NCBI chr 1:180,185,121...180,221,644
Ensembl chr 1:180,199,551...180,230,116

G

nudix hydrolase 4

increases expression

EXP

Buspirone results in increased expression of NUDT4 mRNA

NCBI chr 7:32,074,978...32,091,491
Ensembl chr 7:32,075,002...32,091,491

G

alpha-2u globulin PGCL4

increases expression

EXP

Buspirone results in increased expression of OBP3 mRNA

NCBI chr 5:79,637,234...79,640,810
Ensembl chr 5:79,637,234...79,640,675

G

Obg-like ATPase 1

decreases expression

EXP

Buspirone results in decreased expression of OLA1 mRNA

NCBI chr 3:78,374,440...78,493,401
Ensembl chr 3:78,374,441...78,492,012

G

5-oxoprolinase (ATP-hydrolysing)

increases expression

EXP

Buspirone results in increased expression of OPLAH mRNA

NCBI chr 7:109,892,136...109,932,403
Ensembl chr 7:109,891,405...109,915,979

G

oxysterol binding protein-like 1A

decreases expression

EXP

Buspirone results in decreased expression of OSBPL1A mRNA

NCBI chr18:4,178,734...4,383,511
Ensembl chr18:4,179,631...4,369,421

G

phosphatase domain containing, paladin 1

increases expression

EXP

Buspirone results in increased expression of PALD1 mRNA

NCBI chr20:29,812,650...29,877,733
Ensembl chr20:29,812,650...29,850,063

G

palmdelphin

decreases expression

EXP

Buspirone results in decreased expression of PALMD mRNA

NCBI chr 2:207,574,413...207,626,239
Ensembl chr 2:207,574,249...207,626,239

G

progestin and adipoQ receptor family member 9

decreases expression

EXP

Buspirone results in decreased expression of PAQR9 mRNA

NCBI chr 8:104,993,884...104,996,180
Ensembl chr 8:104,993,827...104,998,285

G

poly (ADP-ribose) polymerase family, member 14

decreases expression

EXP

Buspirone results in decreased expression of PARP14 mRNA

NCBI chr11:78,408,134...78,440,201
Ensembl chr11:78,408,058...78,440,195

G

phenazine biosynthesis-like protein domain containing 1

increases expression

EXP

Buspirone results in increased expression of PBLD1 mRNA

NCBI chr20:25,549,974...25,565,390
Ensembl chr20:25,549,974...25,565,226

G

proliferating cell nuclear antigen

decreases expression

EXP

Buspirone results in decreased expression of PCNA mRNA

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

phosphatidylcholine transfer protein

decreases expression

EXP

Buspirone results in decreased expression of PCTP mRNA

NCBI chr10:75,305,999...75,351,919
Ensembl chr10:75,305,999...75,326,432

G

phosphate cytidylyltransferase 1A, choline

increases expression

EXP

Buspirone results in increased expression of PCYT1A mRNA

NCBI chr11:81,818,914...81,862,623
Ensembl chr11:81,819,285...81,862,395

G

programmed cell death 4

decreases expression

EXP

Buspirone results in decreased expression of PDCD4 mRNA

NCBI chr 1:262,912,659...262,949,581
Ensembl chr 1:262,926,656...262,950,189

G

phosphodiesterase 4B

decreases expression

EXP

Buspirone results in decreased expression of PDE4B mRNA

NCBI chr 5:122,028,956...122,598,267
Ensembl chr 5:122,135,174...122,598,267

G

protein disulfide isomerase family A, member 5

decreases expression

EXP

Buspirone results in decreased expression of PDIA5 mRNA

NCBI chr11:78,777,436...78,892,370
Ensembl chr11:78,777,419...78,864,329

G

protein disulfide isomerase family A, member 6

decreases expression

EXP

Buspirone results in decreased expression of PDIA6 mRNA

NCBI chr 6:45,791,704...45,808,947
Ensembl chr 6:45,791,678...45,810,091

G

PDZ and LIM domain 1

decreases expression

EXP

Buspirone results in decreased expression of PDLIM1 mRNA

NCBI chr 1:248,991,818...249,040,409
Ensembl chr 1:248,991,818...249,047,379

G

peroxisomal biogenesis factor 11 alpha

increases expression

EXP

Buspirone results in increased expression of PEX11A mRNA

NCBI chr 1:143,089,410...143,096,491
Ensembl chr 1:143,089,410...143,096,645

G

phosphogluconate dehydrogenase

decreases expression

EXP

Buspirone results in decreased expression of PGD mRNA

NCBI chr 5:164,865,830...164,882,029
Ensembl chr 5:164,865,830...164,882,029

G

phosphoglycerate kinase 1

decreases expression

EXP

Buspirone results in decreased expression of PGK1 mRNA

NCBI chr X:75,336,988...75,352,962
Ensembl chr X:75,336,687...75,352,959

G

PHD finger protein 11

decreases expression

EXP

Buspirone results in decreased expression of PHF11 mRNA

NCBI chr15:37,568,090...37,592,490
Ensembl chr15:37,568,090...37,591,016

G

phytanoyl-CoA dioxygenase domain containing 1

increases expression

EXP

Buspirone results in increased expression of PHYHD1 mRNA

NCBI chr 3:33,933,487...33,951,614
Ensembl chr 3:33,937,898...33,951,614

G

Pim-3 proto-oncogene, serine/threonine kinase

increases expression

EXP

Buspirone results in increased expression of PIM3 mRNA

NCBI chr 7:121,822,076...121,836,257
Ensembl chr 7:121,832,742...121,836,259

G

PTEN induced kinase 1

increases expression

EXP

Buspirone results in increased expression of PINK1 mRNA

NCBI chr 5:155,813,838...155,825,950
Ensembl chr 5:155,813,838...155,825,950

G

pyruvate kinase L/R

decreases expression

EXP

Buspirone results in decreased expression of PKLR mRNA

NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644

G

phospholipase A2, group XIIA

increases expression

EXP

Buspirone results in increased expression of PLA2G12A mRNA

NCBI chr 2:221,110,722...221,126,966
Ensembl chr 2:221,110,685...221,126,964

G

phospholipase C beta 1

decreases expression

EXP

Buspirone results in decreased expression of PLCB1 mRNA; Buspirone results in decreased expression of PLCB1 protein

NCBI chr 3:142,512,765...143,224,042
Ensembl chr 3:142,513,033...143,225,646

G

perilipin 2

decreases expression

EXP

Buspirone results in decreased expression of PLIN2 mRNA

NCBI chr 5:106,202,634...106,258,748
Ensembl chr 5:106,202,634...106,258,878

G

perilipin 3

decreases expression

EXP

Buspirone results in decreased expression of PLIN3 mRNA

NCBI chr 9:1,198,336...1,210,212
Ensembl chr 9:1,198,336...1,210,231

G

phospholipid phosphatase 3

increases expression

EXP

Buspirone results in increased expression of PLPP3 mRNA

NCBI chr 5:125,156,000...125,231,119
Ensembl chr 5:125,155,945...125,235,667

G

plexin A2

decreases expression

EXP

Buspirone results in decreased expression of PLXNA2 mRNA

NCBI chr13:108,683,155...108,888,336
Ensembl chr13:108,691,530...108,887,453

G

patatin-like phospholipase domain containing 2

increases expression

EXP

Buspirone results in increased expression of PNPLA2 mRNA

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

patatin-like phospholipase domain containing 7

increases expression

EXP

Buspirone results in increased expression of PNPLA7 mRNA

NCBI chr 3:28,180,670...28,259,673
Ensembl chr 3:28,180,751...28,259,672

G

patatin-like phospholipase domain containing 8

increases expression

EXP

Buspirone results in increased expression of PNPLA8 mRNA

NCBI chr 6:67,056,783...67,118,714
Ensembl chr 6:67,056,697...67,120,512

G

DNA polymerase delta 4, accessory subunit

increases expression

EXP

Buspirone results in increased expression of POLD4 mRNA

NCBI chr 1:210,956,110...210,957,863
Ensembl chr 1:210,956,099...210,957,860

G

DNA polymerase gamma 2, accessory subunit

increases expression

EXP

Buspirone results in increased expression of POLG2 mRNA

NCBI chr10:92,212,303...92,222,849
Ensembl chr10:92,212,304...92,222,726

G

RNA polymerase II subunit B

decreases expression

EXP

Buspirone results in decreased expression of POLR2B mRNA

NCBI chr14:31,151,534...31,189,222
Ensembl chr14:31,151,390...31,189,222

G

polymerase (RNA) II (DNA directed) polypeptide H, pseudogene 1

increases expression

EXP

Buspirone results in increased expression of POLR2H-PS1 mRNA

NCBI chr10:105,353,439...105,357,591

G

proopiomelanocortin

increases expression
multiple interactions

ISO

Buspirone results in increased expression of POMC protein
Imipramine inhibits the reaction [Buspirone results in increased expression of POMC protein]

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

cytochrome p450 oxidoreductase

increases expression

EXP

Buspirone results in increased expression of POR mRNA

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

inorganic pyrophosphatase 1

decreases expression

EXP

Buspirone results in decreased expression of PPA1 mRNA

NCBI chr20:30,132,088...30,160,492
Ensembl chr20:30,133,504...30,160,489

G

peroxisome proliferator-activated receptor gamma

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in decreased expression of PPARG mRNA]

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

phosphopantothenoylcysteine synthetase

increases expression

EXP

Buspirone results in increased expression of PPCS mRNA

NCBI chr 5:138,308,394...138,312,047
Ensembl chr 5:138,308,397...138,312,012

G

protoporphyrinogen oxidase

decreases expression

EXP

Buspirone results in decreased expression of PPOX mRNA

NCBI chr13:86,230,111...86,235,028
Ensembl chr13:86,230,111...86,234,246

G

protein phosphatase 1, regulatory (inhibitor) subunit 14A

decreases expression

EXP

Buspirone results in decreased expression of PPP1R14A mRNA

NCBI chr 1:93,708,269...93,718,218
Ensembl chr 1:93,708,218...93,719,147

G

protein phosphatase 1, regulatory subunit 21

decreases expression

EXP

Buspirone results in decreased expression of PPP1R21 mRNA

NCBI chr 6:11,655,059...11,724,219
Ensembl chr 6:11,655,059...11,724,219

G

protein regulator of cytokinesis 1

decreases expression

EXP

Buspirone results in decreased expression of PRC1 mRNA

NCBI chr 1:143,659,312...143,681,019
Ensembl chr 1:143,659,481...143,681,012

G

peroxiredoxin 5

increases expression

EXP

Buspirone results in increased expression of PRDX5 mRNA

NCBI chr 1:213,529,042...213,532,787
Ensembl chr 1:213,529,035...213,533,020

G

protein kinase cAMP-activated catalytic subunit alpha

decreases expression

EXP

Buspirone results in decreased expression of PRKACA mRNA

NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494

G

prolactin

increases secretion
multiple interactions
increases expression

ISO
EXP

Buspirone results in increased secretion of PRL protein
Pindolol inhibits the reaction [Buspirone results in increased secretion of PRL protein]
Buspirone results in increased expression of PRL protein

PMID:18194152 PMID:19762159

NCBI chr17:38,287,355...38,298,234
Ensembl chr17:38,288,162...38,298,217

G

proline and serine rich 2

increases expression

EXP

Buspirone results in increased expression of PROSER2 mRNA

NCBI chr17:77,061,371...77,096,788
Ensembl chr17:77,077,727...77,095,194

G

proline rich 13

decreases expression

EXP

Buspirone results in decreased expression of PRR13 mRNA

NCBI chr 7:135,471,040...135,474,344
Ensembl chr 7:135,470,933...135,474,579

G

serine protease 23

decreases expression

EXP

Buspirone results in decreased expression of PRSS23 mRNA

NCBI chr 1:152,815,301...152,835,005
Ensembl chr 1:152,813,670...152,947,871

G

presenilin enhancer gamma secretase subunit

increases expression

EXP

Buspirone results in increased expression of PSENEN mRNA

NCBI chr 1:94,942,348...94,943,545
Ensembl chr 1:94,942,225...94,943,752

G

proteasome 20S subunit beta 10

decreases expression

EXP

Buspirone results in decreased expression of PSMB10 mRNA

NCBI chr19:50,740,808...50,743,292
Ensembl chr19:50,740,811...50,743,210

G

proteasome 20S subunit beta 3

increases expression

EXP

Buspirone results in increased expression of PSMB3 mRNA

NCBI chr10:83,193,787...83,200,883
Ensembl chr10:83,193,787...83,200,883

G

proteasome 20S subunit beta 4

increases expression

EXP

Buspirone results in increased expression of PSMB4 mRNA

NCBI chr 2:185,131,787...185,134,561
Ensembl chr 2:185,131,786...185,135,287

G

proteasome 20S subunit beta 8

decreases expression

EXP

Buspirone results in decreased expression of PSMB8 mRNA

NCBI chr20:4,654,068...4,657,049
Ensembl chr20:4,654,068...4,657,031

G

proteasome 20S subunit beta 9

decreases expression

EXP

Buspirone results in decreased expression of PSMB9 mRNA

NCBI chr20:4,668,952...4,674,421
Ensembl chr20:4,668,739...4,674,421

G

prostaglandin reductase 3

increases expression

EXP

Buspirone results in increased expression of PTGR3 mRNA

NCBI chr18:79,729,282...79,738,632
Ensembl chr18:79,729,282...79,738,632

G

prothymosin alpha

decreases expression

EXP

Buspirone results in decreased expression of PTMA mRNA

NCBI chr 9:94,624,194...94,628,276
Ensembl chr 9:94,624,196...94,628,276

G

protein tyrosine phosphatase, receptor type, F

decreases expression

EXP

Buspirone results in decreased expression of PTPRF mRNA

NCBI chr 5:137,027,376...137,109,405
Ensembl chr 5:137,028,164...137,095,426

G

PTTG1 regulator of sister chromatid separation, securin

decreases expression

EXP

Buspirone results in decreased expression of PTTG1 mRNA

NCBI chr10:28,394,940...28,406,410
Ensembl chr10:28,394,814...28,406,309

G

PYD and CARD domain containing

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of PYCARD protein]

NCBI chr 1:192,032,124...192,033,419
Ensembl chr 1:192,032,124...192,033,419

G

glycogen phosphorylase L

decreases expression

EXP

Buspirone results in decreased expression of PYGL mRNA

NCBI chr 6:94,433,558...94,476,219
Ensembl chr 6:94,426,346...94,476,269

G

R3H domain containing 2

decreases expression

EXP

Buspirone results in decreased expression of R3HDM2 mRNA

NCBI chr 7:65,097,685...65,225,863
Ensembl chr 7:65,097,923...65,225,862

G

RAB17, member RAS oncogene family

increases expression

EXP

Buspirone results in increased expression of RAB17 mRNA

NCBI chr 9:99,001,044...99,014,340
Ensembl chr 9:99,001,045...99,014,032

G

RAB29, member RAS oncogene family

increases expression

EXP

Buspirone results in increased expression of RAB29 mRNA

NCBI chr13:45,859,930...45,865,468
Ensembl chr13:45,859,961...45,865,610

G

RAB30, member RAS oncogene family

increases expression

EXP

Buspirone results in increased expression of RAB30 mRNA

NCBI chr 1:156,216,137...156,310,778
Ensembl chr 1:156,216,137...156,310,778

G

RAB34, member RAS oncogene family

increases expression

EXP

Buspirone results in increased expression of RAB34 mRNA

NCBI chr10:63,581,542...63,585,608
Ensembl chr10:63,580,997...63,586,083

G

RAB38, member RAS oncogene family

decreases expression

EXP

Buspirone results in decreased expression of RAB38 mRNA

NCBI chr 1:151,595,153...151,675,492
Ensembl chr 1:151,595,078...151,675,493

G

RAB5 interacting factor

increases expression

EXP

Buspirone results in increased expression of RAB5IF mRNA

NCBI chr 3:165,818,060...165,828,071
Ensembl chr 3:165,816,588...165,828,067

G

RAB7A, member RAS oncogene family

decreases expression

EXP

Buspirone results in decreased expression of RAB7A mRNA

NCBI chr 4:122,019,281...122,068,067
Ensembl chr 4:121,983,938...122,064,185

G

Rab acceptor 1

increases expression

EXP

Buspirone results in increased expression of RABAC1 mRNA

NCBI chr 1:89,691,884...89,695,017
Ensembl chr 1:89,691,884...89,695,017

G

RAN, member RAS oncogene family

decreases expression

EXP

Buspirone results in decreased expression of RAN mRNA

NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317

G

RAN GTPase activating protein 1

decreases expression

EXP

Buspirone results in decreased expression of RANGAP1 mRNA

NCBI chr 7:115,104,820...115,130,564
Ensembl chr 7:115,104,823...115,130,564

G

Rap guanine nucleotide exchange factor 4

increases expression

EXP

Buspirone results in increased expression of RAPGEF4 mRNA

NCBI chr 3:77,217,024...77,509,933
Ensembl chr 3:77,217,039...77,509,978

G

retinoic acid receptor, beta

decreases expression

EXP

Buspirone results in decreased expression of RARB mRNA

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

RB transcriptional corepressor 1

decreases expression

EXP

Buspirone results in decreased expression of RB1 mRNA

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

ribosome binding factor A

decreases expression

EXP

Buspirone results in decreased expression of RBFA mRNA

NCBI chr18:75,914,247...75,923,893
Ensembl chr18:75,914,145...75,939,219

G

regulator of calcineurin 1

decreases expression

EXP

Buspirone results in decreased expression of RCAN1 mRNA

NCBI chr11:45,108,123...45,188,065
Ensembl chr11:45,108,124...45,118,236

G

RNA terminal phosphate cyclase-like 1

increases expression

EXP

Buspirone results in increased expression of RCL1 mRNA

NCBI chr 1:236,238,078...236,282,597
Ensembl chr 1:236,238,031...236,315,894

G

retinol dehydrogenase 11

decreases expression

EXP

Buspirone results in decreased expression of RDH11 mRNA

NCBI chr 6:103,712,373...103,728,247
Ensembl chr 6:103,712,374...103,729,741

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of RELA mRNA]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

reticulophagy regulator 1

increases expression

EXP

Buspirone results in increased expression of RETREG1 mRNA

NCBI chr 2:78,045,435...78,205,316
Ensembl chr 2:78,066,031...78,225,356

G

required for excision 1-B domain containing

increases expression

EXP

Buspirone results in increased expression of REX1BD mRNA

NCBI chr16:18,956,023...18,958,494
Ensembl chr16:18,955,969...18,958,494

G

ras homolog family member B

decreases expression

EXP

Buspirone results in decreased expression of RHOB mRNA

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772

G

RNA sensor RIG-1

decreases expression

EXP

Buspirone results in decreased expression of RIGI mRNA

NCBI chr 5:60,117,398...60,165,995
Ensembl chr 5:60,117,398...60,165,995

G

Rho family GTPase 2

increases expression

EXP

Buspirone results in increased expression of RND2 mRNA

NCBI chr10:86,899,395...86,902,992
Ensembl chr10:86,899,395...86,902,992

G

ring finger protein 125

decreases expression

EXP

Buspirone results in decreased expression of RNF125 mRNA

NCBI chr18:12,528,995...12,550,646
Ensembl chr18:12,528,838...12,554,430

G

ring finger protein 139

increases expression

EXP

Buspirone results in increased expression of RNF139 mRNA

NCBI chr 7:92,329,201...92,340,386
Ensembl chr 7:92,329,157...92,341,721

G

ring finger protein 149

increases expression

EXP

Buspirone results in increased expression of RNF149 mRNA

NCBI chr 9:49,322,524...49,350,361
Ensembl chr 9:49,323,857...49,350,042

G

ring finger protein 26

decreases expression

EXP

Buspirone results in decreased expression of RNF26 mRNA

NCBI chr 8:53,351,388...53,353,586
Ensembl chr 8:53,341,487...53,355,777

G

RAR-related orphan receptor C

decreases expression

EXP

Buspirone results in decreased expression of RORC mRNA

NCBI chr 2:184,698,779...184,723,942
Ensembl chr 2:184,698,818...184,724,566

G

replication protein A1

decreases expression

EXP

Buspirone results in decreased expression of RPA1 mRNA

NCBI chr10:60,647,185...60,698,279
Ensembl chr10:60,647,185...60,698,279

G

replication protein A3

decreases expression

EXP

Buspirone results in decreased expression of RPA3 mRNA

NCBI chr 4:37,270,966...37,273,997
Ensembl chr 4:37,270,966...37,274,183

G

ribulose-5-phosphate-3-epimerase

decreases expression

EXP

Buspirone results in decreased expression of RPE mRNA

NCBI chr 9:75,640,867...75,661,009
Ensembl chr 9:75,640,982...75,661,643

G

ribosomal protein L7-like 1

decreases expression

EXP

Buspirone results in decreased expression of RPL7L1 mRNA

NCBI chr 9:21,695,718...21,703,736
Ensembl chr 9:21,695,707...21,703,735

G

ribophorin I

decreases expression

EXP

Buspirone results in decreased expression of RPN1 mRNA

NCBI chr 4:122,100,976...122,122,382
Ensembl chr 4:122,100,813...122,122,382

G

ribonucleotide reductase regulatory subunit M2

decreases expression

EXP

Buspirone results in decreased expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RT1 class II, locus Ba

decreases expression

EXP

Buspirone results in decreased expression of RT1-BA mRNA

NCBI chr20:4,577,057...4,581,650
Ensembl chr20:4,576,843...4,581,653

G

RT1 class II, locus Da

decreases expression

EXP

Buspirone results in decreased expression of RT1-DA mRNA

NCBI chr20:4,515,393...4,520,387
Ensembl chr20:4,513,908...4,520,383

G

RT1 class II, locus DMb

decreases expression

EXP

Buspirone results in decreased expression of HLA-DMB mRNA

NCBI chr20:4,695,009...4,702,560
Ensembl chr20:4,695,010...4,702,246

G

RT1 class Ib, locus S3

decreases expression

EXP

Buspirone results in decreased expression of RT1-S3 mRNA

NCBI chr20:2,675,463...2,680,229

G

S100 calcium binding protein B

decreases response to substance

ISO

S100B results in decreased susceptibility to Buspirone

NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081

G

SUMO1 activating enzyme subunit 1

decreases expression

EXP

Buspirone results in decreased expression of SAE1 mRNA

NCBI chr 1:86,159,114...86,215,089
Ensembl chr 1:86,159,114...86,215,089

G

spalt-like transcription factor 1

increases expression

EXP

Buspirone results in increased expression of SALL1 mRNA

NCBI chr19:34,179,316...34,196,278
Ensembl chr19:34,181,078...34,196,278

G

secretion associated, Ras related GTPase 1B

increases expression

EXP

Buspirone results in increased expression of SAR1B mRNA

NCBI chr10:36,525,365...36,555,009
Ensembl chr10:36,519,384...36,555,005

G

SAP domain containing ribonucleoprotein

decreases expression

EXP

Buspirone results in decreased expression of SARNP mRNA

NCBI chr 7:1,835,597...1,889,833
Ensembl chr 7:1,835,597...1,897,295

G

spermidine/spermine N1-acetyltransferase family member 2

increases expression

EXP

Buspirone results in increased expression of SAT2 mRNA

NCBI chr10:54,839,531...54,841,651
Ensembl chr10:54,839,189...54,841,958

G

scavenger receptor class B, member 1

decreases expression

EXP

Buspirone results in decreased expression of SCARB1 mRNA

NCBI chr12:36,957,302...37,023,982
Ensembl chr12:36,957,496...37,023,980

G

stearoyl-CoA desaturase

decreases expression

EXP

Buspirone results in decreased expression of SCD1 mRNA

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

sec1 family domain containing 1

decreases expression

EXP

Buspirone results in decreased expression of SCFD1 mRNA

NCBI chr 6:74,531,225...74,609,463
Ensembl chr 6:74,531,276...74,633,750

G

selenocysteine lyase

decreases expression

EXP

Buspirone results in decreased expression of SCLY mRNA

NCBI chr 9:99,337,796...99,358,487
Ensembl chr 9:99,327,873...99,358,487

G

syndecan 4

increases expression

EXP

Buspirone results in increased expression of SDC4 mRNA

NCBI chr 3:173,574,239...173,592,923
Ensembl chr 3:173,574,239...173,593,670

G

stromal cell derived factor 2

increases expression

EXP

Buspirone results in increased expression of SDF2 mRNA

NCBI chr10:63,638,634...63,649,109
Ensembl chr10:63,638,634...63,649,108

G

serine dehydratase

increases expression

EXP

Buspirone results in increased expression of SDS mRNA

NCBI chr12:41,743,796...41,751,108
Ensembl chr12:41,743,799...41,748,773

G

SEC13 homolog, nuclear pore and COPII coat complex component

decreases expression

EXP

Buspirone results in decreased expression of SEC13 mRNA

NCBI chr 4:148,433,344...148,446,735
Ensembl chr 4:148,433,349...148,446,755

G

SEC22 homolog B, vesicle trafficking protein

decreases expression

EXP

Buspirone results in decreased expression of SEC22B mRNA

NCBI chr 2:188,188,783...188,209,565
Ensembl chr 2:188,188,751...188,211,600

G

Sec23 homolog B, COPII coat complex component

decreases expression

EXP

Buspirone results in decreased expression of SEC23B mRNA

NCBI chr 3:152,392,340...152,434,813
Ensembl chr 3:152,392,308...152,434,800

G

SEC61 translocon subunit alpha 1

decreases expression

EXP

Buspirone results in decreased expression of SEC61A1 mRNA

NCBI chr 4:122,530,785...122,545,141
Ensembl chr 4:122,530,789...122,545,141

G

SEC63 homolog, protein translocation regulator

decreases expression

EXP

Buspirone results in decreased expression of SEC63 mRNA

NCBI chr20:47,827,291...47,896,248
Ensembl chr20:47,827,291...47,896,248

G

SECIS binding protein 2-like

decreases expression

EXP

Buspirone results in decreased expression of SECISBP2L mRNA

NCBI chr 3:133,443,023...133,489,467
Ensembl chr 3:133,445,317...133,489,291

G

secreted and transmembrane 1B

decreases expression

EXP

Buspirone results in decreased expression of SECTM1B mRNA

NCBI chr10:106,822,397...106,832,105
Ensembl chr10:106,822,397...106,832,104

G

septin 10

decreases expression

EXP

Buspirone results in decreased expression of SEPTIN10 mRNA

NCBI chr20:27,644,862...27,737,817
Ensembl chr20:27,643,876...27,737,902

G

septin 7

decreases expression

EXP

Buspirone results in decreased expression of SEPTIN7 mRNA

NCBI chr 8:31,995,597...32,059,069
Ensembl chr 8:31,995,005...32,059,072

G

septin 9

decreases expression

EXP

Buspirone results in decreased expression of SEPTIN9 mRNA

NCBI chr10:102,908,557...103,077,789
Ensembl chr10:102,908,560...103,077,788

G

serpin family A member 11

increases expression

EXP

Buspirone results in increased expression of SERPINA11 mRNA

NCBI chr 6:128,668,030...128,677,476
Ensembl chr 6:128,668,034...128,677,454

G

serpin family A member 6

decreases expression

EXP

Buspirone results in decreased expression of SERPINA6 mRNA

NCBI chr 6:128,544,828...128,555,064
Ensembl chr 6:128,544,831...128,555,139

G

serpin family B member 9

decreases expression

EXP

Buspirone results in decreased expression of SERPINB9 mRNA

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

splicing factor 3a, subunit 3

decreases expression

EXP

Buspirone results in decreased expression of SF3A3 mRNA

NCBI chr 5:142,246,556...142,272,053
Ensembl chr 5:142,246,568...142,272,052

G

splicing factor proline and glutamine rich

decreases expression

EXP

Buspirone results in decreased expression of SFPQ mRNA

NCBI chr 5:144,621,678...144,637,930
Ensembl chr 5:144,622,476...144,637,926

G

SFT2 domain containing 2

increases expression

EXP

Buspirone results in increased expression of SFT2D2 mRNA

NCBI chr13:80,017,854...80,037,144
Ensembl chr13:80,008,480...80,037,473

G

serum/glucocorticoid regulated kinase 1

decreases expression

EXP

Buspirone results in decreased expression of SGK1 mRNA

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

sphingosine-1-phosphate phosphatase 1

increases expression

EXP

Buspirone results in increased expression of SGPP1 mRNA

NCBI chr 6:100,161,024...100,182,214
Ensembl chr 6:100,161,024...100,182,259

G

SH3 domain binding glutamate-rich protein like 3

decreases expression

EXP

Buspirone results in decreased expression of SH3BGRL3 mRNA

NCBI chr 5:151,637,897...151,639,270
Ensembl chr 5:151,637,674...151,639,395

G

SH3-domain binding protein 5

increases expression

EXP

Buspirone results in increased expression of SH3BP5 mRNA

NCBI chr16:6,589,877...6,676,524
Ensembl chr16:6,589,877...6,655,211

G

serine hydroxymethyltransferase 2

decreases expression

EXP

Buspirone results in decreased expression of SHMT2 mRNA

NCBI chr 7:65,244,247...65,249,580
Ensembl chr 7:65,244,247...65,249,567

G

SID1 transmembrane family, member 2

increases expression

EXP

Buspirone results in increased expression of SIDT2 mRNA

NCBI chr 8:55,129,091...55,146,446
Ensembl chr 8:55,129,091...55,145,408

G

SIN3 transcription regulator family member B

increases expression

EXP

Buspirone results in increased expression of SIN3B mRNA

NCBI chr16:17,157,352...17,194,051
Ensembl chr16:17,157,352...17,270,664

G

sirtuin 5

decreases expression

EXP

Buspirone results in decreased expression of SIRT5 mRNA

NCBI chr17:21,515,982...21,543,529
Ensembl chr17:21,515,985...21,537,442

G

solute carrier family 17 member 3

decreases expression

EXP

Buspirone results in decreased expression of SLC17A3 mRNA

NCBI chr17:41,698,679...41,729,057
Ensembl chr17:41,698,680...41,723,329

G

solute carrier family 22 member 2

multiple interactions

ISO

Buspirone inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 25 member 17

increases expression

EXP

Buspirone results in increased expression of SLC25A17 mRNA

NCBI chr 7:114,724,533...114,767,163
Ensembl chr 7:114,724,533...114,767,345

G

solute carrier family 25 member 20

increases expression

EXP

Buspirone results in increased expression of SLC25A20 mRNA

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

solute carrier family 25 member 22

increases expression

EXP

Buspirone results in increased expression of SLC25A22 mRNA

NCBI chr 1:205,954,713...205,966,188
Ensembl chr 1:205,958,032...205,965,877

G

solute carrier family 26 member 8

increases expression

EXP

Buspirone results in increased expression of SLC26A8 mRNA

NCBI chr20:6,687,207...6,751,184
Ensembl chr20:6,699,445...6,751,184

G

solute carrier family 27 member 5

increases expression

EXP

Buspirone results in increased expression of SLC27A5 mRNA

NCBI chr 1:82,688,742...82,699,335
Ensembl chr 1:82,688,750...82,699,358

G

solute carrier family 28 member 2

decreases expression

EXP

Buspirone results in decreased expression of SLC28A2 mRNA

NCBI chr 3:129,778,425...129,841,292
Ensembl chr 3:129,807,537...129,841,291

G

solute carrier family 34 member 1

increases expression

EXP

Buspirone results in increased expression of SLC34A1 mRNA

NCBI chr17:9,224,010...9,238,983
Ensembl chr17:9,224,010...9,238,983

G

solute carrier family 34 member 2

decreases expression

EXP

Buspirone results in decreased expression of SLC34A2 mRNA

NCBI chr14:62,123,313...62,153,020
Ensembl chr14:62,123,316...62,143,360

G

solute carrier family 35 member B4

decreases expression

EXP

Buspirone results in decreased expression of SLC35B4 mRNA

NCBI chr 4:63,744,188...63,766,200
Ensembl chr 4:63,744,188...63,766,196

G

solute carrier family 37 member 4

increases expression

EXP

Buspirone results in increased expression of SLC37A4 mRNA

NCBI chr 8:53,619,952...53,626,110
Ensembl chr 8:53,620,141...53,626,110

G

solute carrier family 41 member 2

decreases expression

EXP

Buspirone results in decreased expression of SLC41A2 mRNA

NCBI chr 7:22,271,298...22,378,764
Ensembl chr 7:22,271,313...22,378,764

G

solute carrier family 49 member 4

increases expression

EXP

Buspirone results in increased expression of SLC49A4 mRNA

NCBI chr11:78,500,918...78,574,205
Ensembl chr11:78,500,960...78,574,202

G

solute carrier organic anion transporter family, member 1a4

increases expression

EXP

Buspirone results in increased expression of SLCO1A2 mRNA

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

schlafen 3

decreases expression

EXP

Buspirone results in decreased expression of SLFN3 mRNA

NCBI chr10:68,515,815...68,557,674

G

small integral membrane protein 26

increases expression

EXP

Buspirone results in increased expression of SMIM26 mRNA

NCBI chr 3:152,443,397...152,445,102
Ensembl chr 3:152,443,579...152,445,447

G

SPARC related modular calcium binding 1

increases expression

EXP

Buspirone results in increased expression of SMOC1 mRNA

NCBI chr 6:106,432,592...106,593,956
Ensembl chr 6:106,432,603...106,593,956

G

staphylococcal nuclease and tudor domain containing 1

decreases expression

EXP

Buspirone results in decreased expression of SND1 mRNA

NCBI chr 4:58,060,689...58,459,926
Ensembl chr 4:58,060,640...58,459,925

G

small nuclear ribonucleoprotein U11/U12 subunit 25

increases expression

EXP

Buspirone results in increased expression of SNRNP25 mRNA

NCBI chr10:15,924,932...15,928,279
Ensembl chr10:15,924,940...15,928,252

G

superoxide dismutase 3

decreases expression

EXP

Buspirone results in decreased expression of SOD3 mRNA

NCBI chr14:62,822,865...62,828,602
Ensembl chr14:62,811,177...62,829,125

G

secreted protein acidic and cysteine rich

decreases expression

EXP

Buspirone results in decreased expression of SPARC mRNA

NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268

G

spartin

decreases expression

EXP

Buspirone results in decreased expression of SPART mRNA

NCBI chr 2:141,442,770...141,469,388
Ensembl chr 2:141,442,737...141,469,382

G

signal peptidase complex subunit 2

decreases expression

EXP

Buspirone results in decreased expression of SPCS2 mRNA

NCBI chr 1:163,575,842...163,595,269
Ensembl chr 1:163,575,842...163,595,271

G

SPG21 abhydrolase domain containing, maspardin

increases expression

EXP

Buspirone results in increased expression of SPG21 mRNA

NCBI chr 8:74,876,136...74,903,676
Ensembl chr 8:74,876,136...74,903,676

G

serine peptidase inhibitor, Kazal type 1

increases expression

EXP

Buspirone results in increased expression of SPINK1 mRNA

NCBI chr18:36,121,626...36,133,596
Ensembl chr18:36,076,399...36,133,545

G

SPNS lysolipid transporter 1, lysophospholipid

increases expression

EXP

Buspirone results in increased expression of SPNS1 mRNA

NCBI chr 1:190,372,663...190,380,192
Ensembl chr 1:190,372,666...190,379,943

G

serine palmitoyltransferase, small subunit A

increases expression

EXP

Buspirone results in increased expression of SPTSSA mRNA

NCBI chr 6:77,879,931...77,891,344
Ensembl chr 6:77,879,941...77,891,403

G

sterol regulatory element binding transcription factor 1

decreases expression

EXP

Buspirone results in decreased expression of SREBF1 mRNA

NCBI chr10:45,507,152...45,529,164
Ensembl chr10:45,507,152...45,529,164

G

serglycin

decreases expression

EXP

Buspirone results in decreased expression of SRGN mRNA

NCBI chr20:30,985,508...31,022,296
Ensembl chr20:30,985,508...31,000,327

G

signal recognition particle 72

decreases expression

EXP

Buspirone results in decreased expression of SRP72 mRNA

NCBI chr14:31,522,424...31,549,978
Ensembl chr14:31,522,963...31,550,151

G

SRP receptor subunit alpha

decreases expression

EXP

Buspirone results in decreased expression of SRPRA mRNA

NCBI chr 8:41,818,199...41,824,292
Ensembl chr 8:41,818,229...41,824,280

G

SRP receptor subunit beta

decreases expression

EXP

Buspirone results in decreased expression of SRPRB mRNA

NCBI chr 8:112,647,577...112,661,524

G

serine/arginine repetitive matrix 2

increases expression

EXP

Buspirone results in increased expression of SRRM2 mRNA

NCBI chr10:13,320,059...13,353,337
Ensembl chr10:13,320,059...13,353,337

G

serine and arginine rich splicing factor 2

decreases expression

EXP

Buspirone results in decreased expression of SRSF2 mRNA

NCBI chr10:102,550,962...102,554,200
Ensembl chr10:102,553,072...102,554,141

G

serine and arginine rich splicing factor 3

decreases expression

EXP

Buspirone results in decreased expression of SRSF3 mRNA

NCBI chr20:7,093,529...7,103,517
Ensembl chr20:7,093,565...7,103,516

G

serine and arginine rich splicing factor 4

increases expression

EXP

Buspirone results in increased expression of SRSF4 mRNA

NCBI chr 5:149,345,538...149,373,309
Ensembl chr 5:149,345,422...149,374,609

G

signal sequence receptor subunit 1

decreases expression

EXP

Buspirone results in decreased expression of SSR1 mRNA

NCBI chr17:27,039,203...27,067,352
Ensembl chr17:27,039,269...27,067,348

G

SSX family member 2 interacting protein

decreases expression

EXP

Buspirone results in decreased expression of SSX2IP mRNA

NCBI chr 2:237,958,286...237,991,026
Ensembl chr 2:237,958,465...237,991,017

G

ST6 beta-galactoside alpha-2,6-sialyltransferase 1

decreases expression

EXP

Buspirone results in decreased expression of ST6GAL1 mRNA

NCBI chr11:91,031,481...91,158,111
Ensembl chr11:91,032,450...91,040,415

G

SH3 and cysteine rich domain 3

decreases expression

EXP

Buspirone results in decreased expression of STAC3 mRNA

NCBI chr 7:65,227,151...65,235,884
Ensembl chr 7:65,228,352...65,235,878

G

signal transducing adaptor family member 2

increases expression

EXP

Buspirone results in increased expression of STAP2 mRNA

NCBI chr 9:915,546...924,604
Ensembl chr 9:915,550...924,380

G

StAR-related lipid transfer domain containing 5

decreases expression

EXP

Buspirone results in decreased expression of STARD5 mRNA

NCBI chr 1:147,015,304...147,025,170
Ensembl chr 1:147,015,299...147,026,351

G

signal transducer and activator of transcription 1

decreases expression

EXP

Buspirone results in decreased expression of STAT1 mRNA

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

starch binding domain 1

increases expression

EXP

Buspirone results in increased expression of STBD1 mRNA

NCBI chr14:15,754,769...15,758,174
Ensembl chr14:15,754,644...15,761,659

G

STEAP3 metalloreductase

decreases expression

EXP

Buspirone results in decreased expression of STEAP3 mRNA

NCBI chr13:33,904,710...33,950,100
Ensembl chr13:33,904,710...33,950,080

G

stathmin 1

decreases expression

EXP

Buspirone results in decreased expression of STMN1 mRNA

NCBI chr 5:151,964,308...151,970,843
Ensembl chr 5:151,964,351...151,970,842

G

small ubiquitin-like modifier 3

decreases expression

EXP

Buspirone results in decreased expression of SUMO3 mRNA

NCBI chr20:11,009,730...11,020,502
Ensembl chr20:11,009,734...11,020,287

G

Sad1 and UNC84 domain containing 2

increases expression

EXP

Buspirone results in increased expression of SUN2 mRNA

NCBI chr 7:113,155,766...113,172,950
Ensembl chr 7:113,155,766...113,172,940

G

small VCP interacting protein

increases expression

EXP

Buspirone results in increased expression of SVIP mRNA

NCBI chr 1:110,723,051...110,728,741
Ensembl chr 1:110,723,051...110,729,075

G

transgelin 2

decreases expression

EXP

Buspirone results in decreased expression of TAGLN2 mRNA

NCBI chr13:87,499,350...87,506,328
Ensembl chr13:87,499,394...87,506,330

G

threonyl-tRNA synthetase 1

decreases expression

EXP

Buspirone results in decreased expression of TARS1 mRNA

NCBI chr 2:62,095,978...62,114,802
Ensembl chr 2:62,087,763...62,114,802

G

transcription elongation regulator 1

decreases expression

EXP

Buspirone results in decreased expression of TCERG1 mRNA

NCBI chr18:34,756,558...34,817,441
Ensembl chr18:34,756,725...34,817,441

G

T-cell immune regulator 1, ATPase H+ transporting V0 subunit A3

decreases expression

EXP

Buspirone results in decreased expression of TCIRG1 mRNA

NCBI chr 1:210,556,270...210,568,021
Ensembl chr 1:210,556,270...210,568,033

G

T-cell leukemia translocation altered

increases expression

EXP

Buspirone results in increased expression of TCTA mRNA

NCBI chr 8:117,867,153...117,871,132
Ensembl chr 8:117,867,153...117,871,331

G

tryptophan 2,3-dioxygenase

increases expression

EXP

Buspirone results in increased expression of TDO2 mRNA

NCBI chr 2:169,567,656...169,585,586
Ensembl chr 2:169,567,654...169,585,586

G

TEF transcription factor, PAR bZIP family member

increases expression

EXP

Buspirone results in increased expression of TEF mRNA

NCBI chr 7:115,197,180...115,221,930
Ensembl chr 7:115,193,282...115,221,928

G

terminal nucleotidyltransferase 2

decreases expression

EXP

Buspirone results in decreased expression of TENT2 mRNA

NCBI chr 2:26,115,150...26,167,465
Ensembl chr 2:26,115,240...26,167,113

G

testis expressed 264

increases expression

EXP

Buspirone results in increased expression of TEX264 mRNA

NCBI chr 8:116,174,517...116,201,578
Ensembl chr 8:116,174,518...116,201,667

G

trafficking from ER to golgi regulator

decreases expression

EXP

Buspirone results in decreased expression of TFG mRNA

NCBI chr11:57,354,607...57,381,071
Ensembl chr11:57,354,687...57,382,267

G

transglutaminase 2

decreases expression

EXP

Buspirone results in decreased expression of TGM2 mRNA

NCBI chr 3:167,192,612...167,221,845
Ensembl chr 3:167,192,612...167,304,240

G

thyroid hormone responsive

decreases expression

EXP

Buspirone results in decreased expression of THRSP mRNA

NCBI chr 1:161,134,640...161,138,964
Ensembl chr 1:161,133,453...161,139,827

G

translocase of inner mitochondrial membrane 10B

increases expression

EXP

Buspirone results in increased expression of TIMM10B mRNA

NCBI chr 1:169,392,355...169,395,201
Ensembl chr 1:169,392,177...169,395,205

G

triokinase and FMN cyclase

decreases expression

EXP

Buspirone results in decreased expression of TKFC mRNA

NCBI chr 1:216,664,446...216,677,815
Ensembl chr 1:216,661,477...216,677,928

G

transketolase

decreases expression

EXP

Buspirone results in decreased expression of TKT mRNA

NCBI chr16:5,729,381...5,755,170
Ensembl chr16:5,729,991...5,756,431

G

TLE family member 1, transcriptional corepressor

increases expression

EXP

Buspirone results in increased expression of TLE1 mRNA

NCBI chr 5:90,898,182...90,982,118
Ensembl chr 5:90,898,182...90,980,928

G

TM2 domain containing 2

increases expression

EXP

Buspirone results in increased expression of TM2D2 mRNA

NCBI chr16:73,719,331...73,724,853
Ensembl chr16:73,719,332...73,724,981

G

TM2 domain containing 3

increases expression

EXP

Buspirone results in increased expression of TM2D3 mRNA

NCBI chr 1:128,677,680...128,687,580
Ensembl chr 1:128,677,629...128,687,580

G

transmembrane p24 trafficking protein 9

decreases expression

EXP

Buspirone results in decreased expression of TMED9 mRNA

NCBI chr17:9,034,797...9,039,311
Ensembl chr17:9,034,823...9,039,319

G

transmembrane protein 106B

increases expression

EXP

Buspirone results in increased expression of TMEM106B mRNA

NCBI chr 4:42,294,074...42,313,426
Ensembl chr 4:42,294,101...42,313,407

G

transmembrane protein 14C

increases expression

EXP

Buspirone results in increased expression of TMEM14C mRNA

NCBI chr17:23,939,501...23,945,622
Ensembl chr17:23,939,509...23,959,055

G

transmembrane protein 203

increases expression

EXP

Buspirone results in increased expression of TMEM203 mRNA

NCBI chr 3:28,469,062...28,469,890
Ensembl chr 3:28,465,345...28,472,140

G

transmembrane protein 205

increases expression

EXP

Buspirone results in increased expression of TMEM205 mRNA

NCBI chr 8:28,728,172...28,733,908
Ensembl chr 8:28,728,172...28,733,908

G

transmembrane protein 214

decreases expression

EXP

Buspirone results in decreased expression of TMEM214 mRNA

NCBI chr 6:31,222,635...31,231,659
Ensembl chr 6:31,222,635...31,230,381

G

transmembrane protein 250

increases expression

EXP

Buspirone results in increased expression of TMEM250 mRNA

NCBI chr 3:29,360,770...29,364,756
Ensembl chr 3:29,360,770...29,364,462

G

transmembrane protein 256

increases expression

EXP

Buspirone results in increased expression of TMEM256 mRNA

NCBI chr10:55,056,959...55,058,869
Ensembl chr10:55,056,760...55,058,862

G

transmembrane protein 263

decreases expression

EXP

Buspirone results in decreased expression of TMEM263 mRNA

NCBI chr 7:20,497,852...20,516,011
Ensembl chr 7:20,497,852...20,516,428

G

transmembrane protein 33

increases expression

EXP

Buspirone results in increased expression of TMEM33 mRNA

NCBI chr14:41,242,358...41,264,586
Ensembl chr14:41,242,358...41,264,586

G

transmembrane protein 38B

increases expression

EXP

Buspirone results in increased expression of TMEM38B mRNA

NCBI chr 5:73,255,662...73,291,383
Ensembl chr 5:73,255,632...73,292,384

G

transmembrane protein 59

increases expression

EXP

Buspirone results in increased expression of TMEM59 mRNA

NCBI chr 5:127,191,320...127,212,436
Ensembl chr 5:127,191,030...127,217,531

G

transmembrane protein 97

decreases expression

EXP

Buspirone results in decreased expression of TMEM97 mRNA

NCBI chr10:63,936,276...63,945,359
Ensembl chr10:63,936,271...63,945,818

G

thymosin beta 4, X-linked

decreases expression

EXP

Buspirone results in decreased expression of TMSB4X mRNA

NCBI chr X:30,761,611...30,763,612
Ensembl chr X:30,761,612...30,763,613

G

thiol methyltransferase 1A

increases expression

EXP

Buspirone results in increased expression of TMT1A mRNA

NCBI chr 7:133,330,141...133,377,172
Ensembl chr 7:133,330,447...133,338,959

G

thioredoxin-related transmembrane protein 2

decreases expression

EXP

Buspirone results in decreased expression of TMX2 mRNA

NCBI chr 3:90,161,628...90,169,278
Ensembl chr 3:90,160,930...90,169,278

G

tumor necrosis factor

multiple interactions

EXP

Buspirone inhibits the reaction [Methotrexate results in increased expression of TNF protein]

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

tumor protein p53

decreases expression

EXP

Buspirone results in decreased expression of TP53 mRNA

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tropomyosin 1

decreases expression

EXP

Buspirone results in decreased expression of TPM1 mRNA

NCBI chr 8:76,516,654...76,543,661
Ensembl chr 8:76,511,871...76,543,468

G

tropomyosin 3

decreases expression

EXP

Buspirone results in decreased expression of TPM3 mRNA

NCBI chr 2:177,812,534...177,842,661
Ensembl chr 2:177,814,883...177,842,660

G

tropomyosin 4

decreases expression

EXP

Buspirone results in decreased expression of TPM4 mRNA

NCBI chr16:17,718,442...17,732,483
Ensembl chr16:17,717,230...17,732,494

G

tripartite motif-containing 5

decreases expression

EXP

Buspirone results in decreased expression of TRIM5 mRNA

NCBI chr 1:168,132,277...168,149,263
Ensembl chr 1:168,132,308...168,141,657

G

TSC22 domain family, member 3

increases expression

EXP

Buspirone results in increased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

tetratricopeptide repeat domain 13

decreases expression

EXP

Buspirone results in decreased expression of TTC13 mRNA

NCBI chr19:69,534,989...69,589,590
Ensembl chr19:69,534,989...69,589,563

G

tubulin, alpha 1C

decreases expression

EXP

Buspirone results in decreased expression of TUBA1C mRNA

NCBI chr 7:131,636,974...132,078,589
Ensembl chr 7:132,070,536...132,079,311

G

tubulin, alpha 4A

decreases expression

EXP

Buspirone results in decreased expression of TUBA4A mRNA

NCBI chr 9:84,158,871...84,174,041
Ensembl chr 9:84,158,280...84,162,584

G

tubulin, beta 2A class IIa

decreases expression

EXP

Buspirone results in decreased expression of TUBB2A mRNA

NCBI chr17:31,002,186...31,006,057
Ensembl chr17:30,983,387...31,006,838

G

tubulin, beta 4B class IVb

decreases expression

EXP

Buspirone results in decreased expression of TUBB4B mRNA

NCBI chr 3:28,435,999...28,438,455
Ensembl chr 3:28,435,148...28,439,719

G

tubulin, beta 5 class I

decreases expression

EXP

Buspirone results in decreased expression of TUBB5 mRNA

NCBI chr20:2,917,577...2,921,726
Ensembl chr20:2,917,539...2,921,726

G

Tu translation elongation factor, mitochondrial

decreases expression

EXP

Buspirone results in decreased expression of TUFM mRNA

NCBI chr 1:190,504,373...190,507,980
Ensembl chr 1:190,504,373...190,508,952

G

ubiquitin-conjugating enzyme E2C

decreases expression

EXP

Buspirone results in decreased expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

ubiquitin-conjugating enzyme E2S

decreases expression

EXP

Buspirone results in decreased expression of UBE2S mRNA

NCBI chr 1:78,057,659...78,061,719
Ensembl chr 1:78,057,598...78,081,628

G

UBX domain protein 1

increases expression

EXP

Buspirone results in increased expression of UBXN1 mRNA

NCBI chr 1:215,194,418...215,198,343
Ensembl chr 1:215,174,216...215,198,343

G

UDP glucuronosyltransferase family 1 member A6

increases expression

EXP

Buspirone results in increased expression of UGT1A6 mRNA

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

unc-51 like autophagy activating kinase 1

increases expression

EXP

Buspirone results in increased expression of ULK1 mRNA

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746

G

uridine monophosphate synthetase

decreases expression

EXP

Buspirone results in decreased expression of UMPS mRNA

NCBI chr11:80,311,269...80,321,678
Ensembl chr11:80,311,214...80,327,828

G

unconventional SNARE in the ER 1

increases expression

EXP

Buspirone results in increased expression of USE1 mRNA

NCBI chr16:18,069,118...18,075,816
Ensembl chr16:18,070,793...18,075,814

G

vesicle-associated membrane protein 7

increases expression

EXP

Buspirone results in increased expression of VAMP7 mRNA

NCBI chr12:21,842,206...21,958,556
Ensembl chr12:21,842,228...21,958,552

G

vimentin

decreases expression

EXP

Buspirone results in decreased expression of VIM mRNA

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vanin 1

increases expression

EXP

Buspirone results in increased expression of VNN1 mRNA

NCBI chr 1:23,356,324...23,366,629
Ensembl chr 1:23,356,330...23,366,629

G

von Willebrand factor A domain containing 8

increases expression

EXP

Buspirone results in increased expression of VWA8 mRNA

NCBI chr15:60,661,764...60,985,971
Ensembl chr15:60,661,877...60,985,971

G

WASP like actin nucleation promoting factor

increases expression

EXP

Buspirone results in increased expression of WASL mRNA

NCBI chr 4:54,049,081...54,097,653
Ensembl chr 4:54,049,082...54,097,570

G

WW domain binding protein 1-like

increases expression

EXP

Buspirone results in increased expression of WBP1L mRNA

NCBI chr 1:255,413,701...255,470,026
Ensembl chr 1:255,413,524...255,470,026

G

WD repeat domain, phosphoinositide interacting 1

increases expression

EXP

Buspirone results in increased expression of WIPI1 mRNA

NCBI chr10:95,042,451...95,079,679
Ensembl chr10:95,042,441...95,079,293

G

xanthine dehydrogenase

decreases expression

EXP

Buspirone results in decreased expression of XDH mRNA

NCBI chr 6:27,282,319...27,344,022
Ensembl chr 6:27,282,057...27,344,350

G

XPC complex subunit, DNA damage recognition and repair factor

decreases expression

EXP

Buspirone results in decreased expression of XPC mRNA

NCBI chr 4:125,550,833...125,578,084
Ensembl chr 4:125,550,833...125,578,305

G

exportin 1

decreases expression

EXP

Buspirone results in decreased expression of XPO1 mRNA

NCBI chr14:101,434,450...101,476,705
Ensembl chr14:101,434,517...101,476,714

G

xylulokinase

increases expression

EXP

Buspirone results in increased expression of XYLB mRNA

NCBI chr 8:127,971,194...128,012,511
Ensembl chr 8:127,966,100...128,006,571

G

tyrosyl-tRNA synthetase 1

decreases expression

EXP

Buspirone results in decreased expression of YARS1 mRNA

NCBI chr 5:146,820,163...146,848,377
Ensembl chr 5:146,819,358...146,848,377

G

Y box binding protein 3

decreases expression

EXP

Buspirone results in decreased expression of YBX3 mRNA

NCBI chr 4:166,861,180...166,884,532
Ensembl chr 4:166,861,181...166,884,691

G

yippee-like 5

increases expression

EXP

Buspirone results in increased expression of YPEL5 mRNA

NCBI chr 6:28,408,079...28,423,536
Ensembl chr 6:28,408,080...28,412,385

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

decreases expression

EXP

Buspirone results in decreased expression of YWHAH mRNA

NCBI chr14:81,920,819...81,930,202
Ensembl chr14:81,920,590...81,947,930

G

zinc finger and BTB domain containing 20

increases expression

EXP

Buspirone results in increased expression of ZBTB20 mRNA

NCBI chr11:70,558,010...71,297,039
Ensembl chr11:70,580,930...70,736,237

G

zinc finger protein 354A

increases expression

EXP

Buspirone results in increased expression of ZFP354A mRNA

NCBI chr10:35,897,217...35,909,063
Ensembl chr10:35,897,228...35,909,510

G

zinc finger protein 446

increases expression

EXP

Buspirone results in increased expression of ZFP446 mRNA

NCBI chr 1:82,673,920...82,680,414
Ensembl chr 1:82,673,918...82,685,430

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of ABCB1 mRNA
Cycloheximide inhibits the reaction [[Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [[Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein] which results in increased uptake of (N-5-(4-nitrobenzofurazan-7-yl)lysyl(8))cyclosporine]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of and results in increased activity of ABCB1 protein]; Cycloheximide inhibits the reaction [tetrabromobisphenol A results in increased expression of and results in increased activity of ABCB1A protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of and results in increased activity of ABCB1 protein]
Cycloheximide promotes the reaction [Reserpine results in increased expression of ABCB1 mRNA]

PMID:7476894 PMID:18474546 PMID:30830211

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP binding cassette subfamily B member 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of ABCB4 mRNA]

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of ABCC3 mRNA
Cycloheximide results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 5

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of ABCC5 mRNA
Cycloheximide results in decreased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

acyl-CoA synthetase long-chain family member 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of ACSL3 mRNA

NCBI chr 9:87,563,601...87,613,078
Ensembl chr 9:87,563,601...87,613,097

G

acyl-CoA synthetase long-chain family member 6

multiple interactions

EXP

Cycloheximide inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of ACSL6 mRNA]

NCBI chr10:38,940,668...38,999,515
Ensembl chr10:38,940,747...39,002,873

G

ADAM metallopeptidase domain 17

decreases stability
multiple interactions

ISO

Cycloheximide results in decreased stability of ADAM17 protein
cordycepin inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]; N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein]

NCBI chr 6:46,601,583...46,663,690
Ensembl chr 6:46,601,583...46,649,344

G

ADAM metallopeptidase domain 9

multiple interactions

ISO

Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of ADAM9 protein]

NCBI chr16:73,725,186...73,804,284
Ensembl chr16:73,725,114...73,804,646

G

adrenomedullin

multiple interactions
increases expression

ISO

Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of ADM mRNA]
Cycloheximide results in increased expression of ADM mRNA

NCBI chr 1:174,164,178...174,182,372
Ensembl chr 1:174,178,773...174,182,371

G

adenosine A2B receptor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:47,439,701...47,456,091

G

adrenoceptor beta 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of ADRB2 mRNA; Cycloheximide results in increased expression of ADRB2 protein
[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA; Cycloheximide inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of ADRB2 protein]; Formoterol Fumarate promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]; N(6)-benzoyl-cyclic AMP promotes the reaction [Cycloheximide results in increased expression of ADRB2 mRNA]

PMID:22483689 PMID:24705868

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

argonaute RISC catalytic component 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA]

NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:143,926,501...143,998,737

G

aryl hydrocarbon receptor

multiple interactions
increases localization
decreases expression

ISO

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of AHR protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased degradation of and results in decreased expression of AHR protein]
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Tretinoin co-treated with Cycloheximide] results in increased expression of AHR mRNA; AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased degradation of AHR protein]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin affects the localization of AHR protein]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]
Cycloheximide results in increased localization of AHR protein

PMID:9145908 PMID:10777561 PMID:12002481 PMID:12147270 PMID:15385644 More...

NCBI chr 6:57,961,423...57,998,901
Ensembl chr 6:57,961,423...57,998,901

G

A-kinase anchoring protein 5

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP5 mRNA]

NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620

G

A-kinase anchoring protein 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AKAP6 mRNA]

NCBI chr 6:75,919,350...76,359,667
Ensembl chr 6:75,919,513...76,355,036

G

aldo-keto reductase family 1, member C3

multiple interactions

ISO

Cycloheximide inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein]

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

EXP
ISO

Cycloheximide inhibits the reaction [[Hydrogen Peroxide co-treated with sodium arsenite] results in increased phosphorylation of AKT1 protein]
Cycloheximide results in increased phosphorylation of AKT1 protein

PMID:12472888 PMID:28634229

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH1A3 mRNA

NCBI chr 1:129,392,516...129,436,552
Ensembl chr 1:129,392,516...129,427,777

G

aldehyde dehydrogenase 3 family, member A1

multiple interactions

EXP

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of ALDH3A1 mRNA]

NCBI chr10:46,392,464...46,402,151
Ensembl chr10:46,392,411...46,402,151

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ALDH3A2 mRNA

NCBI chr10:46,427,789...46,448,449
Ensembl chr10:46,407,993...46,448,648

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ALOX5AP mRNA]

NCBI chr12:10,785,254...10,809,295
Ensembl chr12:10,785,257...10,817,038

G

alkaline phosphatase, intestinal

decreases activity
multiple interactions

ISO
EXP

Cycloheximide results in decreased activity of ALPI protein
Cycloheximide inhibits the reaction [Fish Oils results in increased activity of ALPI protein]

PMID:15599000 PMID:20362602

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

anti-Mullerian hormone receptor type 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AMHR2 mRNA]

NCBI chr 7:133,579,152...133,588,874
Ensembl chr 7:135,457,922...135,471,104

G

ankyrin 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ANK2 mRNA]

NCBI chr 2:218,052,555...218,628,414
Ensembl chr 2:218,052,555...218,537,259

G

ankyrin repeat domain 27

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ANKRD27 mRNA

NCBI chr 1:97,387,997...97,440,501
Ensembl chr 1:97,388,099...97,440,501

G

amine oxidase, copper containing 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of AOC1 protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased activity of AOC1 protein]

PMID:2860926 PMID:6218830

NCBI chr 4:79,143,126...79,162,705
Ensembl chr 4:79,143,126...79,162,704

G

apoptotic peptidase activating factor 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of APAF1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of APAF1 mRNA

NCBI chr 7:27,381,392...27,466,772
Ensembl chr 7:27,381,855...27,466,772

G

aquaporin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of AQP1 mRNA]

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 4

multiple interactions

EXP

[Lactic Acid co-treated with Cycloheximide] results in increased expression of AQP4 protein

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

amphiregulin

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of AREG mRNA
Cycloheximide results in increased expression of AREG mRNA

PMID:15072547 PMID:15228094

NCBI chr14:17,256,384...17,265,641
Ensembl chr14:17,256,384...17,265,641

G

armadillo repeat containing 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ARMC5 mRNA

NCBI chr 1:192,250,580...192,257,347
Ensembl chr 1:192,249,939...192,257,348

G

aryl hydrocarbon receptor nuclear translocator

multiple interactions

ISO

[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]

PMID:12002481 PMID:20570689

NCBI chr 2:185,686,703...185,745,546
Ensembl chr 2:185,680,683...185,745,546

G

ankyrin repeat and SOCS box-containing 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ASB1 mRNA

NCBI chr 9:99,566,852...99,588,321
Ensembl chr 9:99,567,867...99,583,907

G

asparagine synthetase (glutamine-hydrolyzing)

multiple interactions

EXP

Cycloheximide inhibits the reaction [Methotrexate results in increased activity of ASNS protein]

NCBI chr 4:36,752,061...36,769,970
Ensembl chr 4:36,751,802...36,776,050

G

activating transcription factor 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF3 protein]

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

activating transcription factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased expression of ATF4]]; Cycloheximide inhibits the reaction [Capsaicin results in increased expression of ATF4 protein]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of ATF4 protein]

PMID:18533110 PMID:23593480 PMID:24057571

NCBI chr 7:113,684,681...113,686,739
Ensembl chr 7:113,684,681...113,686,739

G

autophagy related 13

decreases expression

ISO

Cycloheximide results in decreased expression of ATG13 protein

NCBI chr 3:98,102,831...98,136,741
Ensembl chr 3:98,101,552...98,136,743

G

ATPase copper transporting alpha

multiple interactions
decreases expression

EXP

cupric chloride inhibits the reaction [Cycloheximide results in decreased expression of ATP7A protein]

NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093

G

arginine vasopressin receptor 1A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of AVPR1A mRNA]

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837

G

BTB domain and CNC homolog 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of BACH1 protein
tetrachlorobenzoquinone promotes the reaction [Cycloheximide results in decreased expression of BACH1 protein]

NCBI chr11:40,425,721...40,461,118
Ensembl chr11:40,425,664...40,461,277

G

BRCA1 associated deubiquitinase 1

multiple interactions

ISO

BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]

NCBI chr16:6,453,126...6,461,952
Ensembl chr16:6,452,974...6,461,952

G

BCL2 associated X, apoptosis regulator

multiple interactions

EXP

Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

gamma-butyrobetaine hydroxylase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BBOX1 mRNA]

NCBI chr 3:117,277,226...117,326,383
Ensembl chr 3:117,277,226...117,326,064

G

BCL2, apoptosis regulator

multiple interactions

ISO

BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased phosphorylation of BCL2 protein]

PMID:11726273 PMID:22343715 PMID:34303041

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of BCL2L1 protein alternative form
Dexamethasone inhibits the reaction [Cycloheximide results in increased expression of BCL2L1 protein]

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

Bcl2-like 14

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of BCL2L14 mRNA

NCBI chr 4:167,217,561...167,258,723
Ensembl chr 4:168,948,946...168,990,079

G

3-hydroxybutyrate dehydrogenase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of BDH1 mRNA]

NCBI chr11:82,806,125...82,848,133
Ensembl chr11:82,807,503...82,842,636

G

beclin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

bone gamma-carboxyglutamate protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of BGLAP mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of BGLAP mRNA]

NCBI chr 2:176,136,341...176,137,318
Ensembl chr 2:176,136,341...176,137,318

G

BH3 interacting domain death agonist

multiple interactions

ISO

[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; Cycloheximide inhibits the reaction [vorinostat results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]

PMID:11535817 PMID:12925536

NCBI chr 4:155,785,366...155,808,775
Ensembl chr 4:155,785,377...155,808,275

G

BCL2 interacting protein 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]

NCBI chr 1:203,137,778...203,154,962
Ensembl chr 1:203,137,778...203,154,962

G

BRCA1, DNA repair associated

multiple interactions

ISO

Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA1 mRNA]
BAP1 inhibits the reaction [Cycloheximide results in increased degradation of BRCA1 protein]; Cycloheximide inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA]

PMID:10344722 PMID:29576526 PMID:37414201

NCBI chr10:86,917,693...86,978,012
Ensembl chr10:86,917,693...86,977,763

G

BRCA2, DNA repair associated

multiple interactions

ISO

Cycloheximide inhibits the reaction [Nitrogen Mustard Compounds results in decreased expression of BRCA2 mRNA]

NCBI chr12:4,895,092...4,939,340
Ensembl chr12:4,895,447...4,936,194

G

calbindin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CALB1 mRNA]

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

calcium modulating ligand

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CAMLG mRNA]

NCBI chr17:8,997,868...9,009,140
Ensembl chr17:8,997,272...9,009,012

G

caspase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of CASP1 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of CASP1 protein modified form]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP1 mRNA]

PMID:11007951 PMID:26901245

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

caspase 3

multiple interactions
increases activity

ISO
EXP

[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; IFI6 protein inhibits the reaction [Cycloheximide results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [aluminum maltolate results in increased activity of CASP3 protein]; Cycloheximide inhibits the reaction [Cryptoxanthins promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]
obeticholic acid promotes the reaction [Cycloheximide results in increased activity of CASP3 protein]

PMID:12760867 PMID:12925536 PMID:14502240 PMID:15537749 PMID:15685448 More...

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CASP4 mRNA]

NCBI chr 8:10,883,817...10,919,978
Ensembl chr 8:10,883,769...10,920,727

G

caspase 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of CASP7 mRNA]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]

PMID:12760867 PMID:16166294

NCBI chr 1:265,442,647...265,481,938
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

multiple interactions
increases activity

ISO

[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]
Cycloheximide results in increased activity of CASP8 protein

PMID:12760867 PMID:12925536 PMID:15924153 PMID:18222423

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

multiple interactions
increases activity

ISO

[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]
Cycloheximide results in increased activity of CASP9 protein

PMID:12925536 PMID:14502240 PMID:18222423

Ensembl chr 5:159,391,188...159,409,648

G

catalase

multiple interactions

EXP

Cycloheximide inhibits the reaction [Clofibrate results in increased expression of CAT protein]; Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

cation channel, sperm associated 4

affects response to substance

ISO

CATSPER4 gene SNP affects the susceptibility to Cycloheximide

NCBI chr 5:146,427,682...146,447,346
Ensembl chr 5:151,711,194...151,730,750

G

caveolin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of CAV1 mRNA]

NCBI chr 4:46,606,538...46,639,616
Ensembl chr 4:46,600,738...46,639,740

G

chromobox 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CBX1 mRNA

NCBI chr10:81,770,307...81,789,981
Ensembl chr10:82,266,759...82,287,242

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]

PMID:21146893 PMID:22121136

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CCL5 mRNA
Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]

PMID:21146893 PMID:22121136

NCBI chr10:68,820,330...68,824,906
Ensembl chr10:68,738,651...68,824,884

G

cellular communication network factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Acetylcysteine results in increased expression of CCN1 protein]

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CCN2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCN2 mRNA

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cellular communication network factor 3

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of CCN3 mRNA
Cycloheximide results in increased expression of CCN3 mRNA

NCBI chr 7:86,094,000...86,101,022
Ensembl chr 7:87,982,216...87,994,581

G

cellular communication network factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [2,2'-(hydroxynitrosohydrazono)bis-ethanamine results in increased expression of CCN4 mRNA]

NCBI chr 7:100,534,578...100,566,287
Ensembl chr 7:100,534,505...100,563,094

G

cyclin A2

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of CCNA2 mRNA
Cycloheximide results in decreased expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin D1

multiple interactions

ISO

[gingerol co-treated with Cycloheximide] results in increased degradation of CCND1 protein; Cycloheximide inhibits the reaction [CXCL8 protein results in increased expression of CCND1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]

PMID:17606477 PMID:18058799 PMID:25923732

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin D3

affects expression
multiple interactions

ISO

Cycloheximide affects the expression of CCND3 mRNA
Cycloheximide affects the reaction [Estradiol affects the expression of CCND3 mRNA]

NCBI chr 9:20,891,696...20,987,199
Ensembl chr 9:20,891,704...20,987,033

G

chaperonin containing TCP1 subunit 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of CCT5 mRNA

NCBI chr 2:84,302,621...84,313,773
Ensembl chr 2:84,302,623...84,313,779

G

CD38 molecule

multiple interactions

ISO

Cycloheximide affects the reaction [Tretinoin results in increased expression of CD38 mRNA]

NCBI chr14:71,384,532...71,424,794
Ensembl chr14:71,384,532...71,424,505

G

CD3 epsilon subunit of T-cell receptor complex

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD3E mRNA]

NCBI chr 8:54,200,617...54,211,770
Ensembl chr 8:54,200,617...54,211,876

G

CD44 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of CD44 protein]

NCBI chr 3:109,610,824...109,699,776
Ensembl chr 3:109,612,054...109,699,424

G

Cd47 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CD47 mRNA]

NCBI chr11:64,374,816...64,438,763
Ensembl chr11:64,377,926...64,438,272

G

Cd63 molecule

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CD63 mRNA]

NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,922,169...1,924,938

G

CD8 subunit alpha

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CD8A mRNA

NCBI chr 4:104,924,116...104,928,353
Ensembl chr 4:104,900,833...104,928,358

G

CDC42 small effector 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CDC42SE2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CDC42SE2 mRNA

NCBI chr10:38,836,549...38,905,056
Ensembl chr 1:100,424,547...100,424,801
Ensembl chr10:100,424,547...100,424,801

G

cell division cycle associated 5

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of CDCA5 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CDCA5 mRNA

NCBI chr 1:212,807,863...212,821,313
Ensembl chr 1:212,804,014...212,821,309

G

cell division cycle associated 7 like

multiple interactions

ISO

Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of CDCA7L protein]

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:144,908,171...144,982,843

G

cadherin 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Cycloheximide promotes the reaction [necrostatin-1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cyclin dependent kinase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of CDK2 mRNA]

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
decreases expression

ISO
EXP

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]; Cycloheximide inhibits the reaction [Troglitazone results in increased expression of CDKN1A protein]; Furazolidone promotes the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]; PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein]
Cycloheximide promotes the reaction [Dexamethasone results in decreased expression of CDKN1A protein]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CDKN1A mRNA]
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein]
Cycloheximide results in decreased expression of CDKN1A mRNA; Cycloheximide results in decreased expression of CDKN1A protein

PMID:10441511 PMID:12690110 PMID:22542671 PMID:24211769 PMID:26687534 More...

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 2A

increases expression

ISO

Cycloheximide results in increased expression of CDKN2A mRNA

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

CASP8 and FADD-like apoptosis regulator

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of CFLAR protein; Cycloheximide results in decreased expression of CFLAR protein alternative form; Cycloheximide results in decreased expression of CFLAR protein modified form
shogaol promotes the reaction [Cycloheximide results in decreased expression of CFLAR protein modified form]

PMID:12663669 PMID:15924153 PMID:16077199 PMID:16951203 PMID:25619640

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

CF transmembrane conductance regulator

affects expression

EXP

Cycloheximide affects the expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

cholinergic receptor, muscarinic 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dihydrotestosterone results in decreased expression of CHRM1 mRNA]

NCBI chr 1:214,996,180...215,012,136
Ensembl chr 1:214,995,872...215,020,602

G

cytokine inducible SH2-containing protein

increases expression

ISO

Cycloheximide results in increased expression of CISH mRNA

NCBI chr 8:116,850,969...116,855,917
Ensembl chr 8:116,850,773...116,855,986

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of CITED2 mRNA

NCBI chr 1:14,132,303...14,134,746
Ensembl chr 1:14,103,457...14,134,782

G

creatine kinase B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Estradiol results in increased expression of CKB protein]; Cycloheximide inhibits the reaction [Methoxychlor results in increased expression of CKB protein]

NCBI chr 6:136,550,583...136,553,464
Ensembl chr 6:136,549,844...136,553,478

G

chloride voltage-gated channel 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CLCN3 mRNA

NCBI chr16:34,138,004...34,210,984
Ensembl chr16:34,137,952...34,210,984

G

cannabinoid receptor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dronabinol results in increased expression of CNR1 mRNA]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]
Cycloheximide results in decreased expression of and affects the localization of CNR1 protein

PMID:17041005 PMID:22258905 PMID:27513693

NCBI chr 5:53,204,867...53,230,396
Ensembl chr 5:53,204,260...53,239,252

G

collagen type X alpha 1 chain

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of COL10A1 mRNA]

NCBI chr20:39,737,536...39,744,518
Ensembl chr20:39,716,822...39,751,440

G

collagen type I alpha 1 chain

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc Sulfate] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [[Genistein co-treated with Zinc] results in increased expression of COL1A1 mRNA]; Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of COL1A1 mRNA]

PMID:15962303 PMID:17203194

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

cAMP responsive element binding protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA]

NCBI chr 9:73,397,333...73,466,339
Ensembl chr 9:73,397,306...73,466,339

G

CDP-L-ribitol pyrophosphorylase A

affects response to substance

ISO

CRPPA gene SNP affects the susceptibility to Cycloheximide

NCBI chr 6:58,847,550...59,124,309
Ensembl chr 6:58,848,621...59,181,406

G

crystallin, lambda 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CRYL1 mRNA

NCBI chr15:35,542,628...35,661,563
Ensembl chr15:35,542,628...35,661,563

G

colony stimulating factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc results in increased expression of CSF1 mRNA]

PMID:12112025 PMID:17295206 PMID:18636177

NCBI chr 2:198,065,400...198,084,774
Ensembl chr 2:198,065,405...198,084,468

G

colony stimulating factor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein]

PMID:9606035 PMID:10645887

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

casein kinase 1, delta

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA]

NCBI chr10:106,713,497...106,754,953
Ensembl chr10:106,694,279...106,754,953

G

casein kinase 2 beta

multiple interactions
decreases degradation

ISO

Diethylhexyl Phthalate inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]; TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]

NCBI chr20:3,704,833...3,709,999
Ensembl chr20:3,704,904...3,710,525

G

catenin beta 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of CTNNB1 protein
Phenobarbital affects the reaction [Cycloheximide results in decreased expression of CTNNB1 protein]

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Azithromycin results in increased activity of CTSB protein]

NCBI chr15:41,565,607...41,586,479
Ensembl chr15:41,565,611...41,586,478

G

cullin 2

multiple interactions

ISO

CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr17:58,864,274...58,905,447
Ensembl chr17:58,864,274...58,905,132

G

C-X-C motif chemokine ligand 10

multiple interactions

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

cytochrome c, somatic

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of CYCS mRNA]

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

EXP

Cycloheximide results in decreased expression of CYP11A1 protein

NCBI chr 8:67,318,665...67,330,196
Ensembl chr 8:67,270,556...67,330,196

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity
decreases expression

ISO
EXP

Cycloheximide results in decreased activity of CYP19A1 protein
Cycloheximide results in decreased expression of CYP19A1 protein

PMID:16480277 PMID:21126571

NCBI chr 8:63,449,148...63,476,534
Ensembl chr 8:63,449,148...63,476,917

G

cytochrome P450, family 1, subfamily a, polypeptide 1

affects expression
multiple interactions
increases expression

EXP
ISO

Cycloheximide affects the expression of CYP1A1 mRNA
[Cycloheximide results in increased activity of [AHR protein binds to ARNT protein]] which results in increased expression of CYP1A1 mRNA; [Piperonyl Butoxide co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [6-(4-diethylamino)phenyl-7-chloro-5,8-quinolinedione results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Copper results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Lead results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Mercury results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [AHR protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene promotes the reaction [ARNT protein binds to CYP1A1 enhancer]]; Cycloheximide promotes the reaction [Methylcholanthrene results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Semaxinib results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [sodium arsenite results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Dactinomycin promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]
3'-methoxy-4'-nitroflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; [Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein; [Cycloheximide co-treated with Tetrachlorodibenzodioxin] results in increased expression of CYP1A1 mRNA; [Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1A1 mRNA; alpha-naphthoflavone inhibits the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Benzimidazoles promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with Harmaline] results in decreased expression of CYP1A1 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Cycloheximide co-treated with harmalol] results in decreased expression of CYP1A1 protein]; beta-Naphthoflavone promotes the reaction [Cycloheximide results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide promotes the reaction [[Benzo(a)pyrene co-treated with Calcitriol] results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Skatole results in increased expression of CYP1A1 mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]

PMID:1321828 PMID:1849469 PMID:1934297 PMID:2985607 PMID:8647108 More...

NCBI chr 8:66,991,940...66,998,014
Ensembl chr 8:66,991,970...66,998,012

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

ISO

Cycloheximide affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA]

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of CYP1B1 mRNA
Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of CYP1B1 protein]
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of CYP1B1 mRNA; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]

PMID:9145908 PMID:19684285 PMID:21867498

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions

ISO

alpha-naphthoflavone inhibits the reaction [Cycloheximide promotes the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]]; Cycloheximide inhibits the reaction [Calcitriol results in increased expression of CYP24A1 mRNA]

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:179,694,647...179,709,083

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases degradation

ISO
EXP

(4-amidinophenyl)methanesulfonyl fluoride inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; acetonitrile inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Biotin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Carbon Tetrachloride promotes the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Cycloheximide promotes the reaction [Carbon Tetrachloride results in increased degradation of CYP2E1 protein]; Dimethyl Sulfoxide inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Edetic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Egtazic Acid inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Ethanol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; fomepizole inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Glycerol inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; leupeptin inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Cycloheximide inhibits the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol]]; Tosyllysine Chloromethyl Ketone inhibits the reaction [Cycloheximide results in increased degradation of CYP2E1 protein]
Cycloheximide inhibits the reaction [pyridine results in increased activity of CYP2E1 protein]; Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP2E1 protein]

PMID:1968335 PMID:8531136 PMID:9143349

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily f, polypeptide 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Skatole results in increased expression of CYP2F1 mRNA]

NCBI chr 1:91,543,768...91,557,553
Ensembl chr 1:91,543,768...91,557,553

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases expression

EXP
ISO

Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A2 mRNA]
Cycloheximide results in decreased expression of CYP3A4 mRNA

PMID:11181506 PMID:21466820

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [pyridine results in increased expression of CYP3A23-3A1 mRNA]

NCBI chr12:14,369,950...14,398,803
Ensembl chr12:14,368,266...14,398,813

G

dystroglycan 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DAG1 mRNA]

NCBI chr 8:117,769,517...117,834,347
Ensembl chr 8:117,769,517...117,782,199

G

decorin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DCN mRNA]

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

DNA-damage inducible transcript 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [plumbagin results in increased expression of DDIT3 protein]

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

DNA-damage-inducible transcript 4

increases expression
multiple interactions

EXP

Cycloheximide results in increased expression of DDIT4 protein
[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein

NCBI chr20:28,434,938...28,437,037
Ensembl chr20:28,434,944...28,437,037

G

DEAF1 transcription factor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DEAF1 mRNA

NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:205,831,336...205,865,106

G

delta(4)-desaturase, sphingolipid 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DEGS1 mRNA]

NCBI chr13:96,478,645...96,485,302
Ensembl chr13:96,478,646...96,485,302

G

iodothyronine deiodinase 2

multiple interactions
decreases activity

ISO

[Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] inhibits the reaction [2,2',4,4',5-brominated diphenyl ether metabolite results in decreased activity of DIO2 protein]; [Cycloheximide co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased activity of DIO2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [2,2',4,4',5-brominated diphenyl ether results in decreased activity of DIO2 protein]]; Cycloheximide promotes the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Triiodothyronine, Reverse results in decreased activity of DIO2 protein]]; lactacystin inhibits the reaction [Cycloheximide results in decreased activity of DIO2 protein]

PMID:11425850 PMID:26004626

NCBI chr 6:115,396,308...115,410,594
Ensembl chr 6:115,396,308...115,410,594

G

iodothyronine deiodinase 3

multiple interactions

EXP

Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein]

NCBI chr 6:135,107,072...135,108,933
Ensembl chr 6:135,107,074...135,107,985

G

DnaJ heat shock protein family (Hsp40) member B5

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of DNAJB5 mRNA]

NCBI chr 5:61,972,637...61,981,887
Ensembl chr 5:61,972,706...61,981,860

G

deoxyribonuclease 1L3

increases expression

ISO

Cycloheximide results in increased expression of DNASE1L3 protein

NCBI chr15:19,351,683...19,378,536
Ensembl chr15:19,352,493...19,378,531

G

dynamin 1-like

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of DNM1L mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of DNM1L mRNA

NCBI chr11:98,084,049...98,135,663
Ensembl chr11:98,085,397...98,137,420

G

DNA methyltransferase 3 alpha

multiple interactions

EXP

[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein

NCBI chr 6:32,507,316...32,621,678
Ensembl chr 6:32,512,070...32,614,970

G

endothelin 1

multiple interactions

ISO

[Cycloheximide co-treated with EDN1 protein] results in increased expression of ADRB2 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

multiple interactions

EXP

[Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA mRNA; [Dimethyl Sulfoxide co-treated with Cycloheximide] results in decreased expression of EDNRA protein; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRA protein]

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Dimethyl Sulfoxide results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; Cycloheximide inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; Cycloheximide inhibits the reaction [Smoke analog results in increased expression of EDNRB protein]

PMID:20561571 PMID:20716444

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

epidermal growth factor

multiple interactions

EXP

[EGF protein co-treated with Cycloheximide] results in increased expression of DDIT4 protein; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]

PMID:12632255 PMID:22689575

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

epidermal growth factor receptor

increases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased expression of EGFR mRNA
Cycloheximide promotes the reaction [Arsenic Trioxide results in decreased expression of EGFR protein]
Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in increased expression of EGFR protein]

PMID:15228094 PMID:26368632 PMID:30237564

NCBI chr14:95,378,626...95,551,358
Ensembl chr14:95,378,626...95,551,358

G

early growth response 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [resveratrol results in increased expression of EGR1 mRNA]

NCBI chr18:26,737,078...26,740,877
Ensembl chr18:26,736,838...26,740,843

G

early growth response 2

increases expression

ISO

Cycloheximide results in increased expression of EGR2 mRNA

NCBI chr20:21,050,149...21,055,201
Ensembl chr20:21,050,149...21,057,748

G

eukaryotic translation initiation factor 2A

multiple interactions

ISO

Cycloheximide inhibits the reaction [epimedokoreanin B results in increased phosphorylation of EIF2A protein]; Cycloheximide inhibits the reaction [Orlistat results in increased phosphorylation of EIF2A protein]

PMID:17283163 PMID:36027945

NCBI chr 2:144,911,247...144,944,705
Ensembl chr 2:144,911,153...144,945,201

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions

EXP
ISO

Cycloheximide inhibits the reaction [dimethylarsinous acid results in increased phosphorylation of EIF2AK3 protein]
Cycloheximide inhibits the reaction [2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [1,12-benzoperylene results in increased expression of EIF2AK3 mRNA]]

PMID:22425709 PMID:35182551

NCBI chr 4:104,363,838...104,425,271
Ensembl chr 4:104,363,833...104,425,268

G

eukaryotic translation initiation factor 2 subunit alpha

increases expression
increases phosphorylation
multiple interactions

ISO

Cycloheximide results in increased expression of EIF2S1 mRNA
Cycloheximide results in increased phosphorylation of EIF2S1 protein
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of EIF2S1 mRNA

PMID:19684285 PMID:24315374

NCBI chr 6:103,405,880...103,430,549
Ensembl chr 6:103,405,788...103,431,649

G

eukaryotic translation initiation factor 4E

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of CCND1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]
Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]

PMID:22689575 PMID:25923732

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [EIF4EBP1 protein binds to EIF4E protein]; Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

eukaryotic translation initiation factor 4 gamma 1

multiple interactions

EXP

Cycloheximide promotes the reaction [EIF4EBP1 protein binds to EIF4G1 protein]

NCBI chr11:93,726,322...93,746,387
Ensembl chr11:93,726,322...93,746,367

G

eukaryotic translation initiation factor 4 gamma, 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of EIF4G3 mRNA]

NCBI chr 5:155,481,378...155,702,194
Ensembl chr 5:155,481,378...155,702,194

G

eukaryotic translation initiation factor 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of EIF5 mRNA

NCBI chr 6:136,410,333...136,418,827
Ensembl chr 6:136,407,440...136,418,821

G

ELAV like RNA binding protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of ELAVL1 protein]]

NCBI chr12:7,441,699...7,482,625
Ensembl chr12:7,441,699...7,482,631

G

E74 like ETS transcription factor 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ELF4 mRNA]

NCBI chr X:127,587,401...127,639,063
Ensembl chr X:132,468,539...132,478,689

G

ETS transcription factor ELK1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of ELK1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ELK1 mRNA

NCBI chr X:3,692,367...3,709,252
Ensembl chr X:3,693,293...3,709,249

G

elastin

multiple interactions

EXP

Cycloheximide inhibits the reaction [Okadaic Acid results in decreased expression of ELN mRNA]

NCBI chr12:27,604,983...27,648,413
Ensembl chr12:27,604,680...27,648,413

G

ELOVL fatty acid elongase 3

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ELOVL3 mRNA
Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of ELOVL3 mRNA]

NCBI chr 1:244,997,287...245,001,115
Ensembl chr 1:254,938,731...254,942,559

G

ectodermal-neural cortex 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of ENC1 mRNA

NCBI chr 2:30,285,274...30,297,194
Ensembl chr 2:30,283,736...30,315,721

G

endonuclease G

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of ENDOG mRNA]

NCBI chr 3:33,846,935...33,849,531
Ensembl chr 3:33,846,885...33,849,573

G

endothelial PAS domain protein 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]; MALAT1 mRNA inhibits the reaction [Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of EPAS1 protein]]
Cycloheximide results in decreased expression of EPAS1 protein

PMID:23958427 PMID:26735578

NCBI chr 6:13,543,252...13,626,147
Ensembl chr 6:13,544,389...13,624,729

G

erythropoietin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of EPO mRNA]

NCBI chr12:24,841,285...24,844,725
Ensembl chr12:24,841,285...24,844,725

G

epiphycan

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EPYC mRNA]

NCBI chr 7:32,436,620...32,474,326
Ensembl chr 7:34,323,273...34,361,032

G

erb-b2 receptor tyrosine kinase 2

multiple interactions
increases degradation
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of ERBB2 mRNA; Curcumin analog promotes the reaction [Cycloheximide results in increased degradation of ERBB2 protein]; PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]
Cycloheximide results in decreased expression of ERBB2 mRNA; Cycloheximide results in decreased expression of ERBB2 protein

PMID:15072547 PMID:15228094 PMID:20379846 PMID:25866362

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

decreases expression

ISO

Cycloheximide results in decreased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

epiregulin

increases expression

ISO

Cycloheximide results in increased expression of EREG mRNA

NCBI chr14:17,311,485...17,325,260
Ensembl chr14:17,311,485...17,325,260

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of ERN1 protein]

NCBI chr10:91,826,663...91,920,976
Ensembl chr10:91,830,428...91,920,791

G

estrogen receptor 1

multiple interactions
decreases expression

ISO

bisphenol A promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; Estradiol promotes the reaction [Cycloheximide results in decreased expression of ESR1 protein]; naringenin inhibits the reaction [Cycloheximide results in decreased expression of ESR1 protein]

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

multiple interactions

ISO

Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Cycloheximide promotes the reaction [Estradiol results in increased expression of ESR2 mRNA]]

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

estrogen related receptor, alpha

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ESRRA protein
HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]

NCBI chr 1:213,533,309...213,543,432
Ensembl chr 1:213,533,310...213,543,811

G

exostosin glycosyltransferase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of EXT2 mRNA]

NCBI chr 3:100,120,776...100,253,424
Ensembl chr 3:100,120,776...100,253,596

G

coagulation factor XII

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of F12 mRNA]

NCBI chr17:9,212,819...9,220,664
Ensembl chr17:9,212,819...9,220,664

G

coagulation factor II, thrombin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Simvastatin results in decreased activity of F2 protein]

NCBI chr 3:98,051,958...98,065,246
Ensembl chr 3:98,051,960...98,065,246

G

coagulation factor III, tissue factor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in decreased expression of F3 mRNA]

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

Fas cell surface death receptor

multiple interactions
increases response to substance

ISO

Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP3 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP7 protein]; Cycloheximide promotes the reaction [FAS protein results in increased activity of CASP8 protein]
Cycloheximide results in increased susceptibility to FAS protein

PMID:8932996 PMID:12760867

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FASLG mRNA]
[Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A mRNA; [Cycloheximide co-treated with FASLG protein] results in decreased expression of DNMT3A protein

PMID:11007951 PMID:19833194

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fatty acid synthase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Calcitriol results in decreased expression of FASN mRNA]

NCBI chr10:106,570,415...106,588,581
Ensembl chr10:106,570,413...106,588,583

G

fibrillarin

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FBL mRNA

NCBI chr 1:92,597,407...92,606,507
Ensembl chr 1:92,597,258...92,606,506

G

F-box and WD repeat domain containing 7

multiple interactions

ISO

Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein]
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]

PMID:24457827 PMID:25897075

NCBI chr 2:172,447,738...172,609,591
Ensembl chr 2:172,447,738...172,609,591

G

fibrinogen alpha chain

decreases expression

EXP

Cycloheximide results in decreased expression of FGA protein

NCBI chr 2:170,672,169...170,679,572
Ensembl chr 2:170,672,012...170,679,577

G

fibrinogen beta chain

decreases expression

EXP

Cycloheximide results in decreased expression of FGB protein

NCBI chr 2:170,693,966...170,700,875
Ensembl chr 2:170,692,965...170,705,434

G

fibroblast growth factor 2

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dinoprost affects the localization of FGF2 protein]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]

PMID:9798919 PMID:15654655

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

Fibroblast growth factor receptor 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Triiodothyronine results in increased expression of FGFR1 mRNA]

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibrinogen-like 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FGL2 mRNA]

NCBI chr 4:14,602,762...14,608,405
Ensembl chr 4:14,602,771...14,608,405

G

fragile histidine triad diadenosine triphosphatase

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FHIT mRNA

NCBI chr15:16,365,401...17,872,901
Ensembl chr15:16,747,338...17,872,621

G

four and a half LIM domains 1

multiple interactions

EXP

Cycloheximide promotes the reaction [25-hydroxycholesterol results in increased expression of FHL1 mRNA]

NCBI chr X:139,592,794...139,652,290
Ensembl chr X:139,592,604...139,652,282

G

Fms related receptor tyrosine kinase 3

decreases expression

ISO

Cycloheximide results in decreased expression of FLT3 protein mutant form

NCBI chr12:12,660,035...12,735,584
Ensembl chr12:12,659,946...12,735,581

G

flavin containing dimethylaniline monoxygenase 3

increases expression

ISO

Cycloheximide results in increased expression of FMO3 mRNA

NCBI chr13:77,838,899...77,868,869
Ensembl chr13:77,842,602...77,861,256

G

fragile X messenger ribonucleoprotein 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of FMR1 mRNA

NCBI chr X:152,284,857...152,322,686
Ensembl chr X:152,284,841...152,322,675

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

ISO
EXP

Cycloheximide inhibits the reaction [Estradiol results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Genistein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of FOS protein]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]
Cycloheximide results in increased expression of FOS mRNA
Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]
[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA; Cadmium Chloride promotes the reaction [Cycloheximide results in increased expression of FOS mRNA]; Cycloheximide inhibits the reaction [Hydrogen Peroxide results in increased expression of FOS protein]; Cycloheximide promotes the reaction [[EGF protein co-treated with Estradiol] results in increased expression of FOS mRNA]; Cycloheximide promotes the reaction [Cadmium Chloride results in increased expression of FOS mRNA]; Dactinomycin inhibits the reaction [[Cycloheximide co-treated with Cadmium] results in increased expression of FOS mRNA]

PMID:1696944 PMID:9094091 PMID:9417049 PMID:9650640 PMID:12632255 More...

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

fyn-related Src family tyrosine kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FRK mRNA]

NCBI chr20:39,820,441...39,926,065
Ensembl chr20:39,820,295...39,926,362

G

follistatin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FST mRNA]

NCBI chr 2:47,856,345...47,863,670
Ensembl chr 2:47,856,345...47,863,491

G

ferritin heavy chain 1

multiple interactions
decreases expression

ISO

[Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTH1 protein]

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

ferritin light chain 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of FTL protein
[Antimony Potassium Tartrate results in increased abundance of Antimony] promotes the reaction [Cycloheximide results in decreased expression of FTL protein]

NCBI chr 1:105,072,858...105,074,705
Ensembl chr X:45,399,355...45,399,915
Ensembl chr 2:45,399,355...45,399,915
Ensembl chr 1:45,399,355...45,399,915

G

fucosyltransferase 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FUT4 mRNA]

NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:19,868,079...19,872,436

G

frizzled class receptor 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of FZD7 mRNA]

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:68,411,259...68,432,585

G

glucose-6-phosphate dehydrogenase

multiple interactions

EXP

Cycloheximide inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]

NCBI chr X:157,352,364...157,372,144
Ensembl chr X:157,352,373...157,372,144

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,763,697...15,843,598
Ensembl chr18:15,764,277...15,843,588

G

growth arrest-specific 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GAS1 mRNA]

NCBI chr17:4,487,716...4,490,701
Ensembl chr17:4,484,283...4,497,657

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLC mRNA]; Cycloheximide inhibits the reaction [diphenylarsinic acid results in increased expression of GCLC protein]
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of GCLC protein]

PMID:17628625 PMID:19328227 PMID:24437944

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

Cycloheximide inhibits the reaction [arsenite results in increased activity of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of [GCLC protein binds to GCLM protein]]; Cycloheximide inhibits the reaction [arsenite results in increased expression of GCLM mRNA]

NCBI chr 2:213,032,135...213,052,192
Ensembl chr 2:213,031,838...213,055,003

G

growth differentiation factor 15

multiple interactions

ISO

Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 mRNA]; Cycloheximide inhibits the reaction [trichostatin A affects the expression of GDF15 protein]; Cycloheximide inhibits the reaction [troglitazone results in increased expression of GDF15 mRNA]

PMID:14662774 PMID:18801729

NCBI chr16:18,838,436...18,842,022
Ensembl chr16:18,838,436...18,842,022

G

gap junction protein, alpha 1

multiple interactions
decreases expression

EXP

9,10-Dimethyl-1,2-benzanthracene promotes the reaction [Cycloheximide results in decreased expression of GJA1 protein]; Cycloheximide promotes the reaction [Benzo(a)pyrene results in decreased expression of GJA1 protein]

PMID:34283317 PMID:36863560

NCBI chr20:36,302,490...36,315,010
Ensembl chr20:36,302,352...36,319,689

G

glycosylphosphatidylinositol anchor attachment 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of GPAA1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of GPAA1 mRNA

NCBI chr 7:109,932,556...109,936,139
Ensembl chr 7:109,932,544...109,936,138

G

G protein-coupled receptor 37

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GPR37 mRNA]

NCBI chr 4:54,138,860...54,160,927
Ensembl chr 4:55,104,365...55,126,494

G

glutathione peroxidase 4

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of GPX4 protein
triptolide promotes the reaction [Cycloheximide results in decreased expression of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glutamate metabotropic receptor 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 mRNA]; Cycloheximide inhibits the reaction [Dextroamphetamine results in increased expression of GRM5 protein]

NCBI chr 1:150,722,711...151,297,585
Ensembl chr 1:150,733,678...151,296,649

G

granulin precursor

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of GRN mRNA

NCBI chr10:87,887,834...87,893,938
Ensembl chr10:87,886,122...87,893,936

G

glycogen synthase kinase 3 beta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of GSK3B mRNA]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

glutathione S-transferase alpha 5

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of GSTA1 mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]]; Cycloheximide inhibits the reaction [Lead results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of GSTA1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of GSTA1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of GSTA1 mRNA]

NCBI chr 8:87,985,768...87,997,766
Ensembl chr 8:87,985,258...87,997,765

G

heparin-binding EGF-like growth factor

increases expression

ISO

Cycloheximide results in increased expression of HBEGF mRNA

NCBI chr18:28,380,337...28,390,220
Ensembl chr18:28,380,337...28,390,220

G

histone deacetylase 6

multiple interactions

ISO

HDAC6 protein inhibits the reaction [Cycloheximide results in decreased expression of ESRRA protein]

NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370

G

hypoxia inducible factor 1 subunit alpha

increases degradation
decreases expression
multiple interactions

ISO
EXP

Cycloheximide results in increased degradation of HIF1A protein
Cycloheximide results in decreased expression of HIF1A protein
Cycloheximide promotes the reaction [methylmercuric chloride results in decreased expression of HIF1A protein]
[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; [Cycloheximide co-treated with Oxygen deficiency] affects the expression of HIF1A protein; [Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein; Butyric Acid promotes the reaction [Cycloheximide results in decreased expression of HIF1A protein]; Cycloheximide affects the reaction [[Apigenin co-treated with Oxygen deficiency] affects the expression of HIF1A protein]; Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [bruceine D inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased stability of HIF1A protein]; Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of HIF1A protein]; Cycloheximide inhibits the reaction [zinc chloride results in increased expression of HIF1A protein alternative form]; Cycloheximide promotes the reaction [Cobalt results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of HIF1A protein]; Cycloheximide promotes the reaction [sodium arsenite inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]; genipin affects the reaction [[Oxygen deficiency co-treated with Cycloheximide] affects the expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with cobaltous chloride] results in decreased expression of HIF1A protein]; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]; scutellarin inhibits the reaction [[cobaltous chloride co-treated with Glucose co-treated with Cycloheximide] results in decreased expression of HIF1A protein]; scutellarin promotes the reaction [Cycloheximide inhibits the reaction [[cobaltous chloride co-treated with Glucose] results in increased expression of HIF1A protein]]; sodium arsenite inhibits the reaction [Cycloheximide inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of HIF1A protein]; Cycloheximide inhibits the reaction [Polystyrenes analog results in increased expression of HIF1A protein]

PMID:11641398 PMID:11739637 PMID:19958256 PMID:20524035 PMID:22537771 More...

NCBI chr 6:98,357,788...98,405,068
Ensembl chr 6:98,359,910...98,405,323

G

heme oxygenase 1

multiple interactions
decreases expression

ISO
EXP

Cycloheximide inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [mevastatin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Oxygen results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; Cycloheximide results in decreased susceptibility to [surfactin peptide results in increased expression of HMOX1 protein]; USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein]
Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [cobaltous chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]
Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [fisetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [puerarin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [Triterpenes analog results in increased expression of HMOX1 protein]

PMID:9747510 PMID:12441344 PMID:12472888 PMID:15118350 PMID:15588712 More...

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

heterogeneous nuclear ribonucleoprotein H2

increases expression

ISO

Cycloheximide results in increased expression of HNRNPH2 mRNA

NCBI chr X:97,780,890...97,786,846
Ensembl chr X:102,074,179...102,081,025

G

heterogeneous nuclear ribonucleoprotein K

multiple interactions

EXP

Cycloheximide inhibits the reaction [Glycine results in increased expression of HNRNPK protein]

NCBI chr17:6,269,302...6,280,429
Ensembl chr17:6,268,385...6,280,565

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

ISO

Cycloheximide promotes the reaction [Bexarotene results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [tributyltin results in increased expression of HSD11B2 mRNA]; Cycloheximide promotes the reaction [triphenyltin chloride results in increased expression of HSD11B2 mRNA]

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

heat shock transcription factor 1

decreases activity

ISO

Cycloheximide results in decreased activity of HSF1 protein

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family A (Hsp70) member 5

multiple interactions

EXP
ISO

Cycloheximide inhibits the reaction [GIF 0010 results in increased expression of HSPA5 mRNA]; Cycloheximide inhibits the reaction [lead acetate results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Mercuric Chloride results in increased expression of HSPA5 protein]
Cycloheximide inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [Butyric Acid results in increased expression of HSPA5 protein]; Cycloheximide inhibits the reaction [plumbagin results in increased expression of HSPA5 protein]

PMID:9742210 PMID:17915553 PMID:26784903 PMID:31276663 PMID:34560123

NCBI chr 3:38,453,016...38,457,475
Ensembl chr 3:38,453,041...38,458,790

G

HIV-1 Tat interactive protein 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of HTATIP2 mRNA]

NCBI chr 1:108,609,424...108,624,810
Ensembl chr 1:108,605,811...108,624,815

G

intercellular adhesion molecule 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]
Cycloheximide results in decreased expression of ICAM1 protein

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

immediate early response 3

multiple interactions

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of IER3 mRNA

NCBI chr20:2,933,173...2,934,377
Ensembl chr20:2,933,174...2,934,377

G

interferon gamma

multiple interactions

ISO

[Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of ICAM1 protein]; Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein]

PMID:12070711 PMID:16087364

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

intraflagellar transport 27

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of IFT27 mRNA]

NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936

G

insulin-like growth factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [IGF1 protein affects the metabolism of 1,2-diacylglycerol]
IGF1 protein inhibits the reaction [Cycloheximide results in decreased expression of CDKN1A protein]

PMID:2120207 PMID:26687534

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions

ISO

Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein]

NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:79,393,067...79,525,730

G

insulin-like growth factor binding protein 4

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of IGFBP4 mRNA
[Cycloheximide co-treated with Estradiol] results in increased expression of IGFBP4 mRNA

NCBI chr10:84,491,471...84,503,487
Ensembl chr10:84,485,775...84,503,473

G

interleukin 10

multiple interactions
decreases response to substance
increases expression

ISO
EXP

Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]
IL10 protein results in decreased susceptibility to Cycloheximide
Cycloheximide results in increased expression of IL10 mRNA

PMID:19395591 PMID:22183712

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 17A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Glucose results in increased secretion of IL17A protein]

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 18

multiple interactions

EXP

Cycloheximide inhibits the reaction [Aldosterone results in increased expression of IL18 mRNA]

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 alpha

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1A mRNA
Cycloheximide results in increased expression of IL1A mRNA

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions
increases expression

ISO
EXP

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of IL1B mRNA; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL1B protein]; Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [IL1B results in increased secretion of CSF2 protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of IL1B protein]; Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased secretion of IL1B protein modified form]
Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]
Cycloheximide results in increased expression of IL1B mRNA

PMID:8071060 PMID:9606035 PMID:11112151 PMID:11286988 PMID:19684285 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 5

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of IL5 protein
T0901317 inhibits the reaction [Cycloheximide results in decreased expression of IL5 protein]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

multiple interactions
increases expression
decreases secretion
increases secretion

ISO

Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of IL6 protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]
Cycloheximide results in decreased secretion of IL6 protein

PMID:8071060 PMID:11216681 PMID:12185005 PMID:21146893 PMID:24771768

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 cytokine family signal transducer

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IL6ST mRNA]

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

insulin 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [apigenin-6-C-(2''-O-rhamnopyranosyl)-fucopyranoside promotes the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin 2

multiple interactions

ISO

[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein; L-4F peptide promotes the reaction [[Cycloheximide co-treated with INS protein] results in decreased expression of HIF1A protein]

NCBI chr 1:207,272,738...207,421,998
Ensembl chr 1:207,272,742...207,273,805

G

IQ motif containing GTPase activating protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of IQGAP1 mRNA]

NCBI chr 1:144,088,788...144,178,989
Ensembl chr 1:144,088,793...144,179,043

G

insulin receptor substrate 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of IRS1 mRNA
[Cycloheximide co-treated with Estradiol] results in increased expression of IRS1 mRNA

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538

G

integrin subunit beta 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB3 mRNA]

NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800

G

integrin subunit beta 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITGB6 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]

PMID:11007951 PMID:21303922

NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333

G

inositol-tetrakisphosphate 1-kinase

multiple interactions

ISO

ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]

NCBI chr 6:121,710,750...121,844,501
Ensembl chr 6:127,476,808...127,609,062

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Ethanol results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [linsidomine results in increased expression of ITPR1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ITPR1 mRNA]

PMID:11007951 PMID:17241155

NCBI chr 4:142,743,401...143,066,505
Ensembl chr 4:142,743,334...143,066,504

G

influenza virus NS1A binding protein

multiple interactions

ISO

Cycloheximide inhibits the reaction [Doxorubicin results in decreased expression of IVNS1ABP mRNA]

NCBI chr13:65,977,069...65,996,685
Ensembl chr13:65,977,045...65,997,547

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases stability
increases phosphorylation
multiple interactions

EXP
ISO

Cycloheximide results in increased stability of JUN protein
Cycloheximide results in increased phosphorylation of JUN protein
Cycloheximide promotes the reaction [Cadmium results in increased expression of JUN mRNA]
Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of JUN protein]

PMID:1696944 PMID:9751194 PMID:12169099 PMID:23593480

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

KN motif and ankyrin repeat domains 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KANK1 mRNA

NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:232,445,658...232,500,839

G

KIAA0930 homolog

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KIAA0930 mRNA

NCBI chr 7:116,067,974...116,107,678
Ensembl chr 7:117,947,898...117,987,636

G

kininogen 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]

NCBI chr11:91,317,354...91,340,148
Ensembl chr11:91,317,355...91,340,148

G

KRAS proto-oncogene, GTPase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of KRAS mRNA]

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

kringle containing transmembrane protein 1

affects response to substance

ISO

KREMEN1 gene SNP affects the susceptibility to Cycloheximide

NCBI chr14:80,081,870...80,147,489
Ensembl chr14:84,297,700...84,361,614

G

keratin 13

multiple interactions

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of KRT13 mRNA

NCBI chr10:85,051,887...85,056,099
Ensembl chr10:85,552,287...85,556,499

G

keratinocyte associated protein 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of KRTCAP2 mRNA

NCBI chr 2:174,654,409...174,658,405
Ensembl chr 2:176,949,809...176,956,163

G

LCK proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LCK mRNA]

NCBI chr 5:147,172,642...147,201,267
Ensembl chr 5:147,172,642...147,201,267

G

low density lipoprotein receptor

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [Quercetin results in increased expression of LDLR protein]
Cycloheximide results in decreased expression of LDLR protein

NCBI chr 8:28,546,191...28,569,075
Ensembl chr 8:28,546,146...28,570,675

G

leptin

multiple interactions

ISO

LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

leptin receptor

multiple interactions
decreases expression

ISO

LEP protein inhibits the reaction [Cycloheximide results in decreased expression of LEPR protein]

NCBI chr 5:121,409,735...121,593,201
Ensembl chr 5:121,474,099...121,591,215

G

galectin 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of LGALS3 protein]

NCBI chr15:23,099,795...23,111,731
Ensembl chr15:23,086,841...23,111,737

G

luteinizing hormone subunit beta

multiple interactions

EXP

Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]

NCBI chr 1:105,037,457...105,038,446
Ensembl chr 1:105,037,457...105,038,445

G

LIM domain 7

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LMO7 mRNA]

NCBI chr15:84,981,689...85,184,554
Ensembl chr15:84,981,735...85,184,551

G

leupaxin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of LPXN mRNA]

NCBI chr 1:219,353,319...219,387,743
Ensembl chr 1:219,353,708...219,387,742

G

MAF1 homolog, negative regulator of RNA polymerase III

increases degradation
multiple interactions

ISO

Cycloheximide results in increased degradation of MAF1 protein
Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein]; CUL2 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]; Cycloheximide inhibits the reaction [Sirolimus results in increased expression of MAF1 protein]; PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr 7:109,955,876...109,958,909
Ensembl chr 7:109,955,282...109,958,910

G

mitogen activated protein kinase kinase 1

multiple interactions
increases activity

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cycloheximide results in increased expression of MAP2K1 mRNA]
Cycloheximide results in increased activity of MAP2K1 protein

NCBI chr 8:73,578,747...73,650,184
Ensembl chr 8:73,578,752...73,650,184

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

ISO
EXP

Cycloheximide results in increased phosphorylation of MAPK1 protein
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK1 protein]; Cycloheximide promotes the reaction [[sodium arsenite co-treated with Hydrogen Peroxide] results in increased phosphorylation of MAPK1 protein]
Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]]

PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

multiple interactions

ISO

Cycloheximide inhibits the reaction [Asbestos, Crocidolite results in decreased phosphorylation of MAPK14 protein]

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

increases phosphorylation
multiple interactions

ISO
EXP

Cycloheximide results in increased phosphorylation of MAPK3 protein
Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of MAPK3 protein]; Cycloheximide promotes the reaction [sodium arsenite promotes the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]]
Cycloheximide inhibits the reaction [Cyclosporine results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]]

PMID:12472888 PMID:15087236 PMID:16696851 PMID:22155090

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

mitogen-activated protein kinase 7

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MAPK7 mRNA; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAPK7 mRNA]
Cycloheximide results in increased expression of MAPK7 mRNA

PMID:11007951 PMID:19684285

NCBI chr10:46,669,721...46,675,768
Ensembl chr10:46,669,721...46,675,806

G

MAPK activated protein kinase 3

affects response to substance

ISO

MAPKAPK3 gene SNP affects the susceptibility to Cycloheximide

NCBI chr 8:116,808,429...116,842,228
Ensembl chr 8:116,808,429...116,842,228

G

myelin basic protein

affects expression

EXP

Cycloheximide affects the expression of MBP mRNA

NCBI chr18:78,130,652...78,241,174
Ensembl chr18:78,130,325...78,241,174

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with MCL1] results in increased susceptibility to ABT-737; [Resveratrol co-treated with Clofarabine co-treated with Cycloheximide] results in decreased expression of MCL1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MCL1 protein]; Cycloheximide inhibits the reaction [EIF4E protein modified form inhibits the reaction [sodium arsenite results in decreased expression of MCL1 protein]]; Cycloheximide promotes the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCL1 protein]

PMID:14982947 PMID:21880625 PMID:24924397 PMID:25408576 PMID:25923732 More...

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

midkine

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of MDK mRNA]

NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:98,356,789...98,358,743

G

microRNA 21

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [Dihydrotestosterone results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [Estradiol results in decreased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [fludioxonil results in increased expression of MIR21 mRNA]; Cycloheximide inhibits the reaction [N-(2,3-dichloro-4-hydroxyphenyl)-1-methylcyclohexanecarboxamide results in increased expression of MIR21 mRNA]
Cycloheximide results in increased expression of MIR21 mRNA

PMID:19264808 PMID:23052036

NCBI chr10:71,902,600...71,902,691

G

melanocyte inducing transcription factor

multiple interactions

ISO

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [[Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein]; [Cycloheximide co-treated with 4-(1-phenylethyl)-1,3-benzenediol] results in increased degradation of MITF protein

NCBI chr 4:131,965,676...132,177,790
Ensembl chr 4:131,965,714...132,177,790

G

matrix metallopeptidase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MMP1 mRNA]

PMID:15075337 PMID:19136476

NCBI chr 8:12,943,453...12,963,966
Ensembl chr 8:12,943,453...12,963,964

G

matrix metallopeptidase 13

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MMP13 mRNA
Cycloheximide inhibits the reaction [Tretinoin results in increased expression of MMP13 mRNA]
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MMP13 mRNA

PMID:16350840 PMID:19684285

NCBI chr 8:12,782,829...12,793,108
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Vehicle Emissions results in increased expression of MMP2 mRNA]

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

motor neuron and pancreas homeobox 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MNX1 mRNA]

NCBI chr 4:5,866,506...5,871,465
Ensembl chr 4:6,541,645...6,546,604

G

N-methylpurine-DNA glycosylase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MPG mRNA]

NCBI chr10:15,900,697...15,906,981
Ensembl chr10:15,899,635...15,907,052

G

mitochondrial ribosomal protein S7

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of MRPS7 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of MRPS7 mRNA

NCBI chr10:101,342,642...101,345,790
Ensembl chr10:101,342,421...101,346,082

G

mutS homolog 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of MSH3 mRNA]

NCBI chr 2:25,179,400...25,320,857
Ensembl chr 2:25,179,400...25,321,102

G

macrophage scavenger receptor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MSR1 mRNA]

NCBI chr16:59,421,250...59,507,070
Ensembl chr16:59,421,057...59,507,070

G

metallothionein 1A

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MT1 mRNA
2-tert-butylhydroquinone promotes the reaction [Cycloheximide results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [2-tert-butylhydroquinone results in increased expression of MT1 mRNA]; Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]; MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]

PMID:14998373 PMID:19276070

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

mitochondrial carrier 2

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTCH2 mRNA

NCBI chr 3:76,830,549...76,850,189
Ensembl chr 3:97,285,894...97,307,327

G

mitochondrial transcription termination factor 3

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of MTERF3 protein
Ammonium Chloride inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of MTERF3 protein]

NCBI chr 7:63,826,418...63,844,747
Ensembl chr 7:65,711,662...65,729,895

G

metal-regulatory transcription factor 1

multiple interactions

ISO

MTF1 protein affects the reaction [Cycloheximide promotes the reaction [arsenic trichloride results in increased expression of MT1 mRNA]]; MTF1 protein affects the reaction [Cycloheximide results in increased expression of MT1 mRNA]

NCBI chr 5:142,347,024...142,391,810
Ensembl chr 5:142,347,054...142,391,810

G

myotubularin related protein 7

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of MTMR7 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MTMR7 mRNA

NCBI chr16:51,641,267...51,732,212
Ensembl chr16:58,344,767...58,436,615

G

max dimerization protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MXD1 mRNA]

NCBI chr 4:120,654,731...120,678,972
Ensembl chr 4:120,654,731...120,675,129

G

Max dimerization protein 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of MXD3 mRNA

NCBI chr17:9,301,430...9,305,156
Ensembl chr17:9,302,321...9,310,278

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions

ISO
EXP

arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of MYC protein]; FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]
Cycloheximide inhibits the reaction [TAK-243 results in increased sumoylation of MYC protein]
Cycloheximide promotes the reaction [Cadmium results in increased expression of MYC mRNA]

PMID:1696944 PMID:23593480 PMID:24457827 PMID:31285264

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

myosin light chain kinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]

NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659

G

myosin ID

affects response to substance

ISO

MYO1D gene SNP affects the susceptibility to Cycloheximide

NCBI chr10:65,489,153...65,765,812
Ensembl chr10:65,975,122...66,263,958

G

NBR1, autophagy cargo receptor

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of NBR1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NBR1 mRNA

NCBI chr10:86,978,024...87,006,664
Ensembl chr10:86,977,885...87,007,012

G

N-myc downstream regulated 1

multiple interactions
decreases expression

ISO

Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein]

NCBI chr 7:100,573,526...100,614,902
Ensembl chr 7:100,573,523...100,614,913

G

NEDD4 E3 ubiquitin protein ligase

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of NEDD4 protein
Melatonin promotes the reaction [Cycloheximide results in decreased expression of NEDD4 protein]

NCBI chr 8:82,264,751...82,349,642
Ensembl chr 8:82,264,649...82,349,633

G

neurofilament heavy chain

decreases expression
decreases degradation

EXP

Cycloheximide results in decreased expression of NEFH mRNA
Cycloheximide results in decreased degradation of NEFH mRNA

PMID:1280263 PMID:19146868

NCBI chr14:84,044,428...84,054,413
Ensembl chr14:84,044,023...84,054,417

G

neurofilament light chain

decreases expression
decreases degradation

EXP

Cycloheximide results in decreased expression of NEFL mRNA
Cycloheximide results in decreased degradation of NEFL mRNA

PMID:1280263 PMID:19146868

NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515

G

neurofilament medium chain

decreases degradation

EXP

Cycloheximide results in decreased degradation of NEFM mRNA

NCBI chr15:46,535,857...46,541,161
Ensembl chr15:46,535,517...46,541,163

G

NIMA-related kinase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NEK2 mRNA]

NCBI chr13:105,936,809...105,950,054
Ensembl chr13:105,936,788...105,950,056

G

NFE2 like bZIP transcription factor 2

multiple interactions
decreases expression

ISO

[benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Cycloheximide] results in increased expression of NFE2L2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased activity of NFE2L2 protein]; Cycloheximide inhibits the reaction [Particulate Matter analog results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Vehicle Emissions analog results in increased expression of NFE2L2 protein]; exenatide inhibits the reaction [Cycloheximide results in decreased expression of NFE2L2 protein]
[SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; Curcumin inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]]; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [Quercetin results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of NFE2L2 protein]

PMID:12441344 PMID:14510636 PMID:15322212 PMID:22019695 PMID:22197970 More...

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

affects localization
multiple interactions
increases expression

ISO

Cycloheximide affects the localization of NFKB1 protein
FBXW7 protein promotes the reaction [NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]]; NFKB1 gene mutant form inhibits the reaction [arsenite inhibits the reaction [Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in decreased degradation of and results in increased expression of MYC protein]]]
Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]

PMID:16637064 PMID:21146893 PMID:24457827

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions
decreases expression
increases degradation

ISO

Cycloheximide inhibits the reaction [Morphine results in increased expression of NFKBIA mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NFKBIA mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NFKBIA protein]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in decreased expression of NFKBIA protein]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased degradation of NFKBIA protein]

PMID:11007951 PMID:15330761 PMID:16637064 PMID:21692457 PMID:22258905

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nerve growth factor

multiple interactions

ISO

Cycloheximide inhibits the reaction [NGF protein results in increased expression of FOS protein]; Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]

NCBI chr 2:192,589,580...192,642,971
Ensembl chr 2:192,589,582...192,643,834

G

NLR family, pyrin domain containing 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of NLRP3 protein]

NCBI chr10:44,826,299...44,853,373
Ensembl chr10:44,828,014...44,853,394

G

nitric oxide synthase 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Raloxifene Hydrochloride co-treated with 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid] results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of NOS2 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS2 mRNA]

PMID:10760090 PMID:11007951 PMID:28138957

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NOS3 mRNA]

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

neuropeptide Y receptor Y1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of NPY1R mRNA]

NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

ISO
EXP

Cycloheximide results in decreased expression of NQO1 mRNA
Cycloheximide inhibits the reaction [notoginsenoside R1 results in increased expression of NQO1 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]]; Cycloheximide inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [arsenite results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Cadmium results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Lead results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Mercury results in increased expression of NQO1 mRNA]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Chromium results in increased expression of NQO1 mRNA]; Cycloheximide promotes the reaction [Copper results in decreased expression of NQO1 mRNA]

PMID:14510636 PMID:16243960 PMID:18474416 PMID:24437944

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

nuclear receptor subfamily 0, group B, member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of NR0B1 mRNA]

NCBI chr X:54,707,658...54,711,786
Ensembl chr X:54,707,639...54,712,083

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NR1H3 mRNA
Cycloheximide results in increased expression of NR1H3 mRNA

NCBI chr 3:97,614,616...97,632,053
Ensembl chr 3:97,614,616...97,624,532

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [Dexamethasone affects the localization of NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone binds to NR3C1 protein]; Cycloheximide inhibits the reaction [Dexamethasone results in increased degradation of NR3C1 protein]
Cycloheximide promotes the reaction [tubacin results in decreased expression of and results in increased degradation of NR3C1 mRNA]

PMID:21569845 PMID:31778773

NCBI chr18:31,522,783...31,644,508
Ensembl chr18:31,522,783...31,643,843

G

nuclear receptor subfamily 4, group A, member 1

multiple interactions

EXP

Cycloheximide promotes the reaction [LHB protein results in increased expression of NR4A1 mRNA]

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear casein kinase and cyclin-dependent kinase substrate 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of NUCKS1 mRNA

NCBI chr13:45,897,275...45,926,491
Ensembl chr13:45,897,248...45,923,101

G

ornithine decarboxylase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Paraquat results in increased activity of ODC1 protein]

NCBI chr 6:46,058,439...46,065,148
Ensembl chr 6:46,058,463...46,065,146

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions

EXP

Cycloheximide inhibits the reaction [15-deoxyprostaglandin J2 results in increased expression of OPA1 protein alternative form]

NCBI chr11:84,612,943...84,690,025
Ensembl chr11:84,615,340...84,689,955

G

opioid receptor, kappa 1

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of OPRK1 mRNA
Cycloheximide results in increased expression of OPRK1 mRNA

NCBI chr 5:18,657,866...18,675,671
Ensembl chr 5:18,657,871...18,675,671

G

opioid receptor, mu 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dronabinol results in increased expression of OPRM1 mRNA]

NCBI chr 1:45,565,371...45,818,722
Ensembl chr 1:45,565,371...45,638,756

G

orosomucoid 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Dexamethasone results in increased expression of ORM1 mRNA]

NCBI chr 5:81,788,509...81,791,661
Ensembl chr 5:81,788,395...81,791,667

G

proliferation-associated 2G4

multiple interactions

ISO

PA2G4 protein promotes the reaction [Cycloheximide results in decreased expression of ERBB2 protein]

NCBI chr 7:1,569,326...1,576,794
Ensembl chr 7:1,569,327...1,576,802

G

pappalysin

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PAPPA mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PAPPA mRNA

NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:83,513,358...83,751,361

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO
EXP

[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]
Cycloheximide inhibits the reaction [ammonium acetate results in increased expression of PARP1 protein]
Cycloheximide results in increased cleavage of PARP1 protein

PMID:12925536 PMID:15147502 PMID:16051428 PMID:18222423

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PAX3 mRNA]

NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141

G

polycomb group ring finger 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PCGF1 mRNA

NCBI chr 4:117,140,144...117,144,729
Ensembl chr 4:117,142,061...117,145,040

G

phosphoenolpyruvate carboxykinase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone results in decreased expression of PCK1 mRNA]

NCBI chr 3:182,348,572...182,354,521
Ensembl chr 3:182,348,572...182,354,561

G

proliferating cell nuclear antigen

multiple interactions

ISO

Cycloheximide inhibits the reaction [Vitamin K 3 results in decreased expression of PCNA protein]

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

programmed cell death 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PDCD2 mRNA]

NCBI chr 1:65,158,034...65,163,524
Ensembl chr 1:65,158,034...65,163,524

G

proenkephalin

multiple interactions

EXP

Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PENK mRNA]; Cycloheximide promotes the reaction [Colforsin results in increased expression of PENK mRNA]

NCBI chr 5:21,981,381...21,987,074
Ensembl chr 5:21,981,382...21,986,705

G

phosphatidylinositol 4-kinase alpha

multiple interactions

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PI4KA mRNA]

NCBI chr11:83,609,148...83,726,876
Ensembl chr11:97,113,245...97,228,315

G

phosphatidylinositol glycan anchor biosynthesis, class H

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGH mRNA]

NCBI chr 6:97,874,903...97,897,188
Ensembl chr 6:103,601,520...103,630,159

G

phosphatidylinositol glycan anchor biosynthesis, class K

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIGK mRNA]

NCBI chr 2:241,630,021...241,715,493
Ensembl chr 2:244,250,621...244,376,030

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3C3 mRNA]

NCBI chr18:22,119,677...22,203,546
Ensembl chr18:22,119,792...22,203,539

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PIK3CG mRNA]

NCBI chr 6:54,494,247...54,529,563
Ensembl chr 6:54,478,603...54,529,509

G

paired immunoglobin-like type 2 receptor beta 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PILRB mRNA

NCBI chr12:18,516,161...18,525,375

G

phospholipase A2 group IB

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G1B mRNA]

NCBI chr12:46,802,932...46,814,511
Ensembl chr12:46,802,939...46,813,693

G

phospholipase A2 group 4A

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dexamethasone inhibits the reaction [Zymosan results in increased activity of PLA2G4A protein]]

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

plasminogen activator, tissue type

multiple interactions

EXP

Cycloheximide promotes the reaction [Isoproterenol results in increased expression of PLAT mRNA]

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen activator, urokinase receptor

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with IFNA2 protein] results in increased expression of PLAUR mRNA; [Cycloheximide co-treated with IFNG protein] results in increased expression of PLAUR mRNA
Cycloheximide results in increased expression of PLAUR mRNA

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:89,178,453...89,198,130

G

phospholipase D family, member 3

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PLD3 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PLD3 mRNA

NCBI chr 1:91,949,465...91,971,834
Ensembl chr 1:91,949,467...91,961,207

G

phospholamban

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PLN mRNA]

NCBI chr20:33,166,512...33,182,241
Ensembl chr20:33,172,494...33,182,241

G

proteolipid protein 1

multiple interactions
increases expression

EXP

Cycloheximide promotes the reaction [Tretinoin results in increased expression of PLP1 mRNA]
Cycloheximide results in increased expression of PLP1 mRNA

NCBI chr X:104,933,921...104,993,317
Ensembl chr X:104,975,780...104,993,314

G

phorbol-12-myristate-13-acetate-induced protein 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Fenretinide results in increased expression of PMAIP1 protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PMAIP1 protein]

NCBI chr18:62,255,970...62,262,384
Ensembl chr18:62,255,598...62,262,382

G

PML nuclear body scaffold

decreases degradation
multiple interactions

ISO

Cycloheximide results in decreased degradation of PML protein modified form
Cycloheximide inhibits the reaction [arsenic trioxide results in increased degradation of PML protein]

PMID:20943951 PMID:26049103

NCBI chr 8:67,523,164...67,557,801
Ensembl chr 8:67,523,164...67,576,083

G

patatin-like phospholipase domain containing 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [rosiglitazone results in increased expression of PNPLA2 protein]

NCBI chr 1:205,982,279...205,987,361
Ensembl chr 1:205,982,258...205,987,359

G

patatin-like phospholipase domain containing 6

multiple interactions

ISO

Cycloheximide inhibits the reaction [[Colforsin co-treated with 1-Methyl-3-isobutylxanthine] results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]; Cycloheximide inhibits the reaction [Colforsin results in increased activity of PNPLA6 protein]

NCBI chr12:1,574,387...1,603,735
Ensembl chr12:6,372,293...6,401,631

G

proopiomelanocortin

multiple interactions

EXP

Cycloheximide inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones]

NCBI chr 6:32,659,137...32,665,175
Ensembl chr 6:32,659,346...32,665,173

G

cytochrome p450 oxidoreductase

multiple interactions
decreases expression

ISO

POR protein mutant form promotes the reaction [Cycloheximide results in decreased expression of POR protein]

NCBI chr12:26,587,674...26,655,612
Ensembl chr12:26,587,674...26,635,809

G

POU class 5 homeobox 1

multiple interactions

ISO

Cycloheximide promotes the reaction [Cobalt results in increased expression of POU5F1 protein]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of POU5F1 protein]

NCBI chr20:3,227,836...3,232,598
Ensembl chr20:3,227,837...3,232,598

G

peter pan homolog

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPAN mRNA

NCBI chr 8:27,700,147...27,704,127
Ensembl chr 8:27,700,152...27,704,128

G

protein phosphatase 1, regulatory subunit 15A

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of PPP1R15A protein
arsenite inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of PPP1R15A protein]; Cycloheximide affects the reaction [arsenite results in increased expression of PPP1R15A protein]; Cycloheximide inhibits the reaction [Thapsigargin results in increased expression of PPP1R15A protein]

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 3 catalytic subunit beta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPP3CB mRNA]

NCBI chr15:3,809,182...3,854,204
Ensembl chr15:3,809,262...3,854,203

G

protein phosphatase 4, regulatory subunit 3B

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PPP4R3B mRNA

NCBI chr14:107,118,116...107,166,121
Ensembl chr14:107,118,131...107,166,134

G

peroxiredoxin 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRDX4 mRNA]

NCBI chr X:40,026,762...40,044,066
Ensembl chr X:43,876,417...43,893,812

G

protein kinase C, beta

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of PRKCB mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PRKCB mRNA

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

protein kinase C, delta

multiple interactions

EXP

Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCD protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCD protein]

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase C, epsilon

multiple interactions

EXP

Cycloheximide inhibits the reaction [Buthionine Sulfoximine results in increased expression of PRKCE protein]; Cycloheximide inhibits the reaction [diethyl maleate results in increased expression of PRKCE protein]

NCBI chr 6:13,718,050...14,204,931
Ensembl chr 6:13,718,050...14,204,288

G

protein kinase C, zeta

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PRKCZ mRNA]

NCBI chr 5:171,101,774...171,212,694
Ensembl chr 5:171,101,774...171,212,674

G

presenilin 1

multiple interactions

ISO

[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

presenilin 2

multiple interactions

ISO

Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]

NCBI chr13:94,499,451...94,528,419
Ensembl chr13:94,499,928...94,525,116

G

proteasome 26S subunit, non-ATPase 1

multiple interactions

ISO

PSMD1 protein affects the reaction [Cycloheximide results in increased degradation of MAF1 protein]

NCBI chr 9:94,157,971...94,233,218
Ensembl chr 9:94,157,971...94,233,218

G

proteasome activator subunit 3

multiple interactions

ISO

PSME3 protein affects the reaction [Cycloheximide results in decreased expression of CDKN1A protein]

NCBI chr10:86,757,933...86,765,719
Ensembl chr10:86,757,899...86,818,033

G

phosphatase and tensin homolog

multiple interactions

ISO

Cycloheximide affects the reaction [sodium arsenite affects the expression of PTEN protein]; Cycloheximide inhibits the reaction [Lovastatin results in increased expression of PTEN protein]; Cycloheximide inhibits the reaction [Rosiglitazone results in increased expression of PTEN protein]

PMID:16425225 PMID:33256086

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

ISO
EXP

Cycloheximide inhibits the reaction [Dinoprostone promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein]; Cycloheximide inhibits the reaction [Tretinoin results in increased expression of PTGS2 protein]
Cycloheximide results in increased expression of PTGS2 mRNA
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]]; Cycloheximide inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; Cycloheximide inhibits the reaction [KNG1 protein results in increased phosphorylation of PTGS2 protein]; Cycloheximide promotes the reaction [IL1B protein results in increased expression of PTGS2 mRNA]

PMID:7575673 PMID:11112151 PMID:11286988 PMID:16696851 PMID:16894348 More...

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

pleiotrophin

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of PTN mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTN mRNA

NCBI chr 4:66,260,764...66,342,614
Ensembl chr 4:66,260,764...66,342,482

G

protein tyrosine phosphatase 4A1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Medroxyprogesterone Acetate inhibits the reaction [Estradiol results in increased expression of PTP4A1 mRNA]]; Cycloheximide promotes the reaction [Estradiol results in increased expression of PTP4A1 mRNA]

NCBI chr 9:40,710,250...40,718,176
Ensembl chr 9:40,710,250...40,718,176

G

protein tyrosine phosphatase 4A3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of PTP4A3 mRNA

NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:107,541,047...107,549,949

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:106,756,896...106,816,828

G

Rab9 effector protein with kelch motifs

affects response to substance

ISO

RABEPK gene SNP affects the susceptibility to Cycloheximide

NCBI chr 3:38,460,205...38,481,077
Ensembl chr 3:38,460,206...38,480,688

G

Rap guanine nucleotide exchange factor 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RAPGEF1 mRNA

NCBI chr 3:33,296,211...33,414,119
Ensembl chr 3:33,296,230...33,414,119

G

retinoic acid receptor, beta

multiple interactions
increases expression

EXP

Cycloheximide promotes the reaction [Tretinoin results in increased expression of RARB mRNA]
Cycloheximide results in increased expression of RARB mRNA

NCBI chr15:10,837,252...11,482,037
Ensembl chr15:11,131,358...11,482,040

G

retinoic acid receptor responder 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of RARRES2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RARRES2 mRNA

NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457

G

RB transcriptional corepressor 1

multiple interactions

ISO

RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]

NCBI chr15:54,780,858...54,911,989
Ensembl chr15:54,780,858...54,911,857

G

RB transcriptional corepressor like 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of RBL1 mRNA]; palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]; RB1 protein affects the reaction [palbociclib promotes the reaction [Cycloheximide results in decreased expression of RBL1 protein]]

PMID:11007951 PMID:20100483

NCBI chr 3:166,226,187...166,289,862
Ensembl chr 3:166,226,198...166,289,376

G

recombination signal binding protein for immunoglobulin kappa J region

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RBPJ protein
[PSEN1 protein affects the susceptibility to Ammonium Chloride] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to benzyloxycarbonylleucyl-leucyl-leucine aldehyde] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; [PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN1 protein affects the expression of RBPJ protein]; Cycloheximide affects the reaction [PSEN2 protein affects the expression of RBPJ protein]; Cycloheximide inhibits the reaction [Ammonium Chloride results in increased expression of RBPJ protein]; Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of RBPJ protein]; N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester inhibits the reaction [Cycloheximide results in decreased expression of RBPJ protein]; PSEN2 protein affects the reaction [Cycloheximide results in decreased expression of RBPJ protein]

NCBI chr14:61,551,366...61,736,220
Ensembl chr14:61,551,366...61,736,307

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
affects localization

ISO

[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide results in decreased expression of [NFKB1 protein binds to RELA protein]
Cycloheximide affects the localization of RELA protein

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Cycloheximide inhibits the reaction [Terbutaline results in increased secretion of REN protein]

NCBI chr13:47,348,312...47,359,539
Ensembl chr13:47,348,143...47,359,543

G

ret proto-oncogene

decreases expression

EXP

Cycloheximide results in decreased expression of RET protein

NCBI chr 4:152,998,344...153,040,556
Ensembl chr 4:152,998,812...153,040,556

G

regucalcin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RGN mRNA]

NCBI chr X:4,172,537...4,190,112
Ensembl chr X:4,172,537...4,190,251

G

ras homolog family member B

multiple interactions

ISO

Cycloheximide inhibits the reaction [cytotoxic necrotizing factor type 1 results in increased expression of RHOB protein]

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772

G

ras homolog family member C

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RHOC protein
RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]

NCBI chr 2:194,975,586...194,981,637
Ensembl chr 2:194,975,242...194,983,745

G

RPTOR independent companion of MTOR, complex 2

multiple interactions

ISO

Cycloheximide promotes the reaction [FBXW7 protein binds to and results in decreased expression of RICTOR protein]
Cycloheximide inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA]

PMID:25897075 PMID:29576526

NCBI chr 2:57,539,279...57,631,291
Ensembl chr 2:57,539,311...57,631,288

G

ring finger protein 168

multiple interactions

ISO

RNF168 protein promotes the reaction [Cycloheximide results in decreased expression of RHOC protein]

NCBI chr11:81,991,352...82,013,306
Ensembl chr11:81,991,360...82,013,306

G

ring finger protein 4

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of RNF4 protein
Cycloheximide inhibits the reaction [TAK-243 affects the localization of RNF4 protein]

PMID:20943951 PMID:31285264

NCBI chr14:80,625,864...80,647,138
Ensembl chr14:80,625,866...80,647,148

G

ribosomal protein S27-like

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of RPS27L mRNA

NCBI chr 8:76,443,658...76,448,593
Ensembl chr12:33,713,661...33,714,130
Ensembl chr 8:33,713,661...33,714,130

G

ribosomal protein S6 kinase B1

multiple interactions

EXP

Cycloheximide inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]]

NCBI chr10:71,817,794...71,865,211
Ensembl chr10:71,815,614...71,865,238

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Progesterone results in increased expression of RRM2 mRNA]

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RUNX family transcription factor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Cryptoxanthins results in increased expression of RUNX2 mRNA]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of RUNX2 mRNA]

PMID:15962303 PMID:18327666

NCBI chr 9:23,661,278...23,990,248
Ensembl chr 9:23,664,952...23,990,027

G

S100 calcium-binding protein A4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of S100A4 mRNA]

NCBI chr 2:178,388,529...178,390,838
Ensembl chr 2:178,388,526...178,390,837

G

S100 calcium binding protein B

decreases expression

EXP

Cycloheximide results in decreased expression of S100B mRNA

NCBI chr20:12,372,345...12,381,159
Ensembl chr20:12,372,348...12,381,081

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions

ISO

[Cycloheximide co-treated with N(1),N(11)-diethylnorspermine] promotes the reaction [RELA protein binds to SAT1 promoter]; Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]; Cycloheximide promotes the reaction [RELA protein binds to SAT1 promoter]; NFKBIA protein affects the reaction [Cycloheximide promotes the reaction [N(1),N(11)-diethylnorspermine results in increased expression of SAT1 mRNA]]

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374

G

stearoyl-CoA desaturase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Clofibrate results in increased expression of SCD1 mRNA]

NCBI chr 1:253,218,968...253,232,101
Ensembl chr 1:253,218,970...253,231,785

G

SEC11 homolog C, signal peptidase complex subunit

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] affects the expression of SEC11C mRNA

NCBI chr18:59,320,932...59,337,272
Ensembl chr18:61,590,885...61,607,348

G

serpin family B member 9

multiple interactions

ISO

Cycloheximide promotes the reaction [moxestrol results in increased expression of SERPINB9 mRNA]

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

serpin family E member 1

multiple interactions

ISO
EXP

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA]
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide promotes the reaction [FGF2 protein results in increased expression of SERPINE1 mRNA]
Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SERPINE1 mRNA]

PMID:9798919 PMID:11007951 PMID:12111005

NCBI chr12:25,237,977...25,248,356
Ensembl chr12:25,237,952...25,248,357

G

serpin family E member 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SERPINE2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERPINE2 mRNA

NCBI chr 9:88,573,138...88,637,252
Ensembl chr 9:88,573,149...88,637,202

G

SERTA domain containing 2

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SERTAD2 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SERTAD2 mRNA

NCBI chr14:94,733,637...94,838,200
Ensembl chr14:98,934,769...99,041,468

G

sestrin 2

multiple interactions
decreases expression

ISO

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Cycloheximide results in decreased expression of SESN2 protein]; Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of SESN2 protein]

NCBI chr 5:149,986,304...150,005,255
Ensembl chr 5:149,986,317...150,005,255

G

serum/glucocorticoid regulated kinase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Cadmium Chloride results in increased expression of SGK1 protein]

NCBI chr 1:24,799,391...24,916,886
Ensembl chr 1:24,799,396...24,807,231

G

signal-regulatory protein alpha

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SIRPA mRNA]

NCBI chr 3:137,272,932...137,311,279
Ensembl chr 3:137,273,042...137,311,279

G

sirtuin 1

multiple interactions
decreases expression

ISO

Cycloheximide promotes the reaction [antimony trichloride results in decreased expression of SIRT1 protein]; pyrazolanthrone inhibits the reaction [Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]]; Silicon Dioxide promotes the reaction [Cycloheximide results in decreased expression of SIRT1 protein]

PMID:30055241 PMID:31082419

NCBI chr20:25,305,953...25,328,000
Ensembl chr20:25,305,476...25,328,000

G

src-like adaptor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLA mRNA]

NCBI chr 7:100,423,467...100,473,840
Ensembl chr 7:100,424,169...100,473,684

G

solute carrier family 16 member 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC16A1 mRNA

NCBI chr 2:194,805,556...194,832,966
Ensembl chr 2:194,812,502...194,832,977

G

solute carrier family 1 member 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Tretinoin results in increased expression of SLC1A1 mRNA]

NCBI chr 1:235,963,455...236,043,572
Ensembl chr 1:235,963,437...236,045,469

G

solute carrier family 22 member 4

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SLC22A4 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC22A4 mRNA

NCBI chr10:38,634,098...38,687,409
Ensembl chr10:38,634,098...38,679,920

G

solute carrier family 25, member 27

increases expression

ISO

Cycloheximide results in increased expression of SLC25A27 mRNA

NCBI chr 9:17,306,898...17,333,942
Ensembl chr 9:24,804,185...24,831,217

G

solute carrier family 2 member 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC2A1 mRNA

NCBI chr 5:138,002,522...138,030,742
Ensembl chr 5:138,002,522...138,030,742

G

solute carrier family 2 member 4

multiple interactions

EXP

Cycloheximide inhibits the reaction [4-hydroxyisoleucine results in increased localization of SLC2A4 protein]

NCBI chr10:55,164,721...55,170,289
Ensembl chr10:55,164,721...55,170,270

G

solute carrier family 2 member 5

multiple interactions

EXP

Cycloheximide inhibits the reaction [Fructose promotes the reaction [SLC2A5 protein results in increased uptake of Fructose]]

NCBI chr 5:165,857,412...165,892,928
Ensembl chr 5:165,866,172...165,894,038

G

solute carrier family 39 member 4

multiple interactions

ISO

Cycloheximide inhibits the reaction [Zinc deficiency results in increased expression of SLC39A4 mRNA]; Cycloheximide inhibits the reaction [Zinc results in decreased expression of SLC39A4 mRNA]

NCBI chr 7:110,214,017...110,218,202
Ensembl chr 7:110,214,017...110,218,202

G

solute carrier family 3 member 2

increases expression

ISO

Cycloheximide results in increased expression of SLC3A2 mRNA

NCBI chr 1:215,033,601...215,048,064
Ensembl chr 1:215,033,601...215,048,064

G

solute carrier family 5 member 5

increases expression

ISO

Cycloheximide results in increased expression of SLC5A5 mRNA

NCBI chr16:18,580,705...18,590,692
Ensembl chr16:18,580,705...18,590,691

G

solute carrier family 7 member 5

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

survival of motor neuron 1, telomeric

multiple interactions

ISO

Cycloheximide inhibits the reaction [Paraquat results in increased expression of SMN1 mRNA alternative form]

NCBI chr 2:33,224,115...33,235,162
Ensembl chr 2:33,224,095...33,235,162

G

SNW domain containing 1

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SNW1 mRNA

NCBI chr 6:112,826,374...112,850,459
Ensembl chr 6:112,826,381...112,858,180

G

suppressor of cytokine signaling 1

multiple interactions
increases expression

ISO

[afimoxifene co-treated with Cycloheximide] results in increased expression of SOCS1 mRNA
Cycloheximide results in increased expression of SOCS1 mRNA

PMID:16849584 PMID:23237828

NCBI chr10:5,389,574...5,391,265
Ensembl chr10:5,389,334...5,391,847

G

suppressor of cytokine signaling 2

multiple interactions
increases expression

ISO

Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS2 mRNA]
Cycloheximide results in increased expression of SOCS2 mRNA

PMID:15371557 PMID:23237828

NCBI chr 7:31,890,564...31,932,092
Ensembl chr 7:31,874,463...31,930,423

G

suppressor of cytokine signaling 3

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SOCS3 mRNA
Dactinomycin inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]; U 0126 inhibits the reaction [Cycloheximide results in increased expression of SOCS3 mRNA]

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

suppressor of cytokine signaling 4

increases expression

ISO

Cycloheximide results in increased expression of SOCS4 mRNA

NCBI chr15:23,003,130...23,017,615
Ensembl chr15:23,002,883...23,022,499

G

suppressor of cytokine signaling 5

increases expression

ISO

Cycloheximide results in increased expression of SOCS5 mRNA

NCBI chr 6:13,235,157...13,266,161
Ensembl chr 6:13,234,062...13,273,883

G

suppressor of cytokine signaling 6

increases expression

ISO

Cycloheximide results in increased expression of SOCS6 mRNA

NCBI chr18:84,386,587...84,413,927
Ensembl chr18:84,384,573...84,414,053

G

suppressor of cytokine signaling 7

increases expression

ISO

Cycloheximide results in increased expression of SOCS7 mRNA

NCBI chr10:82,848,525...82,885,201
Ensembl chr10:82,848,612...82,885,201

G

superoxide dismutase 2

multiple interactions
increases expression

ISO

Cycloheximide inhibits the reaction [NGF protein results in increased expression of SOD2 protein]; Cycloheximide inhibits the reaction [polysaccharide-K results in increased expression of SOD2]
Cycloheximide results in increased expression of SOD2 mRNA
Cycloheximide promotes the reaction [Paclitaxel results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vinblastine results in increased expression of SOD2 mRNA]; Cycloheximide promotes the reaction [Vincristine results in increased expression of SOD2 mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Cycloheximide results in increased expression of SOD2 mRNA]

PMID:8037686 PMID:9852137 PMID:11154046 PMID:15330761 PMID:20495008

NCBI chr 1:50,043,323...50,050,168
Ensembl chr 1:50,043,325...50,050,168

G

sortilin 1

multiple interactions
increases degradation

EXP
ISO

SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]
Cycloheximide results in increased degradation of SORT1 protein mutant form
Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]; Docosahexaenoic Acids inhibits the reaction [Cycloheximide promotes the reaction [Palmitic Acid results in increased degradation of SORT1 protein]]

PMID:22555848 PMID:24986865 PMID:25805502

NCBI chr 2:198,609,466...198,690,481
Ensembl chr 2:198,612,148...198,690,481

G

SOS Ras/Rac guanine nucleotide exchange factor 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOS1 mRNA]

NCBI chr 6:20,286,117...20,363,350
Ensembl chr 6:20,286,117...20,363,350

G

spectrin, alpha, non-erythrocytic 1

multiple interactions

ISO

[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

NCBI chr 3:33,639,020...33,703,890
Ensembl chr 3:33,607,210...33,703,889

G

sequestosome 1

multiple interactions
decreases expression

ISO

[sodium arsenite results in increased abundance of arsenite] inhibits the reaction [Cycloheximide results in decreased expression of SQSTM1 protein]; Cycloheximide promotes the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]

PMID:31781319 PMID:34405320

NCBI chr10:35,026,598...35,037,750
Ensembl chr10:35,026,598...35,037,750

G

SRC proto-oncogene, non-receptor tyrosine kinase

increases localization

EXP

Cycloheximide results in increased localization of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

serine racemase

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [methyllycaconitine results in increased expression of SRR protein]

NCBI chr10:60,267,936...60,285,094
Ensembl chr10:60,268,859...60,285,100

G

single stranded DNA binding protein 1

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of SSBP1 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SSBP1 mRNA

NCBI chr 4:70,232,740...70,242,824
Ensembl chr 4:70,232,794...70,243,700

G

ST18 C2H2C-type zinc finger transcription factor

increases expression

ISO

Cycloheximide results in increased expression of ST18 mRNA

NCBI chr 5:17,369,383...17,701,094
Ensembl chr 5:17,371,000...17,458,676

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of ST8SIA1 mRNA
Cycloheximide results in increased expression of ST8SIA1 mRNA

NCBI chr 4:177,513,966...177,651,553
Ensembl chr 4:177,520,926...177,651,553

G

serine/threonine kinase 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STK3 mRNA]

NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:67,938,378...68,208,508

G

syntaxin 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of STX2 mRNA]

NCBI chr12:33,315,447...33,350,788
Ensembl chr12:33,315,750...33,350,788

G

sulfotransferase family 1A member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 mRNA]

NCBI chr 1:190,702,592...190,706,112
Ensembl chr 1:190,702,592...190,706,131

G

sulfotransferase family 2B member 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SULT2B1 mRNA]

NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:105,336,614...105,397,744

G

SPT4 homolog, DSIF elongation factor subunit

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of SUPT4H1 mRNA]

NCBI chr10:73,036,560...73,042,821
Ensembl chr10:73,036,343...73,043,088

G

synaptopodin

multiple interactions
increases expression

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of SYNPO mRNA
Cycloheximide results in increased expression of SYNPO mRNA

NCBI chr18:54,048,299...54,106,388
Ensembl chr18:56,319,571...56,353,306

G

tachykinin, precursor 1

multiple interactions

EXP

Cycloheximide inhibits the reaction [KNG1 protein results in increased secretion of TAC1 protein]

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

transforming, acidic coiled-coil containing protein 1

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of TACC1 mRNA
Cycloheximide results in increased expression of TACC1 mRNA

NCBI chr16:73,515,016...73,598,395
Ensembl chr16:73,514,889...73,598,394

G

TAR DNA binding protein

multiple interactions
decreases expression

ISO

Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of and results in decreased stability of TARDBP protein mutant form]; epoxomicin inhibits the reaction [Cycloheximide results in decreased expression of TARDBP protein]

NCBI chr 5:164,330,452...164,348,435
Ensembl chr 5:164,334,924...164,345,204

G

taste receptor, type 2, member 106

multiple interactions

ISO

TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK1 protein]; TAS2R105 protein affects the reaction [Cycloheximide results in increased phosphorylation of MAPK3 protein]

NCBI chr 4:165,313,210...165,314,133
Ensembl chr 4:167,044,628...167,045,551

G

T-box transcription factor 3

increases expression

ISO

cycloheximide co-treated with all-trans-retinoic acid increases expression of TBX3 mRNA in melanoma cells

RGD

NCBI chr12:42,540,378...42,555,490
Ensembl chr12:42,540,378...42,554,171

G

testin gene

multiple interactions
decreases secretion
decreases expression

EXP

Cycloheximide inhibits the reaction [lonidamine results in increased expression of TESTIN mRNA]; Cycloheximide inhibits the reaction [lonidamine results in increased secretion of TESTIN protein]
Cycloheximide results in decreased secretion of TESTIN protein
Cycloheximide results in decreased expression of TESTIN mRNA

NCBI chr17:3,824,222...3,859,385
Ensembl chr17:3,852,404...3,864,993

G

transcription factor AP-2 alpha

decreases stability
multiple interactions

ISO

Cycloheximide results in decreased stability of TFAP2A protein
LINC-ROR promotes the reaction [Cycloheximide results in decreased stability of TFAP2A protein]

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

trefoil factor 1

multiple interactions
increases expression

ISO

[Cycloheximide co-treated with Estradiol] results in increased expression of TFF1 mRNA; Cycloheximide inhibits the reaction [bisphenol A results in increased expression of TFF1 mRNA]
Cycloheximide results in increased expression of TFF1 mRNA

PMID:15072547 PMID:20875696

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956

G

transforming growth factor alpha

increases expression

ISO

Cycloheximide results in increased expression of TGFA mRNA

NCBI chr 4:120,175,549...120,258,342
Ensembl chr 4:120,175,593...120,258,339

G

transforming growth factor, beta 1

multiple interactions
decreases activity

EXP
ISO

Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of BAX protein]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of SERPINE1 mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]
Cycloheximide results in decreased activity of TGFB1 protein
Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA]]; Cycloheximide inhibits the reaction [TGFB1 protein results in decreased expression of AHR mRNA]; Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]

PMID:9145908 PMID:9790906 PMID:9798919 PMID:21303922 PMID:31652400

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta receptor 2

multiple interactions

ISO

Cycloheximide inhibits the reaction [tolfenamic acid results in decreased expression of TGFBR2 protein]

NCBI chr 8:124,672,677...124,761,741
Ensembl chr 8:124,674,986...124,761,469

G

thrombomodulin

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THBD mRNA]

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582

G

thrombospondin 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Testosterone results in decreased expression of THBS1 mRNA]

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

Thy-1 cell surface antigen

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of THY1 mRNA]

NCBI chr 8:53,286,396...53,291,541
Ensembl chr 8:53,286,148...53,291,540

G

TIA1 cytotoxic granule-associated RNA binding protein

multiple interactions

EXP

Cycloheximide inhibits the reaction [sodium arsenite affects the localization of TIA1 protein]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]

PMID:19171178 PMID:22555848

NCBI chr 4:120,410,180...120,440,676
Ensembl chr 4:120,410,251...120,440,665

G

translocase of inner mitochondrial membrane 17A

multiple interactions
decreases expression

ISO

Cycloheximide results in decreased expression of and results in increased degradation of TIMM17A protein; YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein]
Cycloheximide results in decreased expression of TIMM17A protein

NCBI chr13:46,731,117...46,742,604
Ensembl chr13:49,282,918...49,307,904

G

TIMP metallopeptidase inhibitor 1

decreases response to substance

EXP

TIMP1 protein results in decreased susceptibility to Cycloheximide

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TCDD-inducible poly(ADP-ribose) polymerase

multiple interactions
increases expression

ISO

AHR protein promotes the reaction [Cycloheximide results in increased expression of TIPARP mRNA]; Cycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of TIPARP mRNA]

NCBI chr 2:149,753,682...149,780,327
Ensembl chr 2:152,063,751...152,090,406

G

tight junction protein 1

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [IFNG protein results in increased expression of TJP1 protein]
Cycloheximide results in decreased expression of TJP1 protein

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

transmembrane 7 superfamily member 3

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TM7SF3 mRNA

NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:181,248,822...181,280,844

G

transmembrane protein 263

increases expression
multiple interactions

ISO

Cycloheximide results in increased expression of TMEM263 mRNA
[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of TMEM263 mRNA

NCBI chr 7:20,497,852...20,516,011
Ensembl chr 7:20,497,852...20,516,428

G

tumor necrosis factor

increases response to substance
multiple interactions

ISO
EXP

TNF protein results in increased susceptibility to Cycloheximide
[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein; [Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNF] results in increased cleavage of BID protein; [TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; [TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein; Cycloheximide inhibits the reaction [CXCL8 protein affects the secretion of TNF protein]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CNR1 mRNA]]; Cycloheximide inhibits the reaction [Morphine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]]; Cycloheximide inhibits the reaction [SM 164 results in increased expression of TNF mRNA]; Cycloheximide inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL2 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]; Cycloheximide inhibits the reaction [TNF protein results in increased expression of MYLK protein]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL2 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CCL5 protein]]; Cycloheximide inhibits the reaction [tofacitinib inhibits the reaction [TNF protein results in increased expression of CXCL10 protein]]; Cycloheximide inhibits the reaction [Zinc deficiency promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF protein]]; Cycloheximide promotes the reaction [TNF protein results in increased expression of SOD2 mRNA]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased activity of CASP9 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP3 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of and results in increased activity of CASP8 protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of BID protein]; ITPK1 inhibits the reaction [[Cycloheximide co-treated with TNF] results in increased cleavage of PARP1 protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of BID protein]; ITPK1 mutant form promotes the reaction [[Cycloheximide co-treated with TNF protein] results in increased cleavage of PARP1 protein]; ITPK1 mutant form results in increased susceptibility to [Cycloheximide co-treated with TNF protein]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]; TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]; Ursodeoxycholic Acid analog inhibits the reaction [[TNF protein co-treated with Cycloheximide] results in increased secretion of CXCL8 protein]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL2 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CCL5 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of CXCL8 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of IL6 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased expression of NFKB1 mRNA]]; Ursodeoxycholic Acid analog inhibits the reaction [TNF protein promotes the reaction [Cycloheximide results in increased secretion of IL6 protein]]; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]
Cycloheximide inhibits the reaction [TNF protein results in decreased export of Potassium]; Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]; SORT1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; SORT1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [Pentanoic Acids results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]; TIA1 mutant form inhibits the reaction [sodium arsenite results in decreased susceptibility to [TNF protein co-treated with Cycloheximide]]
[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein; Cycloheximide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Cycloheximide inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; Cycloheximide promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

PMID:8037686 PMID:8071060 PMID:12185005 PMID:12812920 PMID:12925536 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF alpha induced protein 1

multiple interactions

ISO

TNFAIP1 protein inhibits the reaction [Cycloheximide results in decreased degradation of CSNK2B protein]

NCBI chr10:63,915,824...63,930,514
Ensembl chr10:63,915,825...63,930,514

G

TNF alpha induced protein 3

multiple interactions

ISO

[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA; Ursodeoxycholic Acid analog promotes the reaction [[TNF protein co-treated with Cycloheximide] results in increased expression of TNFAIP3 mRNA]

NCBI chr 1:15,528,921...15,543,993
Ensembl chr 1:15,528,921...15,543,979

G

TNF receptor superfamily member 10b

multiple interactions

ISO
EXP

Cycloheximide inhibits the reaction [Docetaxel results in increased expression of TNFRSF10A protein]; Cycloheximide inhibits the reaction [Paclitaxel results in increased expression of TNFRSF10A protein]
Cycloheximide inhibits the reaction [tetrachlorobenzoquinone results in increased expression of TNFRSF10B mRNA]

PMID:11212279 PMID:27484784

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 11B

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in decreased expression of TNFRSF11B mRNA

NCBI chr 7:87,456,318...87,484,324
Ensembl chr 7:87,456,319...87,485,075

G

TNF receptor superfamily member 8

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNFRSF8 mRNA]

NCBI chr 5:162,406,387...162,451,620
Ensembl chr 5:162,406,387...162,451,620

G

TNF superfamily member 10

multiple interactions

ISO

[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP9 protein; [Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [sodium arsenite results in increased expression of and results in increased localization of TNFRSF10B protein]] results in increased susceptibility to [TNFSF10 protein co-treated with Cycloheximide]; BCL2 protein inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[Cycloheximide co-treated with TNFSF10 protein] results in increased cleavage of and results in increased activity of CASP8 protein]; Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF10 mRNA]

PMID:11007951 PMID:18222423 PMID:22343715

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 11

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TNFSF11 mRNA]
Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Cryptoxanthins] promotes the reaction [Zinc Sulfate results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [[CSF1 protein co-treated with TNFSF11 protein co-treated with Zinc Sulfate] promotes the reaction [Cryptoxanthins results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Genistein promotes the reaction [[Zinc Sulfate co-treated with CSF1 protein co-treated with TNFSF11 protein] results in increased expression of CASP3 mRNA]]; Cycloheximide inhibits the reaction [Zinc Sulfate results in increased expression of TNFSF11 mRNA]

PMID:11007951 PMID:17295206 PMID:18327666 PMID:18636177

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

troponin C1, slow skeletal and cardiac type

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of TNNC1 mRNA]

NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070

G

tumor protein p53

increases response to substance
increases degradation
decreases expression
multiple interactions

ISO
EXP

TP53 mutant form results in increased susceptibility to Cycloheximide
Cycloheximide results in increased degradation of TP53 protein
Cycloheximide results in decreased expression of TP53 protein
Cycloheximide inhibits the reaction [Cyclosporine results in increased expression of TRP53 protein]
Cycloheximide inhibits the reaction [TGFB1 protein results in increased expression of TP53 protein]
Cycloheximide inhibits the reaction [Fluorouracil results in increased expression of TP53 protein]; Cycloheximide promotes the reaction [Chlorpyrifos results in decreased expression of TP53 protein]; leptomycin B inhibits the reaction [Cycloheximide results in increased degradation of TP53 protein]

PMID:9790906 PMID:10760090 PMID:15016801 PMID:20943951 PMID:21875941 More...

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

tumor protein p53 inducible protein 11

multiple interactions
decreases expression

ISO

Cycloheximide inhibits the reaction [arsenic trioxide results in increased expression of TP53I11 mRNA]
Cycloheximide results in decreased expression of TP53I11 mRNA

NCBI chr 3:79,144,824...79,160,056
Ensembl chr 3:99,600,159...99,615,432

G

tumor protein p63

multiple interactions

ISO

Cycloheximide inhibits the reaction [trichostatin A results in increased expression of TP63 protein alternative form]

NCBI chr11:88,343,647...88,554,543
Ensembl chr11:88,343,651...88,554,177

G

transient receptor potential cation channel, subfamily V, member 4

increases degradation
multiple interactions

ISO

Cycloheximide results in increased degradation of TRPV4 protein
tanshinone inhibits the reaction [Cycloheximide results in increased degradation of TRPV4 protein]

NCBI chr12:47,599,161...47,638,143
Ensembl chr12:47,599,035...47,638,143

G

tubulin gamma complex component 3

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of TUBGCP3 mRNA]

NCBI chr16:76,851,859...76,912,499
Ensembl chr16:83,553,959...83,614,623

G

thioredoxin reductase 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Acrolein results in increased expression of TXNRD1 mRNA]; Cycloheximide inhibits the reaction [sulforaphane results in increased expression of TXNRD1 mRNA]

PMID:12663510 PMID:15652504

NCBI chr 7:22,717,620...22,802,553
Ensembl chr 7:22,719,317...22,739,817

G

thymidine phosphorylase

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of TYMP protein
salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]; tanespimycin inhibits the reaction [salinomycin inhibits the reaction [Cycloheximide results in decreased expression of TYMP protein]]

NCBI chr 7:122,318,396...122,323,716
Ensembl chr 7:122,316,520...122,324,003

G

thymidylate synthetase

multiple interactions
decreases expression

ISO

cinobufagin promotes the reaction [Cycloheximide results in decreased expression of TYMS protein]; Cycloheximide inhibits the reaction [trichostatin A results in decreased expression of TYMS mRNA]

PMID:17172411 PMID:35427566

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

tyrosinase

multiple interactions

ISO

Cycloheximide inhibits the reaction [Quercetin results in increased activity of TYR protein]
[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein; SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein]

PMID:14717847 PMID:29621941

NCBI chr 1:150,527,687...150,622,857
Ensembl chr 1:150,527,687...150,622,857

G

ubiquitin C-terminal hydrolase L1

multiple interactions

EXP

Cycloheximide inhibits the reaction [Mevinphos results in increased expression of UCHL1 protein]

NCBI chr14:41,838,859...41,849,743
Ensembl chr14:41,838,861...41,849,417

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions
decreases expression

ISO

[Cycloheximide co-treated with Estradiol] results in decreased expression of UGT1A1 mRNA
Cycloheximide results in decreased expression of UGT1A1 mRNA

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

EXP

Cycloheximide inhibits the reaction [Paraquat results in increased expression of UGT1A6 mRNA]

NCBI chr 9:96,195,018...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

unc-51 like autophagy activating kinase 1

decreases expression
multiple interactions

ISO

Cycloheximide results in decreased expression of ULK1 protein
Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]

NCBI chr12:51,511,492...51,537,746
Ensembl chr12:51,511,492...51,537,746

G

ubiquitin specific peptidase 7

multiple interactions

ISO

USP7 protein inhibits the reaction [Cycloheximide results in decreased expression of HMOX1 protein]; USP7 protein mutant form affects the reaction [Cycloheximide results in decreased expression of HMOX1 protein]

NCBI chr10:7,335,508...7,432,018
Ensembl chr10:7,367,604...7,432,013

G

vasodilator-stimulated phosphoprotein

multiple interactions

ISO

VASP mutant form promotes the reaction [[TNF co-treated with Cycloheximide] results in increased cleavage of SPTAN1 protein]

NCBI chr 1:88,038,026...88,053,783
Ensembl chr 1:88,038,037...88,058,650

G

vascular cell adhesion molecule 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Lipopolysaccharides results in increased expression of VCAM1 protein]

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

multiple interactions
increases expression

EXP
ISO

Cycloheximide promotes the reaction [Estradiol results in increased expression of VEGFA mRNA alternative form]
Cycloheximide results in increased expression of VEGFA mRNA
Cycloheximide inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [nickel chloride results in increased expression of VEGFA mRNA]; Cycloheximide promotes the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]
[Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA

PMID:8344219 PMID:8537383 PMID:10788502 PMID:11641398

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor D

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VEGFD mRNA]

NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167

G

vir like m6A methyltransferase associated

affects response to substance

ISO

VIRMA gene SNP affects the susceptibility to Cycloheximide

NCBI chr 5:24,961,208...25,024,660
Ensembl chr 5:29,758,147...29,822,156

G

very low density lipoprotein receptor

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VLDLR mRNA]

NCBI chr 1:234,239,769...234,272,150
Ensembl chr 1:234,240,121...234,272,154

G

visinin-like 1

multiple interactions

ISO

Cycloheximide inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of VSNL1 mRNA]

NCBI chr 6:39,757,721...39,878,556
Ensembl chr 6:39,757,722...39,878,556

G

WW domain-containing oxidoreductase

affects response to substance

ISO

WWOX gene SNP affects the susceptibility to Cycloheximide

NCBI chr19:59,338,402...60,269,323
Ensembl chr19:59,341,233...60,269,441

G

X-linked inhibitor of apoptosis

multiple interactions

ISO

Cycloheximide inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA]

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

Yes1 associated transcriptional regulator

multiple interactions

ISO

[Tetrachlorodibenzodioxin co-treated with Cycloheximide] results in increased expression of YAP1 mRNA

NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437

G

YME1-like 1 ATPase

multiple interactions

ISO

YME1L1 mutant form inhibits the reaction [Cycloheximide results in increased degradation of TIMM17A protein]

NCBI chr17:85,287,607...85,326,068
Ensembl chr17:90,195,584...90,356,331

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

caspase 1

multiple interactions

EXP

Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]

NCBI chr 8:10,746,338...10,882,295
Ensembl chr 8:10,746,333...10,882,275

G

cereblon

multiple interactions
affects binding
increases response to substance

ISO

lenalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]
lenalidomide binds to [CRBN protein binds to DDB1 protein]; lenalidomide binds to [SALL4 protein binds to CRBN protein]
CRBN results in increased susceptibility to lenalidomide

PMID:25043012 PMID:25108355 PMID:26186254 PMID:30067223

NCBI chr 4:141,255,400...141,276,722
Ensembl chr 4:141,257,243...141,276,038

G

casein kinase 1, alpha 1

multiple interactions

ISO

lenalidomide results in increased degradation of and results in decreased expression of CSNK1A1 protein

NCBI chr18:57,285,156...57,320,540
Ensembl chr18:57,287,412...57,320,538

G

damage-specific DNA binding protein 1

affects binding

ISO

lenalidomide binds to [CRBN protein binds to DDB1 protein]

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

coagulation factor II (thrombin) receptor

decreases expression

ISO

lenalidomide results in decreased expression of F2R mRNA; lenalidomide results in decreased expression of F2R protein

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579

G

coagulation factor III, tissue factor

multiple interactions

ISO

[Dexamethasone co-treated with Lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with Lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein; [Dexamethasone co-treated with Lenalidomide] results in increased expression of F3 mRNA; [Dexamethasone co-treated with Lenalidomide] results in increased expression of F3 protein

NCBI chr 2:212,511,675...212,523,375
Ensembl chr 2:212,511,680...212,523,369

G

family with sequence similarity 83, member F

multiple interactions

ISO

lenalidomide results in increased degradation of and results in decreased expression of FAM83F protein

NCBI chr 7:114,091,356...114,120,640
Ensembl chr 7:114,091,335...114,120,638

G

Fas ligand

multiple interactions

ISO

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

Fibroblast growth factor receptor 1

affects expression

ISO

Lenalidomide affects the expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibroblast growth factor receptor 2

decreases expression

ISO

Lenalidomide results in decreased expression of FGFR2 mRNA; Lenalidomide results in decreased expression of FGFR2 protein

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

fibroblast growth factor receptor 3

decreases expression

ISO

Lenalidomide results in decreased expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

interleukin 12B

multiple interactions

ISO

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 1 alpha

multiple interactions

ISO

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1A mRNA]

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

multiple interactions

ISO
EXP

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1B mRNA]
Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of IL1B protein]

PMID:16510725 PMID:30660605

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

decreases expression

ISO

lenalidomide results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor antagonist

multiple interactions

ISO

lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

multiple interactions

ISO

lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 6 cytokine family signal transducer

decreases expression

ISO

lenalidomide results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

insulin 1

multiple interactions

EXP

Lenalidomide inhibits the reaction [Arsenic Trioxide inhibits the reaction [[Glucose co-treated with Lipopolysaccharides] results in increased secretion of INS1 protein]]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

Meis homeobox 2

multiple interactions

ISO

lenalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]

NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751

G

RAB28, member RAS oncogene family

multiple interactions

ISO

lenalidomide results in increased degradation of and results in decreased expression of RAB28 protein

NCBI chr14:69,245,846...69,322,968
Ensembl chr14:73,458,249...73,535,369

G

spalt-like transcription factor 4

affects binding
multiple interactions

ISO

lenalidomide binds to [SALL4 protein binds to CRBN protein]
lenalidomide results in increased degradation of and results in decreased expression of SALL4 protein

NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743

G

superoxide dismutase 1

multiple interactions

ISO

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1A mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL1B mRNA]; lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]; lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

TEK receptor tyrosine kinase

decreases expression

ISO

lenalidomide results in decreased expression of TEK mRNA

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:114,723,006...114,849,991

G

transforming growth factor, beta 1

multiple interactions

ISO

lenalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta receptor 1

decreases expression

ISO

lenalidomide results in decreased expression of TGFBR1 mRNA; lenalidomide results in decreased expression of TGFBR1 protein

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260

G

tumor necrosis factor

multiple interactions

ISO
EXP

lenalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]
Lenalidomide inhibits the reaction [[Arsenic Trioxide co-treated with Lipopolysaccharides] results in increased expression of TNF protein]

PMID:16510725 PMID:30660605

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 1A

decreases expression

ISO

lenalidomide results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF receptor superfamily member 1B

decreases expression

ISO

lenalidomide results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411

G

zinc finger protein 827

multiple interactions

ISO

lenalidomide results in increased degradation of and results in decreased expression of ZNF827 protein

NCBI chr19:45,624,849...45,791,739
Ensembl chr19:45,614,604...45,844,430

piperidin-2-one

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases abundance

ISO

CYP2E1 protein results in increased abundance of 2-piperidone

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bromodomain containing 4

multiple interactions

ISO

pomalidomide inhibits the reaction [ARV-825 results in increased degradation of BRD4 protein]

NCBI chr 7:11,866,997...11,946,575
Ensembl chr 7:11,866,997...11,946,923

G

caspase 3

multiple interactions

ISO

[afuresertib co-treated with pomalidomide co-treated with Dexamethasone] results in increased cleavage of CASP3 protein

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

multiple interactions

ISO

[afuresertib co-treated with pomalidomide co-treated with Dexamethasone] results in increased cleavage of CASP8 protein

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

C-C motif chemokine ligand 2

increases secretion

ISO

pomalidomide results in increased secretion of CCL2 protein

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

CCAAT/enhancer binding protein alpha

increases expression

ISO

pomalidomide results in increased expression of CEBPA mRNA

NCBI chr 1:96,896,584...96,899,256
Ensembl chr 1:96,896,171...96,899,309

G

CCAAT/enhancer binding protein delta

increases expression

ISO

pomalidomide results in increased expression of CEBPD mRNA

NCBI chr11:98,268,856...98,269,994
Ensembl chr11:98,265,651...98,280,824

G

CCAAT/enhancer binding protein epsilon

increases expression

ISO

pomalidomide results in increased expression of CEBPE mRNA

NCBI chr15:32,139,716...32,141,476
Ensembl chr15:32,139,716...32,141,476

G

cereblon

multiple interactions
affects binding
increases response to substance

ISO

[pomalidomide co-treated with Dexamethasone co-treated with afuresertib] results in increased expression of CRBN protein; [pomalidomide co-treated with Dexamethasone] results in increased expression of CRBN protein; pomalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]
pomalidomide binds to [SALL4 protein binds to CRBN protein]
CRBN results in increased susceptibility to pomalidomide

PMID:25043012 PMID:26186254 PMID:29928335 PMID:30067223

NCBI chr 4:141,255,400...141,276,722
Ensembl chr 4:141,257,243...141,276,038

G

colony stimulating factor 2

decreases secretion

ISO

pomalidomide results in decreased secretion of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

colony stimulating factor 3

increases secretion

ISO

pomalidomide results in increased secretion of CSF3 protein

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases oxidation

ISO

CYP2C19 protein results in increased oxidation of pomalidomide

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily j, polypeptide 4

increases oxidation

ISO

CYP2J2 protein results in increased oxidation of pomalidomide

NCBI chr 5:116,295,691...116,323,219
Ensembl chr 5:116,295,694...116,323,042

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases oxidation

ISO

CYP3A4 protein results in increased oxidation of pomalidomide

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

DTW domain containing 1

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of DTWD1 protein

NCBI chr 3:113,392,402...113,409,322
Ensembl chr 3:133,841,935...133,860,316

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone] results in decreased phosphorylation of EIF4EBP1 protein; afuresertib promotes the reaction [[pomalidomide co-treated with Dexamethasone] results in decreased phosphorylation of EIF4EBP1 protein]

NCBI chr16:71,495,457...71,508,845
Ensembl chr16:71,487,930...71,508,874

G

family with sequence similarity 83, member F

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of FAM83F protein

NCBI chr 7:114,091,356...114,120,640
Ensembl chr 7:114,091,335...114,120,638

G

Fibroblast growth factor receptor 1

decreases expression

ISO

pomalidomide results in decreased expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibroblast growth factor receptor 3

affects expression

ISO

pomalidomide affects the expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

forkhead box O1

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone] affects the phosphorylation of FOXO1 protein; afuresertib affects the reaction [[pomalidomide co-treated with Dexamethasone] affects the phosphorylation of FOXO1 protein]

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

GATA binding protein 1

decreases expression

ISO

pomalidomide results in decreased expression of GATA1 mRNA; pomalidomide results in decreased expression of GATA1 protein

NCBI chr X:17,193,291...17,209,462
Ensembl chr X:17,201,633...17,209,459

G

GATA binding protein 2

decreases expression

ISO

pomalidomide results in decreased expression of GATA2 mRNA

NCBI chr 4:122,211,501...122,225,058
Ensembl chr 4:122,211,829...122,225,055

G

growth factor independent 1 transcriptional repressor

increases expression

ISO

pomalidomide results in increased expression of GFI1 mRNA

NCBI chr14:2,185,489...2,204,191
Ensembl chr14:2,187,286...2,196,730

G

growth factor independent 1B transcriptional repressor

decreases expression

ISO

pomalidomide results in decreased expression of GFI1B mRNA

NCBI chr 3:11,940,232...11,952,989
Ensembl chr 3:32,338,214...32,350,916

G

inhibitor of DNA binding 1

increases expression

ISO

pomalidomide results in increased expression of ID1 mRNA

NCBI chr 3:161,671,525...161,672,691
Ensembl chr 3:161,671,538...161,672,685

G

inhibitor of DNA binding 2

increases expression

ISO

pomalidomide results in increased expression of ID2 mRNA

NCBI chr 6:47,469,162...47,470,995
Ensembl chr 6:47,457,554...47,472,961

G

IKAROS family zinc finger 1

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone] results in decreased expression of IKZF1 protein; afuresertib promotes the reaction [[pomalidomide co-treated with Dexamethasone] results in decreased expression of IKZF1 protein]

NCBI chr14:90,468,696...90,556,522
Ensembl chr14:90,469,172...90,557,574

G

IKAROS family zinc finger 3

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone] results in decreased expression of IKZF3 protein; afuresertib promotes the reaction [[pomalidomide co-treated with Dexamethasone] results in decreased expression of IKZF3 protein]

NCBI chr10:83,956,850...84,049,861
Ensembl chr10:83,962,030...84,049,861

G

interleukin 10

increases secretion

ISO

pomalidomide results in increased secretion of IL10 protein

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 13

decreases secretion

ISO

pomalidomide results in decreased secretion of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 2

multiple interactions

ISO

Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]; pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein]; rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]]

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 5

decreases secretion

ISO

pomalidomide results in decreased secretion of IL5 protein

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interferon regulatory factor 4

multiple interactions

ISO

[pomalidomide co-treated with Dexamethasone co-treated with afuresertib] results in decreased expression of IRF4 protein; [pomalidomide co-treated with Dexamethasone] results in decreased expression of IRF4 protein

NCBI chr17:33,930,460...33,948,842
Ensembl chr17:33,930,471...33,948,730

G

JunD proto-oncogene, AP-1 transcription factor subunit

decreases expression

ISO

pomalidomide results in decreased expression of JUND mRNA

NCBI chr16:18,768,093...18,769,771
Ensembl chr16:18,764,985...18,782,148

G

KLF transcription factor 1

decreases expression

ISO

pomalidomide results in decreased expression of KLF1 mRNA

NCBI chr19:23,250,627...23,253,802
Ensembl chr19:40,155,480...40,158,607

G

LIM domain only 2

decreases expression

ISO

pomalidomide results in decreased expression of LMO2 mRNA

NCBI chr 3:110,810,162...110,832,895
Ensembl chr 3:110,809,912...110,833,075

G

Meis homeobox 2

multiple interactions

ISO

pomalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]

NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751

G

nuclear factor, erythroid 2

decreases expression

ISO

pomalidomide results in decreased expression of NFE2 mRNA

NCBI chr 7:136,261,234...136,273,850
Ensembl chr 7:136,261,236...136,268,585

G

protein kinase C, theta

multiple interactions

ISO

pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein]

NCBI chr17:72,156,215...72,288,508
Ensembl chr17:72,156,215...72,288,508

G

RAB28, member RAS oncogene family

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of RAB28 protein

NCBI chr14:69,245,846...69,322,968
Ensembl chr14:73,458,249...73,535,369

G

spalt-like transcription factor 4

affects binding
multiple interactions

ISO

pomalidomide binds to [SALL4 protein binds to CRBN protein]
pomalidomide results in increased degradation of and results in decreased expression of SALL4 protein

NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743

G

Spi-1 proto-oncogene

increases expression
decreases expression

ISO

pomalidomide results in increased expression of SPI1 mRNA
pomalidomide results in decreased expression of SPI1 protein

PMID:15292067 PMID:16373662

NCBI chr 3:97,529,509...97,548,204
Ensembl chr 3:97,527,572...97,549,540

G

WIZ zinc finger

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of WIZ protein

NCBI chr 7:12,017,374...12,045,812
Ensembl chr 7:12,017,374...12,045,787

G

zinc finger and BTB domain containing 39

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of ZBTB39 protein

NCBI chr 7:63,576,998...63,584,549
Ensembl chr 7:65,462,018...65,485,601

G

zinc finger protein 653

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of ZNF653 protein

NCBI chr 8:28,862,618...28,881,439
Ensembl chr 8:28,862,618...28,881,070

G

zinc finger protein 91

multiple interactions

ISO

pomalidomide results in increased degradation of and results in decreased expression of ZFP91 protein

NCBI chr 1:219,316,002...219,353,654
Ensembl chr 1:219,314,392...219,352,418

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminoadipate aminotransferase

decreases expression

ISO

Thalidomide results in decreased expression of AADAT mRNA

NCBI chr16:29,509,392...29,544,332
Ensembl chr16:34,520,238...34,566,540

G

ATP binding cassette subfamily A member 1

increases response to substance

ISO

ABCA1 gene SNP results in increased susceptibility to Thalidomide

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily B member 1A

decreases expression
decreases activity

ISO

Thalidomide results in decreased expression of ABCB1 mRNA; Thalidomide results in decreased expression of ABCB1 protein
Thalidomide results in decreased activity of ABCB1 protein

PMID:15920492 PMID:19840843

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

increases expression
increases activity

EXP

Thalidomide results in increased expression of ABCB1B protein
Thalidomide results in increased activity of ABCB1B protein

NCBI chr 4:26,197,706...26,280,156
Ensembl chr 4:26,106,903...26,279,567

G

acid phosphatase 5, tartrate resistant

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in decreased expression of ACP5 protein

NCBI chr 8:28,939,984...28,946,639
Ensembl chr 8:28,939,985...28,943,929

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

EXP

[Thalidomide co-treated with Dimethylnitrosamine] results in decreased expression of ACTA2 protein; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 mRNA]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]
Thalidomide results in decreased expression of ACTA2 protein

PMID:16604421 PMID:16943688 PMID:17030452 PMID:17174718

NCBI chr 1:241,159,723...241,172,503
Ensembl chr 1:241,159,724...241,172,503

G

actinin alpha 2

decreases expression

ISO

Thalidomide results in decreased expression of ACTN2 mRNA

PMID:26006729 PMID:26217789

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

actin related protein 6

decreases expression

ISO

Thalidomide results in decreased expression of ACTR6 mRNA

NCBI chr 7:26,037,574...26,058,362
Ensembl chr 7:26,037,574...26,060,604

G

adenylosuccinate synthase 1

decreases expression

ISO

Thalidomide results in decreased expression of ADSS1 mRNA

NCBI chr 6:137,500,549...137,523,087
Ensembl chr 6:137,501,001...137,523,086

G

ALF transcription elongation factor 2

decreases expression

ISO

Thalidomide results in decreased expression of AFF2 mRNA

NCBI chr X:152,972,579...153,477,080
Ensembl chr X:152,972,581...153,477,080

G

AKT serine/threonine kinase 1

decreases phosphorylation
increases phosphorylation
decreases activity

ISO

Thalidomide analog results in decreased phosphorylation of AKT1 protein
Thalidomide analog results in increased phosphorylation of AKT1 protein
Thalidomide results in decreased activity of AKT1 protein

PMID:15067094 PMID:15858615

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldehyde dehydrogenase 1 family, member A2

decreases expression

ISO

Thalidomide results in decreased expression of ALDH1A2 mRNA

NCBI chr 8:80,758,641...80,837,891
Ensembl chr 8:80,758,142...80,837,883

G

alkaline phosphatase, intestinal

increases expression

ISO

Thalidomide results in increased expression of ALPI mRNA

NCBI chr 9:95,221,314...95,224,780
Ensembl chr 9:95,221,314...95,224,780

G

alpha-methylacyl-CoA racemase

decreases expression

ISO

Thalidomide results in decreased expression of AMACR mRNA

NCBI chr 2:61,673,291...61,685,381
Ensembl chr 2:61,670,475...61,685,379

G

angiopoietin 2

affects expression

ISO

Thalidomide affects the expression of ANGPT2 mRNA

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:77,790,563...77,841,239

G

ankyrin repeat domain 37

decreases expression

ISO

Thalidomide results in decreased expression of ANKRD37 mRNA

NCBI chr16:53,001,487...53,004,545
Ensembl chr16:52,994,740...53,004,545

G

annexin A2

decreases expression

ISO

Thalidomide results in decreased expression of ANXA2 mRNA; Thalidomide results in decreased expression of ANXA2 protein

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631

G

APAF1 interacting protein

decreases expression

ISO

Thalidomide results in decreased expression of APIP mRNA

NCBI chr 3:89,431,964...89,458,000
Ensembl chr 3:109,886,953...109,915,862

G

apelin

decreases expression

ISO

Thalidomide results in decreased expression of APLN mRNA

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:132,081,759...132,091,246

G

aquaporin 4

increases expression

ISO

Thalidomide results in increased expression of AQP4 mRNA

NCBI chr18:6,782,389...6,799,034
Ensembl chr18:6,782,389...6,799,098

G

aquaporin 5

increases expression

ISO

Thalidomide results in increased expression of AQP5 mRNA

NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:132,601,059...132,605,062

G

Rho GDP dissociation inhibitor alpha

increases expression

ISO

Thalidomide results in increased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:106,353,491...106,356,347

G

actin related protein 2/3 complex, subunit 4

decreases expression

ISO

Thalidomide results in decreased expression of ARPC4 mRNA

NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:148,077,240...148,088,428

G

aristaless related homeobox

increases expression

ISO

Thalidomide results in increased expression of ARX mRNA

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:62,010,097...62,022,002

G

adipocyte-related X-chromosome expressed sequence 1

decreases expression

ISO

Thalidomide results in decreased expression of ARXES1 mRNA

NCBI chr X:98,950,530...98,952,049

G

ankyrin repeat and SOCS box-containing 12

decreases expression

ISO

Thalidomide results in decreased expression of ASB12 mRNA

NCBI chr X:60,328,325...60,478,031
Ensembl chr X:64,338,225...64,425,500

G

activating transcription factor 3

increases expression

ISO

Thalidomide analog results in increased expression of ATF3 mRNA

NCBI chr13:105,274,103...105,331,653
Ensembl chr13:105,282,440...105,295,750

G

aurora kinase A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

EXP

Thalidomide results in increased expression of BAX mRNA
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]

PMID:18291259 PMID:33015978

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

B-cell receptor-associated protein 29

decreases expression

ISO

Thalidomide results in decreased expression of BCAP29 mRNA

NCBI chr 6:48,182,702...48,222,698
Ensembl chr 6:53,910,216...53,949,963

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

ISO
EXP

[oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 mRNA; [oblimersen co-treated with Thalidomide co-treated with Dexamethasone] results in decreased expression of BCL2 protein
Thalidomide results in decreased expression of BCL2 protein
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]

PMID:15867202 PMID:15982930 PMID:33015978

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

decreases expression

ISO

Thalidomide results in decreased expression of BCL2L1 protein

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

bradykinin receptor B1

multiple interactions

ISO

Thalidomide inhibits the reaction [bradykinin, des-Arg(9)- results in increased expression of BDKRB1 protein]

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

beclin 1

multiple interactions

ISO

Thalidomide promotes the reaction [temozolomide results in increased expression of BECN1 protein]

NCBI chr10:86,731,649...86,747,002
Ensembl chr10:86,731,650...86,747,002

G

BCL2 interacting protein like

increases expression

ISO

Thalidomide results in increased expression of BNIPL mRNA

NCBI chr 2:182,818,593...182,830,421
Ensembl chr 2:185,507,593...185,517,582

G

biorientation of chromosomes in cell division 1

decreases expression

ISO

Thalidomide results in decreased expression of BOD1 mRNA

NCBI chr10:15,993,454...15,999,795
Ensembl chr10:16,497,876...16,504,253

G

bone marrow stromal cell antigen 2

decreases expression

ISO

Thalidomide results in decreased expression of BST2 mRNA

NCBI chr16:18,250,593...18,254,967
Ensembl chr16:18,251,847...18,254,967

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA

NCBI chr 3:126,017,019...126,069,470
Ensembl chr 3:126,017,045...126,069,796

G

complement C3

decreases expression

ISO

Thalidomide results in decreased expression of C3 protein

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

calcium voltage-gated channel subunit alpha1 C

decreases expression

ISO

Thalidomide results in decreased expression of CACNA1C mRNA

PMID:26006729 PMID:26217789

NCBI chr 4:153,431,169...154,051,932
Ensembl chr 4:153,436,427...154,051,762

G

calcium voltage-gated channel auxiliary subunit beta 4

decreases expression

ISO

Thalidomide results in decreased expression of CACNB4 mRNA

NCBI chr 3:57,315,900...57,578,271
Ensembl chr 3:57,315,900...57,578,220

G

calbindin 1

decreases expression

ISO

Thalidomide results in decreased expression of CALB1 mRNA

NCBI chr 5:34,172,612...34,199,555
Ensembl chr 5:34,172,664...34,200,160

G

caspase 3

decreases activity
increases activity
increases expression

ISO
EXP

Thalidomide results in decreased activity of CASP3 protein
Thalidomide results in increased activity of CASP3 protein
Thalidomide results in increased expression of CASP3 mRNA

PMID:14682394 PMID:15067094 PMID:18291259

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 8

increases cleavage
decreases expression

ISO

Thalidomide analog results in increased cleavage of CASP8 protein
Thalidomide results in decreased expression of CASP8 mRNA

PMID:15858615 PMID:26217789

NCBI chr 9:67,747,109...67,806,699
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

decreases activity

ISO

Thalidomide results in decreased activity of CASP9 protein

Ensembl chr 5:159,391,188...159,409,648

G

cytosolic arginine sensor for mTORC1 subunit 1

decreases expression

ISO

Thalidomide results in decreased expression of CASTOR1 mRNA

NCBI chr14:79,086,136...79,090,549
Ensembl chr14:83,309,504...83,314,127

G

catalase

multiple interactions

ISO

CAT protein inhibits the reaction [Thalidomide results in decreased activity of MYB protein]

NCBI chr 3:110,297,340...110,329,526
Ensembl chr 3:110,297,342...110,329,526

G

carbonyl reductase 1

decreases expression

ISO

Thalidomide results in decreased expression of CBR1 mRNA

NCBI chr11:46,346,405...46,348,815
Ensembl chr11:46,378,411...46,381,104
Ensembl chr11:46,378,411...46,381,104

G

coiled-coil domain containing 141

decreases expression

ISO

Thalidomide results in decreased expression of CCDC141 mRNA

NCBI chr 3:82,357,046...82,517,199
Ensembl chr 3:82,357,681...82,517,710

G

C-C motif chemokine ligand 2

decreases expression

ISO

Thalidomide analog results in decreased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 3

increases expression

EXP

Thalidomide results in increased expression of CCL3 mRNA

NCBI chr10:68,948,889...68,950,439
Ensembl chr10:68,948,889...68,950,439

G

cyclin A2

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA

NCBI chr 2:121,355,363...121,361,762
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D1

decreases expression

ISO

Thalidomide analog results in decreased expression of CCND1 mRNA

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

cyclin O

increases expression

ISO

Thalidomide results in increased expression of CCNO mRNA

NCBI chr 2:44,630,873...44,633,912
Ensembl chr 2:46,350,717...46,367,113

G

CD24 molecule

affects expression

ISO

Thalidomide affects the expression of CD24A mRNA

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD274 molecule

decreases expression
multiple interactions

ISO

Thalidomide results in decreased expression of CD274 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of CD274 protein]

NCBI chr 1:236,526,215...236,549,956
Ensembl chr 1:236,496,463...236,549,951

G

cell division cycle 20

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA

NCBI chr 5:137,251,596...137,255,799
Ensembl chr 5:137,251,596...137,255,799

G

CDC42 effector protein 5

decreases expression

ISO

Thalidomide results in decreased expression of CDC42EP5 mRNA

PMID:26006729 PMID:26217789

NCBI chr 1:70,035,921...70,038,990

G

cadherin 1

increases expression
multiple interactions

ISO

Thalidomide results in increased expression of CDH1 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in increased expression of CDH1 protein]

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 10

decreases expression

ISO

Thalidomide results in decreased expression of CDH10 mRNA

NCBI chr 2:70,355,521...70,577,880
Ensembl chr 2:70,357,217...70,578,332

G

cadherin 2

decreases expression
multiple interactions

ISO

Thalidomide results in decreased expression of CDH2 protein
FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of CDH2 protein]

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cadherin 6

increases expression

ISO

Thalidomide results in increased expression of CDH6 mRNA

NCBI chr 2:62,079,139...62,225,298
Ensembl chr 2:63,806,135...63,952,287

G

cyclin-dependent kinase 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

centromere protein A

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA

NCBI chr 6:31,420,062...31,431,703

G

centromere protein F

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA

NCBI chr13:103,715,344...103,760,931
Ensembl chr13:103,715,344...103,760,886

G

cerberus 1, DAN family BMP antagonist

decreases expression

ISO

Thalidomide results in decreased expression of CER1 mRNA

NCBI chr 5:102,352,364...102,355,720
Ensembl chr 5:102,352,368...102,355,720

G

cripto, FRL-1, cryptic family 1

decreases expression

ISO

Thalidomide results in decreased expression of CFC1 mRNA

NCBI chr 9:36,742,106...36,751,931
Ensembl chr 9:44,235,020...44,247,845

G

CASP8 and FADD-like apoptosis regulator

decreases expression

ISO

Thalidomide results in decreased expression of CFLAR protein

NCBI chr 9:67,679,502...67,747,226
Ensembl chr 9:67,679,559...67,726,434

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

EXP

Thalidomide inhibits the reaction [TNF protein results in increased expression of CHUK protein]

NCBI chr 1:252,908,748...252,944,273
Ensembl chr 1:252,908,749...252,944,273

G

churchill domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of CHURC1 mRNA

NCBI chr 6:101,203,778...101,218,364
Ensembl chr 6:101,203,841...101,237,748

G

claudin 4

increases expression

ISO

Thalidomide results in increased expression of CLDN4 mRNA

NCBI chr12:27,388,160...27,389,958
Ensembl chr12:27,387,981...27,389,958

G

claudin domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of CLDND1 mRNA

NCBI chr11:55,352,321...55,358,779
Ensembl chr11:55,352,321...55,358,907

G

C-type lectin domain containing 9A

decreases expression

ISO

Thalidomide results in decreased expression of CLEC9A mRNA

NCBI chr 4:162,859,742...162,875,742
Ensembl chr 4:164,546,311...164,561,380

G

collagen type I alpha 1 chain

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of COL1A1 protein]

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type I alpha 2 chain

multiple interactions

EXP

Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of COL1A2 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of COL1A2 mRNA]

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

complexin 3

decreases expression

ISO

Thalidomide results in decreased expression of CPLX3 mRNA

NCBI chr 8:66,899,438...66,906,200
Ensembl chr 8:66,899,438...66,906,200

G

cereblon

multiple interactions
affects binding
affects response to substance

ISO

Thalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]
Thalidomide binds to [SALL4 protein binds to CRBN protein]; Thalidomide binds to CRBN protein
CRBN gene SNP affects the susceptibility to Thalidomide
Thalidomide binds to [CRBN protein binds to DDB1 protein]

PMID:25043012 PMID:25108355 PMID:27751757 PMID:30067223

NCBI chr 4:141,255,400...141,276,722
Ensembl chr 4:141,257,243...141,276,038

G

cAMP responsive element binding protein 5

decreases expression

ISO

Thalidomide results in decreased expression of CREB5 mRNA

NCBI chr 4:83,723,587...84,124,786
Ensembl chr 4:83,723,194...84,120,793

G

CREB3 regulatory factor

increases expression

ISO

Thalidomide analog results in increased expression of CREBRF mRNA

NCBI chr10:16,903,607...16,967,450
Ensembl chr10:16,903,547...16,966,430

G

cripto, EGF-CFC family member

decreases expression

ISO

Thalidomide results in decreased expression of CRIPTO mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948

G

C-reactive protein

decreases expression

ISO

Thalidomide results in decreased expression of CRP protein

NCBI chr13:87,694,062...87,695,978
Ensembl chr13:87,657,317...87,707,514

G

colony stimulating factor 2

decreases activity

ISO

Thalidomide results in decreased activity of CSF2 protein

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

colony stimulating factor 3

decreases activity

ISO

Thalidomide results in decreased activity of CSF3 protein

NCBI chr10:84,157,485...84,159,860
Ensembl chr10:84,157,211...84,159,860

G

chondroitin sulfate N-acetylgalactosaminyltransferase 2

decreases expression

ISO

Thalidomide results in decreased expression of CSGALNACT2 mRNA

NCBI chr 4:152,944,154...152,981,237
Ensembl chr 4:152,950,028...152,981,220

G

C-X-C motif chemokine ligand 10

increases expression

ISO

Thalidomide results in increased expression of CXCL10

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine receptor 1

decreases expression

ISO

Thalidomide results in decreased expression of CXCR1 protein

NCBI chr 9:83,216,040...83,220,225
Ensembl chr 9:83,215,292...83,226,872

G

C-X-C motif chemokine receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of CXCR2 protein

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

cytochrome c, somatic

increases expression

ISO

Thalidomide results in increased expression of CYCS protein

NCBI chr 4:80,982,667...80,984,767
Ensembl chr 4:80,982,668...80,984,816
Ensembl chr18:80,982,668...80,984,816

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

ISO

Thalidomide results in increased expression of CYP2B6 mRNA

PMID:24460184 PMID:28496040

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases hydroxylation
increases oxidation
multiple interactions

ISO

CYP2C19 protein results in increased hydroxylation of Thalidomide
CYP2C19 protein results in increased oxidation of Thalidomide
[CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5'-hydroxythalidomide; [CYP2C19 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide; [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5'-hydroxythalidomide; [CYP2C19 protein results in increased oxidation of Thalidomide] which results in increased abundance of 5-hydroxythalidomide

PMID:20443640 PMID:24350712

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
increases hydroxylation
multiple interactions
increases metabolic processing

ISO

Thalidomide results in increased expression of CYP3A4 mRNA; Thalidomide results in increased expression of CYP3A4 protein
CYP3A4 protein results in increased hydroxylation of Thalidomide
[CYP3A4 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide
CYP3A4 protein results in increased metabolism of Thalidomide

PMID:20443640 PMID:24460184 PMID:28496040 PMID:28745489

NCBI chr12:14,321,771...14,343,886
Ensembl chr12:14,321,771...14,343,857

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions
increases hydroxylation
increases expression
increases metabolic processing

ISO

[CYP3A5 protein results in increased hydroxylation of Thalidomide] which results in increased chemical synthesis of 5-hydroxythalidomide
Thalidomide results in increased expression of CYP3A5 mRNA
CYP3A5 protein results in increased metabolism of Thalidomide

PMID:20443640 PMID:28496040 PMID:28745489

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytohesin 3

decreases expression

ISO

Thalidomide results in decreased expression of CYTH3 mRNA

NCBI chr12:15,953,781...16,076,584
Ensembl chr12:15,953,791...16,047,506

G

dishevelled associated activator of morphogenesis 2

decreases expression

ISO

Thalidomide results in decreased expression of DAAM2 mRNA

NCBI chr 9:11,428,913...11,546,982
Ensembl chr 9:18,926,623...19,044,671

G

dihydrolipoamide branched chain transacylase E2

decreases expression

ISO

Thalidomide results in decreased expression of DBT mRNA

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:207,166,652...207,195,525

G

damage-specific DNA binding protein 1

affects binding

ISO

Thalidomide binds to [CRBN protein binds to DDB1 protein]

NCBI chr 1:216,677,810...216,703,605
Ensembl chr 1:216,677,810...216,703,596

G

DNA-damage inducible transcript 3

increases expression

ISO

Thalidomide analog results in increased expression of DDIT3 mRNA

NCBI chr 7:65,001,695...65,006,517
Ensembl chr 7:65,005,501...65,006,509

G

defensin beta 15

increases expression

ISO

Thalidomide results in increased expression of DEFB15 mRNA

NCBI chr16:76,843,661...76,846,359
Ensembl chr16:76,843,661...76,846,359

G

desmin

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of DES protein]

NCBI chr 9:84,299,626...84,307,344
Ensembl chr 9:84,298,447...84,307,347

G

Dexi homolog

increases expression

ISO

Thalidomide results in increased expression of DEXI mRNA

NCBI chr10:5,632,400...5,645,653
Ensembl chr10:5,632,961...5,645,648

G

DLG associated protein 5

decreases expression

ISO

Thalidomide results in decreased expression of DLGAP5 mRNA

NCBI chr15:23,113,678...23,144,281
Ensembl chr15:23,113,678...23,144,176

G

delta like non-canonical Notch ligand 1

decreases expression

ISO

Thalidomide results in decreased expression of DLK1 mRNA

NCBI chr 6:134,192,491...134,199,779
Ensembl chr 6:134,192,518...134,200,529

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

DnaJ heat shock protein family (Hsp40) member B4

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB4 mRNA

NCBI chr 2:243,790,296...243,819,042
Ensembl chr 2:243,790,297...243,819,042

G

DnaJ heat shock protein family (Hsp40) member B9

increases expression

ISO

Thalidomide analog results in increased expression of DNAJB9 mRNA

NCBI chr 6:66,997,842...67,007,371
Ensembl chr 6:66,997,842...67,009,344

G

DnaJ heat shock protein family (Hsp40) member C19

decreases expression

ISO

Thalidomide results in decreased expression of DNAJC19 mRNA

NCBI chr 2:118,851,497...118,875,813
Ensembl chr 2:118,869,413...118,873,781

G

dihydrouridine synthase 4-like

decreases expression

ISO

Thalidomide results in decreased expression of DUS4L mRNA

NCBI chr 6:53,955,609...53,970,050
Ensembl chr 6:53,955,609...53,970,087

G

dual specificity phosphatase 1

increases expression

ISO

Thalidomide analog results in increased expression of DUSP1 mRNA

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

dual specificity phosphatase 10

increases expression

ISO

Thalidomide analog results in increased expression of DUSP10 mRNA

NCBI chr13:98,145,317...98,183,304
Ensembl chr13:98,145,893...98,183,304

G

dual specificity phosphatase 8

increases expression

ISO

Thalidomide analog results in increased expression of DUSP8 mRNA

NCBI chr 1:206,596,912...206,613,728
Ensembl chr 1:206,598,942...206,612,441

G

eukaryotic translation elongation factor 1 epsilon 1

decreases expression

ISO

Thalidomide results in decreased expression of EEF1E1 mRNA

NCBI chr17:26,354,247...26,364,953
Ensembl chr17:26,354,228...26,370,687

G

EF-hand calcium binding domain 2

decreases expression

ISO

Thalidomide results in decreased expression of EFCAB2 mRNA

NCBI chr13:90,152,002...90,237,918
Ensembl chr13:92,684,086...92,782,558

G

eukaryotic translation initiation factor 1B

decreases expression

ISO

Thalidomide results in decreased expression of EIF1B mRNA

NCBI chr 8:120,203,561...120,206,176
Ensembl chr 8:129,078,293...129,083,772
Ensembl chr 5:129,078,293...129,083,772

G

eukaryotic translation initiation factor 4E

decreases expression

EXP

Thalidomide results in decreased expression of EIF4E protein

NCBI chr 2:229,736,309...229,772,628
Ensembl chr 2:229,739,897...229,774,105

G

elastase, neutrophil expressed

multiple interactions

ISO

Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of ELANE protein]; Thalidomide inhibits the reaction [lipoteichoic acid results in increased secretion of ELANE protein]

NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:10,467,877...10,469,725

G

ER membrane protein complex subunit 8

decreases expression

ISO

Thalidomide results in decreased expression of EMC8 mRNA

NCBI chr19:65,620,365...65,630,328
Ensembl chr19:65,620,375...65,630,235

G

EPH receptor A10

decreases expression

ISO

Thalidomide results in decreased expression of EPHA10 mRNA

NCBI chr 5:137,139,588...137,175,637
Ensembl chr 5:142,424,296...142,460,305

G

Eph receptor B1

decreases expression

ISO

Thalidomide results in decreased expression of EPHB1 mRNA

NCBI chr 8:111,386,432...111,823,759
Ensembl chr 8:111,386,432...111,823,759

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

[ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

esterase D

decreases expression

ISO

Thalidomide results in decreased expression of ESD mRNA

NCBI chr15:56,453,082...56,472,582
Ensembl chr15:56,453,044...56,473,508

G

EYA transcriptional coactivator and phosphatase 1

decreases expression

ISO

Thalidomide results in decreased expression of EYA1 mRNA

NCBI chr 5:9,646,599...9,884,609
Ensembl chr 5:9,646,591...9,884,614

G

coagulation factor II (thrombin) receptor

decreases expression

ISO

Thalidomide results in decreased expression of F2R mRNA; Thalidomide results in decreased expression of F2R protein

NCBI chr 2:28,604,066...28,620,579
Ensembl chr 2:28,604,066...28,620,579

G

fatty acid binding protein 5

decreases expression

ISO

Thalidomide results in decreased expression of FABP5 mRNA

NCBI chr 2:93,672,451...93,676,186
Ensembl chr 2:93,672,458...93,676,127

G

fatty acid binding protein 7

affects expression

ISO

Thalidomide affects the expression of FABP7 mRNA

NCBI chr20:37,667,125...37,673,299
Ensembl chr20:37,669,601...37,675,907

G

family with sequence similarity 174, member B

decreases expression

ISO

Thalidomide results in decreased expression of FAM174B mRNA

NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:136,925,151...137,035,589

G

Fas cell surface death receptor

decreases expression
increases expression

ISO
EXP

Thalidomide results in decreased expression of FAS protein
Thalidomide results in increased expression of FAS mRNA

PMID:16531263 PMID:18291259

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

multiple interactions
decreases expression

ISO

Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]
Thalidomide results in decreased expression of FASLG protein

PMID:16510725 PMID:16531263

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

flap structure-specific endonuclease 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA

NCBI chr 1:216,270,016...216,274,873
Ensembl chr 1:216,269,163...216,275,016

G

FYVE, RhoGEF and PH domain containing 3

increases expression

ISO

Thalidomide results in increased expression of FGD3 mRNA

NCBI chr17:15,324,848...15,387,271
Ensembl chr17:15,543,236...15,593,676

G

fibroblast growth factor 2

increases response to substance
affects expression
affects secretion
multiple interactions
decreases activity
decreases expression

ISO
EXP

FGF2 protein results in increased susceptibility to Thalidomide
Thalidomide affects the expression of FGF2 mRNA; Thalidomide affects the expression of FGF2 protein
Thalidomide affects the secretion of FGF2 protein
Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein]
Thalidomide results in decreased activity of FGF2 protein
[Temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]
Thalidomide results in decreased expression of FGF2 protein

PMID:11555579 PMID:12644816 PMID:14558594 PMID:15863203 PMID:15939924 More...

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibroblast growth factor 8

increases expression

ISO

Thalidomide results in increased expression of FGF8 mRNA

NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605

G

Fibroblast growth factor receptor 1

affects expression

ISO

Thalidomide affects the expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

fibroblast growth factor receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of FGFR2 mRNA; Thalidomide results in decreased expression of FGFR2 protein

NCBI chr 1:194,175,703...194,280,914
Ensembl chr 1:194,175,705...194,280,914

G

fibroblast growth factor receptor 3

affects expression

ISO

Thalidomide affects the expression of FGFR3 mRNA

NCBI chr14:81,211,800...81,227,215
Ensembl chr14:81,211,800...81,227,209

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of FOS mRNA

NCBI chr 6:110,852,188...110,855,054
Ensembl chr 6:110,852,190...110,855,598

G

FosB proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of FOSB mRNA

NCBI chr 1:88,082,324...88,089,506
Ensembl chr 1:88,082,127...88,089,477

G

forkhead box C2

decreases expression

ISO

Thalidomide results in decreased expression of FOXC2 mRNA

NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977

G

FAD-dependent oxidoreductase domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of FOXRED1 mRNA

NCBI chr 8:41,789,557...41,818,064
Ensembl chr 8:41,808,843...41,817,980

G

frizzled class receptor 8

decreases expression

ISO

Thalidomide results in decreased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

ISO

Thalidomide inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]

NCBI chr 7:9,428,689...9,430,991
Ensembl chr 7:9,428,689...9,430,718

G

galactose mutarotase

decreases expression

ISO

Thalidomide results in decreased expression of GALM mRNA

NCBI chr 6:20,589,775...20,641,516
Ensembl chr 6:20,589,776...20,644,417

G

GATA binding protein 3

increases expression

EXP

Thalidomide results in increased expression of GATA3 protein

NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670

G

glucosaminyl (N-acetyl) transferase 2

decreases expression

ISO

Thalidomide results in decreased expression of GCNT2 mRNA

NCBI chr17:24,002,592...24,107,339
Ensembl chr17:24,002,597...24,106,989

G

gem (nuclear organelle) associated protein 2

decreases expression

ISO

Thalidomide results in decreased expression of GEMIN2 mRNA

NCBI chr 6:82,442,419...82,456,050
Ensembl chr 6:82,442,350...82,456,048

G

GDNF family receptor alpha 2

decreases expression

ISO

Thalidomide results in decreased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:52,351,514...52,477,782

G

glutamic-oxaloacetic transaminase 1

increases expression

ISO

Thalidomide results in increased expression of GOT1 mRNA

NCBI chr 1:252,306,541...252,337,622
Ensembl chr 1:252,284,434...252,329,871

G

glycoprotein 2

increases expression

ISO

Thalidomide results in increased expression of GP2 mRNA

NCBI chr 1:183,228,395...183,243,954
Ensembl chr 1:183,228,395...183,243,954

G

G patch domain containing 4

decreases expression

ISO

Thalidomide results in decreased expression of GPATCH4 mRNA

NCBI chr 2:175,797,503...175,816,547
Ensembl chr 2:175,807,682...175,817,358

G

glutathione peroxidase 1

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased activity of GPX1 protein]

NCBI chr 8:117,905,462...117,906,588
Ensembl chr 8:117,905,280...117,906,581

G

glutathione peroxidase 8

decreases expression

ISO

Thalidomide results in decreased expression of GPX8 mRNA

NCBI chr 2:46,409,646...46,413,401
Ensembl chr 2:46,409,139...46,413,406

G

glutamate ionotropic receptor AMPA type subunit 3

decreases expression

ISO

Thalidomide results in decreased expression of GRIA3 mRNA

NCBI chr X:125,103,975...125,369,690
Ensembl chr X:125,103,782...125,369,679

G

glutamate ionotropic receptor AMPA type subunit 4

increases expression

ISO

Thalidomide results in increased expression of GRIA4 mRNA

NCBI chr 8:1,562,118...2,035,035
Ensembl chr 8:9,847,052...10,319,881

G

glutamate ionotropic receptor NMDA type subunit 2A

decreases expression

ISO

Thalidomide results in decreased expression of GRIN2A mRNA

NCBI chr10:6,136,458...6,560,003
Ensembl chr10:6,138,037...6,551,378

G

glutamate ionotropic receptor NMDA type subunit 2C

decreases expression

ISO

Thalidomide results in decreased expression of GRIN2C mRNA

NCBI chr10:100,987,410...101,006,064
Ensembl chr10:100,987,513...101,005,409

G

general transcription factor IIE subunit 1

decreases expression

ISO

Thalidomide results in decreased expression of GTF2E1 mRNA

NCBI chr11:76,687,382...76,720,253
Ensembl chr11:76,687,772...76,720,784

G

GULP PTB domain containing engulfment adaptor 1

decreases expression

ISO

Thalidomide results in decreased expression of GULP1 mRNA

NCBI chr 9:54,114,823...54,391,058
Ensembl chr 9:54,114,731...54,397,452

G

H2B clustered histone 12

decreases expression

ISO

Thalidomide results in decreased expression of H2BC12 mRNA

NCBI chr17:47,181,477...47,181,940
Ensembl chr17:47,121,467...47,182,816

G

H3 clustered histone 1

decreases expression

ISO

Thalidomide results in decreased expression of H3C1 mRNA

NCBI chr17:41,796,236...41,796,759
Ensembl chr17:41,795,396...41,797,281
Ensembl chr17:41,795,396...41,797,281

G

hyperpolarization-activated cyclic nucleotide-gated potassium channel 1

decreases expression

ISO

Thalidomide results in decreased expression of HCN1 mRNA

NCBI chr 2:51,228,710...51,632,806
Ensembl chr 2:51,228,710...51,632,806

G

histone deacetylase 6

multiple interactions

EXP

HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]]; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]]; Thalidomide inhibits the reaction [Paraquat results in increased expression of HDAC6 mRNA]

NCBI chr X:17,222,538...17,244,373
Ensembl chr X:17,222,856...17,244,370

G

homocysteine inducible ER protein with ubiquitin like domain 1

increases expression

ISO

Thalidomide analog results in increased expression of HERPUD1 mRNA

NCBI chr19:10,604,360...10,624,168
Ensembl chr19:10,604,362...10,624,081

G

hepatocyte growth factor

affects expression
decreases activity
affects secretion

ISO

Thalidomide affects the expression of HGF mRNA; Thalidomide affects the expression of HGF protein
Thalidomide results in decreased activity of HGF protein
Thalidomide affects the secretion of HGF protein

PMID:15939924 PMID:17557286

NCBI chr 4:19,628,902...19,700,467
Ensembl chr 4:19,632,267...19,700,851

G

HIRA interacting protein 3

decreases expression

ISO

Thalidomide results in decreased expression of HIRIP3 mRNA

NCBI chr 1:190,903,065...190,905,610
Ensembl chr 1:190,902,593...190,905,607

G

histone cluster 1, H2bc

decreases expression

ISO

Thalidomide results in decreased expression of H2BC4 mRNA

NCBI chr17:47,388,085...47,392,349
Ensembl chr17:47,404,375...47,419,020

G

high mobility group nucleosome binding domain 5

decreases expression

ISO

Thalidomide results in decreased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:78,161,442...78,169,924

G

homeo box B7

increases expression

ISO

Thalidomide results in increased expression of HOXB7 mRNA

NCBI chr10:81,749,159...81,752,577
Ensembl chr10:81,749,097...81,752,550

G

homeo box B9

increases expression

ISO

Thalidomide results in increased expression of HOXB9 mRNA

NCBI chr10:81,733,857...81,737,363
Ensembl chr10:81,733,658...81,738,872

G

hydroxysteroid 11-beta dehydrogenase 2

decreases expression

ISO

Thalidomide results in decreased expression of HSD11B2 mRNA

NCBI chr19:50,307,569...50,312,812
Ensembl chr19:50,307,569...50,312,812

G

heat shock transcription factor 1

decreases expression

ISO

Thalidomide results in decreased expression of HSF1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 7:110,076,710...110,103,665
Ensembl chr 7:110,076,710...110,103,665

G

heat shock protein family B (small) member 1

decreases expression

ISO

Thalidomide results in decreased expression of HSPB1 mRNA

NCBI chr12:26,430,640...26,432,301
Ensembl chr12:26,430,640...26,432,301

G

heat shock protein family H (Hsp110) member 1

increases expression

ISO

Thalidomide analog results in increased expression of HSPH1 mRNA

NCBI chr12:10,427,368...10,446,602
Ensembl chr12:10,427,297...10,446,891

G

intercellular adhesion molecule 1

increases response to substance
decreases expression

ISO
EXP

ICAM1 gene SNP results in increased susceptibility to Thalidomide
Thalidomide results in decreased expression of ICAM1 mRNA; Thalidomide results in decreased expression of ICAM1 protein

PMID:17174718 PMID:21245421

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

Idnk, gluconokinase

decreases expression

ISO

Thalidomide results in decreased expression of IDNK mRNA

NCBI chr17:6,489,397...6,496,520
Ensembl chr17:6,488,982...6,499,822

G

interferon gamma

multiple interactions
affects expression
increases expression
decreases expression

ISO
EXP

[Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG protein
Thalidomide affects the expression of IFNG mRNA
Thalidomide results in increased expression of IFNG; Thalidomide results in increased expression of IFNG protein
Thalidomide inhibits the reaction [irinotecan results in increased expression of IFNG protein]; Thalidomide promotes the reaction [irinotecan results in increased expression of IFNG protein]
Thalidomide results in decreased expression of IFNG protein

PMID:15588918 PMID:16078585 PMID:16454849 PMID:16514283 PMID:16815871 More...

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

intraflagellar transport 27

decreases expression

ISO

Thalidomide results in decreased expression of IFT27 mRNA

PMID:26006729 PMID:26217789

NCBI chr 7:111,619,145...111,635,129
Ensembl chr 7:111,619,077...111,634,936

G

intraflagellar transport 70A1

decreases expression

ISO

Thalidomide results in decreased expression of IFT70A1 mRNA

NCBI chr 3:60,901,896...60,905,350

G

intraflagellar transport 74

decreases expression

ISO

Thalidomide results in decreased expression of IFT74 mRNA

NCBI chr 5:114,576,106...114,679,581
Ensembl chr 5:114,593,397...114,679,581

G

insulin-like growth factor 1

affects expression

ISO

Thalidomide affects the expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor binding protein 3

affects expression
decreases expression

ISO

Thalidomide affects the expression of IGFBP3 mRNA
Thalidomide results in decreased expression of IGFBP3 mRNA

PMID:15939924 PMID:26217789

NCBI chr14:86,270,208...86,277,944
Ensembl chr14:86,270,208...86,277,944

G

interleukin 10

affects expression
decreases expression

ISO

Thalidomide affects the expression of IL10 mRNA
Thalidomide results in decreased expression of IL10 protein

PMID:16454849 PMID:16514283

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 12A

multiple interactions

ISO

Thalidomide results in decreased expression of [IL12A protein binds to IL12B protein]

NCBI chr 2:155,275,734...155,282,997
Ensembl chr 2:155,275,625...155,282,997

G

interleukin 12B

multiple interactions

ISO

Thalidomide results in decreased expression of [IL12A protein binds to IL12B protein]
Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]

PMID:11788559 PMID:16510725

NCBI chr10:29,390,300...29,405,194
Ensembl chr10:29,389,905...29,405,194

G

interleukin 18

increases expression

ISO

Thalidomide results in increased expression of IL18

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 1 beta

decreases expression
multiple interactions

ISO
EXP

Thalidomide results in decreased expression of IL1B protein
Thalidomide inhibits the reaction [irinotecan results in increased expression of IL1B protein]; Thalidomide promotes the reaction [irinotecan results in increased expression of IL1B protein]
Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of IL1B protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL1B mRNA]

PMID:15863203 PMID:16815871 PMID:23510834 PMID:25478868

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

decreases expression

ISO

Thalidomide results in decreased expression of IL1R1 mRNA

NCBI chr 9:50,000,558...50,076,579
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor antagonist

multiple interactions

ISO

Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

multiple interactions
decreases expression

ISO
EXP

[Thalidomide co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 protein
Thalidomide results in decreased expression of IL2 protein
Thalidomide inhibits the reaction [irinotecan results in decreased expression of IL2 protein]; Thalidomide promotes the reaction [irinotecan results in decreased expression of IL2 protein]

PMID:15588918 PMID:16815871

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 4

increases expression

EXP

Thalidomide results in increased expression of IL4 protein

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 6

decreases secretion
decreases activity
multiple interactions

ISO
EXP

Thalidomide analog results in decreased secretion of IL6 protein
Thalidomide results in decreased activity of IL6 protein
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]
Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of IL6 protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 mRNA]

PMID:15858615 PMID:16815871 PMID:17557286 PMID:23510834 PMID:25478868 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 cytokine family signal transducer

decreases expression

ISO

Thalidomide results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

inhibitor of growth family, member 3

increases expression

ISO

Thalidomide analog results in increased expression of ING3 mRNA

NCBI chr 4:51,439,218...51,469,502
Ensembl chr 4:51,443,763...51,470,951

G

intracisternal A particle-promoted polypeptide

decreases expression

ISO

Thalidomide results in decreased expression of IPP mRNA

NCBI chr 5:135,199,198...135,237,912
Ensembl chr 5:135,180,109...135,238,000

G

Jun proto-oncogene, AP-1 transcription factor subunit

increases expression

ISO

Thalidomide analog results in increased expression of JUN mRNA

NCBI chr 5:115,009,900...115,012,993
Ensembl chr 5:114,973,151...115,013,285

G

kalirin, RhoGEF kinase

decreases expression

ISO

Thalidomide results in decreased expression of KALRN mRNA

NCBI chr11:79,703,345...80,309,210
Ensembl chr11:79,703,366...80,133,329

G

kinase insert domain receptor

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of KDR mRNA]

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

kinesin family member 2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA

NCBI chr 5:135,873,925...135,899,267
Ensembl chr 5:135,873,925...135,899,212

G

kelch-like family member 4

decreases expression

ISO

Thalidomide results in decreased expression of KLHL4 mRNA

NCBI chr X:79,429,193...79,719,482
Ensembl chr X:83,819,076...83,916,328

G

kallikrein 1

decreases expression

ISO

Thalidomide results in decreased expression of KLK1 mRNA

NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:103,779,164...103,783,270

G

kallikrein 1-related peptidase C10

decreases expression

ISO

Thalidomide results in decreased expression of KLK3 protein

NCBI chr 1:103,539,527...103,543,586
Ensembl chr 1:103,539,527...103,543,586

G

keratin associated protein 1-1

increases expression

ISO

Thalidomide results in increased expression of KRTAP1-4 mRNA

NCBI chr10:84,545,765...84,546,331
Ensembl chr10:85,041,910...85,042,476

G

large tumor suppressor kinase 2

increases expression

ISO

Thalidomide analog results in increased expression of LATS2 mRNA

NCBI chr15:35,940,632...35,992,225
Ensembl chr15:35,940,632...35,980,842

G

leucine rich repeat protein 1

decreases expression

ISO

Thalidomide results in decreased expression of LRR1 mRNA

NCBI chr 6:87,643,195...87,651,894
Ensembl chr 6:93,379,169...93,387,950

G

lactotransferrin

multiple interactions

ISO

Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of LTF protein]; Thalidomide inhibits the reaction [lipoteichoic acid results in increased secretion of LTF protein]

NCBI chr 8:119,878,344...119,901,189
Ensembl chr 8:119,878,344...119,901,189

G

lymphocyte antigen 96

decreases expression

ISO

Thalidomide results in decreased expression of LY96 mRNA

PMID:26006729 PMID:26217789

NCBI chr 5:7,365,536...7,397,864
Ensembl chr 5:7,365,557...7,395,816

G

LYR motif containing 2

decreases expression

ISO

Thalidomide results in decreased expression of LYRM2 mRNA

NCBI chr 5:51,994,540...51,996,818
Ensembl chr 5:51,994,543...51,997,979

G

LYR motif containing 4

decreases expression

ISO

Thalidomide results in decreased expression of LYRM4 mRNA

NCBI chr17:28,746,457...28,861,849
Ensembl chr17:28,951,924...29,143,177

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

ISO

Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein]

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen activated protein kinase 1

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 14

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK14 protein

NCBI chr20:6,751,288...6,812,294
Ensembl chr20:6,751,357...6,812,294

G

mitogen activated protein kinase 3

increases phosphorylation

ISO

Thalidomide analog results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression

ISO

Thalidomide analog results in decreased expression of MCL1 protein

NCBI chr 2:185,884,840...185,912,532
Ensembl chr 2:185,908,168...185,938,782

G

minichromosome maintenance complex component 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA

NCBI chr19:13,488,813...13,510,131
Ensembl chr19:13,488,813...13,517,758

G

Meis homeobox 2

multiple interactions

ISO

Thalidomide inhibits the reaction [CRBN protein binds to and results in increased ubiquitination of and results in increased degradation of MEIS2 protein]

NCBI chr 3:123,197,066...123,399,002
Ensembl chr 3:123,197,066...123,397,751

G

mesenchyme homeobox 1

decreases expression

ISO

Thalidomide results in decreased expression of MEOX1 mRNA

NCBI chr10:87,318,668...87,338,169
Ensembl chr10:87,318,695...87,337,976

G

mesoderm posterior bHLH transcription factor 2

decreases expression

ISO

Thalidomide results in decreased expression of MESP2 mRNA

NCBI chr 1:133,756,601...133,759,207
Ensembl chr 1:143,165,849...143,168,511

G

methyltransferase 5, N6-adenosine

decreases expression

ISO

Thalidomide results in decreased expression of METTL5 mRNA

NCBI chr 3:54,625,790...54,638,066
Ensembl chr 3:75,026,861...75,045,831

G

microRNA 126a

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR126]

NCBI chr 3:29,813,150...29,813,267

G

microRNA 141

multiple interactions

EXP

MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in decreased expression of BCL2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of BAX protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of FGF2 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of IL6 protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR141]

NCBI chr 4:157,523,239...157,523,332

G

microRNA 206

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR206]

NCBI chr 9:23,094,249...23,094,332
Ensembl chr 9:30,590,697...30,590,780

G

microRNA 21

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR21]

NCBI chr10:71,902,600...71,902,691

G

microRNA 221

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR221]

NCBI chr X:6,023,182...6,023,290
Ensembl chr X:6,023,182...6,023,290

G

microRNA 222

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in increased expression of MIR222]

NCBI chr X:6,022,621...6,022,723
Ensembl chr X:6,022,621...6,022,723

G

microRNA 301b

increases expression

ISO

Thalidomide results in increased expression of MIR301B mRNA

NCBI chr11:83,879,816...83,879,893
Ensembl chr11:97,384,033...97,384,110

G

microRNA 30e

decreases expression

ISO

Thalidomide results in decreased expression of MIR30E mRNA

NCBI chr 5:139,637,450...139,637,541
Ensembl chr 5:139,637,450...139,637,541

G

microRNA 338

multiple interactions

EXP

Thalidomide inhibits the reaction [Paraquat results in decreased expression of MIR338]

NCBI chr10:105,297,923...105,297,988

G

microRNA 449c

increases expression

ISO

Thalidomide results in increased expression of MIR449C mRNA

NCBI chr 2:44,669,179...44,669,277
Ensembl chr 2:46,402,375...46,402,473

G

Mix paired-like homeobox 1

decreases expression

ISO

Thalidomide results in decreased expression of MIXL1 mRNA

NCBI chr13:92,422,031...92,426,065
Ensembl chr13:94,953,907...94,957,938

G

marker of proliferation Ki-67

multiple interactions
decreases expression

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA
Thalidomide results in decreased expression of MKI67 protein

PMID:18720364 PMID:34520751

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

myeloid leukemia factor 2

decreases expression

ISO

Thalidomide results in decreased expression of MLF2 mRNA

NCBI chr 4:157,739,651...157,744,325
Ensembl chr 4:159,411,732...159,430,571

G

membrane metallo-endopeptidase

decreases expression

ISO

Thalidomide results in decreased expression of MME mRNA

NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463

G

matrix metallopeptidase 2

multiple interactions
decreases expression

ISO

Thalidomide promotes the reaction [FGF2 protein results in decreased expression of MMP2 protein]
Thalidomide results in decreased expression of MMP2 protein

PMID:14558594 PMID:15863203

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 9

decreases expression

ISO

Thalidomide results in decreased expression of MMP9 protein

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

monooxygenase, DBH-like 1

decreases expression

ISO

Thalidomide results in decreased expression of MOXD1 mRNA

NCBI chr 1:22,894,543...22,984,599
Ensembl chr 1:22,894,543...22,984,223

G

myeloperoxidase

multiple interactions

ISO

Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased activity of MPO protein]; Thalidomide inhibits the reaction [Indomethacin results in increased activity of MPO protein]

PMID:15138204 PMID:25478868

NCBI chr10:73,092,124...73,102,057
Ensembl chr10:73,092,400...73,102,056

G

MAGUK p55 scaffold protein 1

decreases expression

ISO

Thalidomide results in decreased expression of MPP1 mRNA

G

mitochondrial ribosomal protein L32

decreases expression

ISO

Thalidomide results in decreased expression of MRPL32 mRNA

NCBI chr17:50,565,133...50,568,000
Ensembl chr17:55,260,270...55,263,517

G

mitochondrial ribosomal protein L34

decreases expression

ISO

Thalidomide results in decreased expression of MRPL34 mRNA

NCBI chr16:18,186,447...18,187,182
Ensembl chr16:18,185,306...18,187,181

G

mitochondrial ribosomal protein L47

decreases expression

ISO

Thalidomide results in decreased expression of MRPL47 mRNA

NCBI chr 2:117,436,199...117,447,790
Ensembl chr 2:117,428,621...117,447,517

G

mitochondrial ribosomal protein L52

decreases expression

ISO

Thalidomide results in decreased expression of MRPL52 mRNA

NCBI chr15:27,882,777...27,886,131
Ensembl chr15:31,852,760...31,856,162

G

mitochondrial ribosomal protein S21

decreases expression

ISO

Thalidomide results in decreased expression of MRPS21 mRNA

NCBI chr 2:186,095,729...186,103,351
Ensembl chr 2:186,095,732...186,103,351

G

mitochondrial fission regulator 2

decreases expression

ISO

Thalidomide results in decreased expression of MTFR2 mRNA

NCBI chr 1:15,123,232...15,138,632

G

MYB proto-oncogene, transcription factor

multiple interactions
decreases activity
decreases phosphorylation

ISO

CAT protein inhibits the reaction [Thalidomide results in decreased activity of MYB protein]
Thalidomide results in decreased phosphorylation of MYB protein

NCBI chr 1:17,759,309...17,793,306
Ensembl chr 1:17,759,309...17,792,547

G

myosin binding protein C3

decreases expression

ISO

Thalidomide results in decreased expression of MYBPC3 mRNA

PMID:26006729 PMID:26217789

NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:97,551,061...97,569,216

G

MYD88, innate immune signal transduction adaptor

decreases expression

ISO

Thalidomide results in decreased expression of MYD88 mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:127,952,161...127,956,230
Ensembl chr 8:127,952,161...127,956,230

G

myosin heavy chain 6

affects expression

ISO

Thalidomide affects the expression of MYH6 mRNA

PMID:26006729 PMID:26217789

NCBI chr15:32,388,102...32,413,663
Ensembl chr15:32,387,487...32,411,333

G

myosin light chain 3

affects expression
decreases expression

ISO

Thalidomide affects the expression of MYL3 mRNA
Thalidomide results in decreased expression of MYL3 mRNA

PMID:26006729 PMID:26217789

NCBI chr 8:119,617,077...119,623,215
Ensembl chr 8:119,616,868...119,623,216

G

myosin light chain 7

decreases expression

ISO

Thalidomide results in decreased expression of MYL7 mRNA

NCBI chr14:80,780,684...80,783,259
Ensembl chr14:84,993,736...84,997,372

G

myosin light chain kinase

increases expression

ISO

Thalidomide results in increased expression of MYLK mRNA

NCBI chr11:79,288,243...79,535,450
Ensembl chr11:79,288,243...79,535,659

G

myomesin 1

decreases expression

ISO

Thalidomide results in decreased expression of MYOM1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 9:118,362,547...118,485,954
Ensembl chr 9:118,362,621...118,485,952

G

N(alpha)-acetyltransferase 20, NatB catalytic subunit

decreases expression

ISO

Thalidomide results in decreased expression of NAA20 mRNA

NCBI chr 3:133,322,036...133,336,843
Ensembl chr 3:153,775,338...153,790,916

G

Nanog homeobox

decreases expression

ISO

Thalidomide results in decreased expression of NANOG mRNA

NCBI chr 4:157,615,687...157,623,061
Ensembl chr 4:157,615,687...157,623,061

G

NAD(P)HX epimerase

decreases expression

ISO

Thalidomide results in decreased expression of NAXE mRNA

NCBI chr 2:175,816,824...175,818,903
Ensembl chr 2:175,816,824...175,818,889

G

NADH:ubiquinone oxidoreductase subunit B8

decreases expression

ISO

Thalidomide results in decreased expression of NDUFB8 mRNA

NCBI chr 1:253,357,878...253,362,936
Ensembl chr 1:253,357,841...253,362,936

G

nebulette

decreases expression

ISO

Thalidomide results in decreased expression of NEBL mRNA

NCBI chr17:85,022,953...85,374,848
Ensembl chr17:85,022,963...85,374,172

G

neuronal differentiation 4

increases expression

ISO

Thalidomide results in increased expression of NEUROD4 mRNA

NCBI chr 7:7,090,048...7,102,018
Ensembl chr 7:7,740,852...7,752,824

G

neurogenin 2

increases expression

ISO

Thalidomide results in increased expression of NEUROG2 mRNA

NCBI chr 2:218,767,205...218,769,772
Ensembl chr 2:218,765,949...218,769,784

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

Thalidomide promotes the reaction [Paraquat results in increased expression of NFE2L2 mRNA]; Thalidomide promotes the reaction [Paraquat results in increased expression of NFE2L2 protein]

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions
decreases expression

ISO
EXP

[resveratrol co-treated with Thalidomide] results in decreased activity of [RELA protein binds to NFKB1 protein]
Thalidomide results in decreased expression of NFKB1 protein

PMID:16333628 PMID:17164350

NCBI chr 2:226,689,745...226,805,897
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

multiple interactions
increases expression

ISO
EXP

Thalidomide inhibits the reaction [TGFB1 protein results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased transport of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFKBIA protein]; Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]
Thalidomide results in increased expression of NFKBIA protein

PMID:15687330 PMID:16288038 PMID:16604421 PMID:16943688 PMID:17174718 More...

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

nescient helix loop helix 1

increases expression

ISO

Thalidomide results in increased expression of NHLH1 mRNA

NCBI chr13:84,517,347...84,522,548
Ensembl chr13:87,049,629...87,055,033

G

neuromedin S

increases expression

ISO

Thalidomide results in increased expression of NMS mRNA

NCBI chr 9:41,169,634...41,180,697
Ensembl chr 9:48,665,398...48,676,461

G

nitric oxide synthase 2

multiple interactions

EXP

Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of NOS2 mRNA]

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

natriuretic peptide B

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in increased expression of NPPB protein

NCBI chr 5:163,699,955...163,701,314
Ensembl chr 5:163,699,839...163,701,310

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

decreases expression

ISO

Thalidomide results in decreased expression of NQO2 mRNA

NCBI chr17:31,114,825...31,144,062
Ensembl chr17:31,114,529...31,143,662

G

nuclear receptor subfamily 1, group I, member 2

increases expression

ISO

Thalidomide results in increased expression of NR1I2 mRNA

NCBI chr11:75,965,717...76,006,733
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 4, group A, member 1

increases expression

ISO

Thalidomide analog results in increased expression of NR4A1 mRNA

NCBI chr 7:134,247,153...134,268,044
Ensembl chr 7:134,247,192...134,268,041

G

nuclear receptor subfamily 4, group A, member 2

increases expression

ISO

Thalidomide analog results in increased expression of NR4A2 mRNA

NCBI chr 3:62,098,739...62,115,926
Ensembl chr 3:62,098,743...62,106,769

G

neuropilin 1

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of NRP1 mRNA]

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

neuropilin 2

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in decreased expression of NRP2 mRNA]

NCBI chr 9:71,616,602...71,731,869
Ensembl chr 9:71,616,657...71,731,871

G

neurexin 1

decreases expression

ISO

Thalidomide results in decreased expression of NRXN1 mRNA

NCBI chr 6:8,931,360...10,077,381
Ensembl chr 6:8,935,523...10,077,374

G

5'-nucleotidase, cytosolic IIIA

decreases expression

ISO

Thalidomide results in decreased expression of NT5C3 mRNA

NCBI chr 4:87,491,828...87,534,838
Ensembl chr 4:87,491,828...87,534,838

G

5' nucleotidase, ecto

decreases expression

ISO

Thalidomide results in decreased expression of NT5E mRNA

NCBI chr 8:98,150,925...98,195,646
Ensembl chr 8:98,150,900...98,195,645

G

N-terminal asparagine amidase

decreases expression

ISO

Thalidomide results in decreased expression of NTAN1 mRNA

NCBI chr10:2,618,239...2,633,185
Ensembl chr10:2,618,235...2,633,810

G

nudix hydrolase 14

decreases expression

ISO

Thalidomide results in decreased expression of NUDT14 mRNA

NCBI chr 6:132,010,309...132,017,298
Ensembl chr 6:137,831,373...137,838,370

G

nudix hydrolase 22

decreases expression

ISO

Thalidomide results in decreased expression of NUDT22 mRNA

NCBI chr 1:213,612,008...213,615,626
Ensembl chr 1:213,612,009...213,615,713

G

nucleoporin 62 C-terminal like

decreases expression

ISO

Thalidomide results in decreased expression of NUP62CL mRNA

NCBI chr X:103,668,458...103,724,957
Ensembl chr X:108,457,043...108,512,664

G

nucleolar and spindle associated protein 1

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA

NCBI chr 3:127,057,220...127,092,779
Ensembl chr 3:127,057,265...127,087,237

G

2'-5' oligoadenylate synthetase 1A

decreases expression

ISO

Thalidomide results in decreased expression of OAS1G mRNA

NCBI chr12:41,330,423...41,341,130
Ensembl chr12:41,285,211...41,341,128

G

occludin

multiple interactions

ISO

Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in decreased expression of OCLN protein]

NCBI chr 2:33,391,303...33,442,207
Ensembl chr 2:33,391,303...33,430,411

G

oligodendrocyte transcription factor 2

increases expression

ISO

Thalidomide results in increased expression of OLIG2 mRNA

NCBI chr11:43,961,585...43,964,961
Ensembl chr11:43,958,940...43,968,634

G

oligodendrocyte transcription factor 3

increases expression

ISO

Thalidomide results in increased expression of OLIG3 mRNA

NCBI chr 1:15,900,881...15,902,953
Ensembl chr 1:15,900,736...15,902,274

G

olfactory receptor family 10 subfamily Q member 1

increases expression

ISO

Thalidomide results in increased expression of OR10Q1 mRNA

NCBI chr 1:210,861,364...210,862,320
Ensembl chr 1:220,285,910...220,286,866

G

olfactory receptor family 1 subfamily D member 2

increases expression

ISO

Thalidomide results in increased expression of OR1D2 mRNA

NCBI chr10:59,212,947...59,213,882
Ensembl chr10:59,711,377...59,712,312

G

olfactory receptor family 2 subfamily AG member 1

increases expression

ISO

Thalidomide results in increased expression of OR2AG1 mRNA

NCBI chr 1:160,683,723...160,684,673
Ensembl chr 1:170,095,543...170,096,493

G

olfactory receptor family 2 subfamily Y member 1I

increases expression

ISO

Thalidomide results in increased expression of OR2Y1 mRNA

NCBI chr10:33,737,199...33,738,128

G

olfactory receptor family 51 subfamily Q member 1D

increases expression

ISO

Thalidomide results in increased expression of OR51Q1 mRNA

NCBI chr 1:158,426,462...158,427,427
Ensembl chr 1:167,838,348...167,839,313

G

olfactory receptor family 5 subfamily I member 1

increases expression

ISO

Thalidomide results in increased expression of OR5I1 mRNA

NCBI chr 3:73,267,616...73,268,560
Ensembl chr 3:93,723,878...93,724,828

G

olfactory receptor family 5 subfamily P member 80

increases expression

ISO

Thalidomide results in increased expression of OR5P80 mRNA

NCBI chr 1:162,509,473...162,510,405
Ensembl chr 1:171,942,039...171,942,971

G

olfactory receptor family 8 subfamily A member 1B

decreases expression

ISO

Thalidomide results in decreased expression of OR8A1B mRNA

NCBI chr 8:37,434,903...37,435,832
Ensembl chr 8:45,623,650...45,624,579

G

olfactory receptor family 9 subfamily K member 2

increases expression

ISO

Thalidomide results in increased expression of OR9K2 mRNA

NCBI chr 7:6,868,254...6,869,213
Ensembl chr 7:7,519,060...7,520,019

G

osteoclast stimulating factor 1

decreases expression

ISO

Thalidomide results in decreased expression of OSTF1 mRNA

NCBI chr 1:225,428,661...225,475,851
Ensembl chr 1:225,428,661...225,541,027

G

PP2A Aalpha (PPP2R1A) and B55A (PPP2R2A) interacting phosphatase regulator 1

decreases expression

ISO

Thalidomide results in decreased expression of PABIR1 mRNA

NCBI chr 1:231,541,411...231,542,717
Ensembl chr 1:231,537,357...231,612,411

G

poly (ADP-ribose) polymerase 1

multiple interactions
increases cleavage

ISO

[Curcumin co-treated with Thalidomide] results in increased cleavage of PARP1 protein
Thalidomide analog results in increased cleavage of PARP1 protein

PMID:15858615 PMID:19372569

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 3

decreases expression

ISO

Thalidomide results in decreased expression of PAX3 mRNA

NCBI chr 9:87,015,960...87,112,531
Ensembl chr 9:87,016,999...87,124,141

G

paired box 6

increases expression

ISO

Thalidomide results in increased expression of PAX6 mRNA

NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763

G

programmed cell death 10

decreases expression

ISO

Thalidomide results in decreased expression of PDCD10 mRNA

NCBI chr 2:162,602,516...162,644,690
Ensembl chr 2:162,602,516...162,644,612

G

PDZ and LIM domain 3

decreases expression

ISO

Thalidomide results in decreased expression of PDLIM3 mRNA

NCBI chr16:53,085,020...53,116,495
Ensembl chr16:53,085,020...53,116,217

G

platelet and endothelial cell adhesion molecule 1

decreases expression

EXP
ISO

Thalidomide results in decreased expression of PECAM1 protein

PMID:18291259 PMID:34520751

NCBI chr10:92,090,263...92,152,002
Ensembl chr10:92,090,235...92,151,839

G

prefoldin subunit 6

decreases expression

ISO

Thalidomide results in decreased expression of PFDN6 mRNA

NCBI chr20:4,945,959...4,947,433
Ensembl chr20:4,947,844...4,949,318

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ISO

[ERBB2 protein co-treated with PIK3CA protein mutant form] results in increased susceptibility to Thalidomide metabolite

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

paired immunoglobin-like type 2 receptor alpha

decreases expression

ISO

Thalidomide results in decreased expression of PILRA mRNA

NCBI chr12:17,787,169...17,798,149

G

Pim-1 proto-oncogene, serine/threonine kinase

decreases expression

ISO

Thalidomide results in decreased expression of PIM1 protein

NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764

G

plasminogen activator, urokinase

decreases expression

ISO

Thalidomide results in decreased expression of PLAU protein

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

plasminogen activator, urokinase receptor

multiple interactions
decreases expression

ISO

Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR protein]
Thalidomide results in decreased expression of PLAUR protein

NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:89,178,453...89,198,130

G

phospholipid transfer protein

decreases expression

ISO

Thalidomide results in decreased expression of PLTP mRNA

NCBI chr 3:173,994,162...174,011,982
Ensembl chr 3:173,994,162...174,012,505

G

RNA polymerase II, I and III subunit K

decreases expression

ISO

Thalidomide results in decreased expression of POLR2K mRNA

NCBI chr 7:69,241,233...69,244,579
Ensembl chr 7:69,232,179...69,244,578

G

popeye domain cAMP effector 2

decreases expression

ISO

Thalidomide results in decreased expression of POPDC2 mRNA

NCBI chr11:75,850,068...75,897,094
Ensembl chr11:75,880,274...75,896,269

G

peroxisome proliferator-activated receptor delta

increases response to substance

ISO

PPARD gene SNP results in increased susceptibility to Thalidomide

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

protein phosphatase 1, regulatory (inhibitor) subunit 11

decreases expression

ISO

Thalidomide results in decreased expression of PPP1R11 mRNA

NCBI chr20:1,606,583...1,610,090
Ensembl chr20:1,606,577...1,613,212

G

protein phosphatase 1, regulatory subunit 15A

increases expression

ISO

Thalidomide analog results in increased expression of PPP1R15A mRNA

NCBI chr 1:105,136,521...105,139,596
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 1, regulatory (inhibitor) subunit 1A

decreases expression

ISO

Thalidomide results in decreased expression of PPP1R1A mRNA

NCBI chr 7:136,533,031...136,540,687
Ensembl chr 7:136,523,604...136,540,683

G

PRELI domain containing 2

decreases expression

ISO

Thalidomide results in decreased expression of PRELID2 mRNA

NCBI chr18:34,120,989...34,212,699
Ensembl chr18:34,125,373...34,212,167

G

perforin 1

increases expression

ISO

Thalidomide results in increased expression of PRF1

NCBI chr20:29,789,040...29,794,550
Ensembl chr20:29,788,972...29,795,124

G

protein kinase C, delta

decreases expression

ISO

Thalidomide results in decreased expression of PRKCD mRNA

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase cGMP-dependent 1

decreases expression

ISO

Thalidomide results in decreased expression of PRKG1 mRNA

NCBI chr 1:237,818,950...239,052,184
Ensembl chr 1:237,823,053...239,103,005

G

proline rich 5

decreases expression

ISO

Thalidomide results in decreased expression of PRR5 mRNA

NCBI chr 7:115,795,351...115,837,880
Ensembl chr 7:117,675,383...117,717,831

G

peroxiredoxin like 2A

decreases expression

ISO

Thalidomide results in decreased expression of PRXL2A mRNA

NCBI chr16:16,900,697...16,920,521
Ensembl chr16:16,900,699...16,920,561

G

proteasome activator subunit 2

increases expression

ISO

Thalidomide results in increased expression of PSME2 mRNA

NCBI chr15:33,048,452...33,053,055
Ensembl chr15:33,048,457...33,053,102

G

phosphatase and tensin homolog

increases expression

ISO

Thalidomide results in increased expression of PTEN protein

NCBI chr 1:240,043,707...240,110,330
Ensembl chr 1:240,043,707...240,110,330

G

prostaglandin-endoperoxide synthase 2

increases degradation
decreases expression
multiple interactions
decreases stability

ISO
EXP

Thalidomide results in increased degradation of PTGS2 protein
Thalidomide results in decreased expression of PTGS2 protein
Thalidomide inhibits the reaction [Ifosfamide results in increased expression of PTGS2 protein]
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
Thalidomide results in decreased stability of PTGS2 mRNA

PMID:11705847 PMID:15982930 PMID:17638016

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

RAB2B, member RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAB2B mRNA

PMID:26006729 PMID:26217789

NCBI chr15:27,441,860...27,462,479
Ensembl chr15:27,442,816...27,462,479

G

RAB8A, member RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAB8A mRNA

NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,688,050...17,709,477

G

RAP1B, member of RAS oncogene family

decreases expression

ISO

Thalidomide results in decreased expression of RAP1B mRNA

NCBI chr 7:53,423,039...53,456,349
Ensembl chr 7:55,308,922...55,342,217

G

Ras association domain family member 9

decreases expression

ISO

Thalidomide results in decreased expression of RASSF9 mRNA

NCBI chr 7:37,599,720...37,631,553
Ensembl chr 7:39,409,870...39,519,675

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
decreases expression

ISO
EXP

[irinotecan co-treated with Thalidomide co-treated with Celecoxib] results in increased expression of RELA protein; [irinotecan co-treated with Thalidomide] results in increased expression of RELA protein; [resveratrol co-treated with Thalidomide] results in decreased activity of [RELA protein binds to NFKB1 protein]; Thalidomide inhibits the reaction [TNF protein results in increased transport of RELA protein]
[Thalidomide co-treated with Dimethylnitrosamine] results in decreased transport of RELA protein; HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of RELA mRNA]
Thalidomide results in decreased expression of RELA protein
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of RELA protein]; Thalidomide inhibits the reaction [Paraquat affects the localization of RELA protein]

PMID:15687330 PMID:16078585 PMID:16333628 PMID:16604421 PMID:16685529 More...

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

RELB proto-oncogene, NF-kB subunit

increases expression

ISO

Thalidomide analog results in increased expression of RELB mRNA

NCBI chr 1:88,385,717...88,413,380
Ensembl chr 1:88,385,717...88,413,420

G

replication factor C subunit 3

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA

NCBI chr12:5,836,546...5,847,331
Ensembl chr12:5,836,553...5,847,340

G

ras homolog family member A

affects expression

ISO

Thalidomide affects the expression of RHOA mRNA

NCBI chr 8:117,870,548...117,904,303
Ensembl chr 8:117,870,270...117,904,302

G

ribonuclease H2, subunit C

decreases expression

ISO

Thalidomide results in decreased expression of RNASEH2C mRNA

NCBI chr 1:212,323,916...212,325,011
Ensembl chr 1:212,323,939...212,329,571

G

ring finger protein 138

decreases expression

ISO

Thalidomide results in decreased expression of RNF138 mRNA

NCBI chr18:12,558,430...12,590,849
Ensembl chr18:12,566,502...12,590,848

G

ring finger protein 166

multiple interactions

ISO

Thalidomide results in increased degradation of and results in decreased expression of RNF166 protein

NCBI chr19:67,437,974...67,447,814
Ensembl chr19:67,437,974...67,447,814

G

ribosomal protein S15

increases expression

ISO

Thalidomide results in increased expression of RPS15 mRNA

NCBI chr 7:10,066,572...10,068,167
Ensembl chr 7:10,066,677...10,068,123

G

ribosomal protein S6 kinase A2

decreases expression

ISO

Thalidomide results in decreased expression of RPS6KA2 mRNA

NCBI chr 1:55,178,988...55,454,271
Ensembl chr 1:55,179,319...55,454,338

G

RAS related

decreases expression

ISO

Thalidomide results in decreased expression of RRAS mRNA

PMID:26006729 PMID:26217789

NCBI chr 1:95,500,582...95,504,362
Ensembl chr 1:104,634,951...104,640,841

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA

NCBI chr 6:47,044,755...47,075,370
Ensembl chr 6:47,067,690...47,075,370

G

RT1 class Ia, locus A2

affects expression

ISO

Thalidomide affects the expression of HLA-E mRNA

NCBI chr20:4,872,720...4,876,425

G

RT1 class I, locus CE16

increases expression

ISO

Thalidomide results in increased expression of H2-Q1 mRNA

NCBI chr20:3,261,656...3,265,548

G

reticulon 2

decreases expression

ISO

Thalidomide results in decreased expression of RTN2 mRNA

NCBI chr 1:88,063,124...88,076,082
Ensembl chr 1:88,063,119...88,076,043

G

ryanodine receptor 2

decreases expression

ISO

Thalidomide results in decreased expression of RYR2 mRNA

PMID:26006729 PMID:26217789

NCBI chr17:63,081,527...63,667,141
Ensembl chr17:63,081,527...63,666,705

G

spalt-like transcription factor 4

increases expression
multiple interactions
affects binding

ISO

Thalidomide results in increased expression of SALL4 mRNA
Bortezomib inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; pevonedistat inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; TAK-243 inhibits the reaction [Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein]; Thalidomide results in increased degradation of and results in decreased expression of SALL4 protein
Thalidomide binds to [SALL4 protein binds to CRBN protein]

NCBI chr 3:177,891,705...177,909,743
Ensembl chr 3:177,891,705...177,909,743

G

Sin3A associated protein 30

decreases expression

ISO

Thalidomide results in decreased expression of SAP30 mRNA

NCBI chr16:37,758,494...37,763,825
Ensembl chr16:37,757,656...37,763,823

G

spermidine/spermine N1-acetyl transferase 1

decreases expression

ISO

Thalidomide results in decreased expression of SAT1 mRNA

NCBI chr X:44,008,089...44,011,376
Ensembl chr X:44,006,781...44,011,374

G

sodium voltage-gated channel alpha subunit 7

decreases expression

ISO

Thalidomide results in decreased expression of SCN7A mRNA

NCBI chr 3:71,743,873...71,846,454
Ensembl chr 3:71,743,873...71,846,284

G

succinate dehydrogenase complex assembly factor 1

decreases expression

ISO

Thalidomide results in decreased expression of SDHAF1 mRNA

NCBI chr 1:94,703,662...94,704,611
Ensembl chr 1:94,702,409...94,706,092

G

succinate dehydrogenase complex subunit C

decreases expression

ISO

Thalidomide results in decreased expression of SDHC mRNA

NCBI chr13:86,077,133...86,098,025
Ensembl chr13:86,077,134...86,098,044

G

selenoprotein S

decreases expression

ISO

Thalidomide results in decreased expression of SELENOS mRNA

NCBI chr 1:129,070,240...129,080,007
Ensembl chr 1:129,070,230...129,077,991

G

selectin L

decreases expression

ISO

Thalidomide results in decreased expression of SELL protein

NCBI chr13:78,950,100...78,969,604
Ensembl chr13:78,950,015...78,969,600

G

serpin family B member 2

increases response to substance

ISO

SERPINB2 gene SNP results in increased susceptibility to Thalidomide

NCBI chr13:24,051,933...24,065,032
Ensembl chr13:24,056,021...24,065,031

G

secreted frizzled-related protein 2

increases expression

ISO

Thalidomide results in increased expression of SFRP2 mRNA

NCBI chr 2:171,387,536...171,395,081
Ensembl chr 2:171,387,385...171,395,079

G

SH3 domain binding glutamate-rich protein

decreases expression

ISO

Thalidomide results in decreased expression of SH3BGR mRNA

NCBI chr11:35,503,663...35,527,853
Ensembl chr11:48,973,097...48,997,326

G

solute carrier family 12, member 6

increases response to substance

ISO

SLC12A6 gene SNP results in increased susceptibility to Thalidomide

NCBI chr 3:119,525,521...119,624,655
Ensembl chr 3:119,526,295...119,624,653

G

solute carrier family 13 member 4

decreases expression

ISO

Thalidomide results in decreased expression of SLC13A4 mRNA

NCBI chr 4:64,910,505...64,955,986
Ensembl chr 4:64,910,507...64,955,986

G

solute carrier family 22 member 2

multiple interactions

ISO

Thalidomide inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:50,668,817...50,711,019
Ensembl chr 1:50,668,817...50,711,019

G

solute carrier family 25 member 20

decreases expression

ISO

Thalidomide results in decreased expression of SLC25A20 mRNA

NCBI chr 8:118,243,573...118,265,027
Ensembl chr 8:118,243,519...118,265,027

G

solute carrier family 25, member 30

decreases expression

ISO

Thalidomide results in decreased expression of SLC25A30 mRNA

NCBI chr15:51,076,998...51,099,613
Ensembl chr15:57,486,350...57,502,690

G

solute carrier family 2 member 3

increases expression

ISO

Thalidomide results in increased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 44, member 3

decreases expression

ISO

Thalidomide results in decreased expression of SLC44A3 mRNA

NCBI chr 2:212,234,425...212,312,886
Ensembl chr 2:212,236,853...212,312,982

G

solute carrier family 8 member A1

decreases expression

ISO

Thalidomide results in decreased expression of SLC8A1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964

G

solute carrier organic anion transporter family, member 4C1

decreases expression

ISO

Thalidomide results in decreased expression of SLCO4C1 mRNA

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:104,624,802...104,676,462

G

sphingomyelin phosphodiesterase 2

multiple interactions

ISO

sphingosine 1-phosphate inhibits the reaction [Thalidomide results in increased activity of SMPD2 protein]

NCBI chr20:44,986,229...44,989,343
Ensembl chr20:46,568,629...46,571,741

G

SET and MYND domain containing 1

decreases expression

ISO

Thalidomide results in decreased expression of SMYD1 mRNA

PMID:26006729 PMID:26217789

NCBI chr 4:104,757,281...104,811,307
Ensembl chr 4:104,760,475...104,870,081

G

synaptosome associated protein 25

increases expression

EXP

Thalidomide results in increased expression of SNAP25 mRNA; Thalidomide results in increased expression of SNAP25 protein

NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448

G

small nucleolar RNA, C/D box 104

increases expression

ISO

Thalidomide results in increased expression of SNORD104 mRNA

NCBI chr10:91,435,313...91,435,382
Ensembl chr10:91,935,074...91,935,143

G

small nucleolar RNA, C/D box 111

increases expression

ISO

Thalidomide results in increased expression of SNORD111 mRNA

NCBI chr19:38,812,486...38,812,574
Ensembl chr19:55,721,859...55,721,947

G

small nucleolar RNA, C/D box 123

increases expression

ISO

Thalidomide results in increased expression of SNORD123 mRNA

NCBI chr 2:83,306,918...83,306,987
Ensembl chr 2:85,017,799...85,017,868

G

small nuclear ribonucleoprotein D1 polypeptide

decreases expression

ISO

Thalidomide results in decreased expression of SNRPD1 mRNA

NCBI chr18:1,969,351...1,980,207
Ensembl chr18:1,969,674...1,980,207

G

sorting nexin 16

increases expression

ISO

Thalidomide analog results in increased expression of SNX16 mRNA

NCBI chr 2:93,242,779...93,265,048
Ensembl chr 2:93,243,494...93,265,050

G

sorting nexin 24

decreases expression

ISO

Thalidomide results in decreased expression of SNX24 mRNA

NCBI chr18:48,869,804...49,024,352
Ensembl chr18:48,869,882...49,024,350

G

superoxide dismutase 1

multiple interactions

ISO
EXP

Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of FASL mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of IL12B mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of IL1RN mRNA]; Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]
Thalidomide inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]

PMID:16510725 PMID:17030452

NCBI chr11:42,942,742...42,948,399
Ensembl chr11:42,942,678...42,948,399

G

SRY-box transcription factor 1

decreases expression

ISO

Thalidomide results in decreased expression of SOX1 mRNA

NCBI chr16:77,135,577...77,139,592
Ensembl chr16:83,802,160...83,841,775

G

SRY-box transcription factor 17

decreases localization

ISO

Thalidomide results in decreased localization of SOX17 protein

NCBI chr 5:19,814,345...19,819,859
Ensembl chr 5:19,814,360...19,819,854

G

Sp1 transcription factor

decreases activity

ISO

Thalidomide results in decreased activity of SP1 protein

NCBI chr 7:135,419,864...135,450,513
Ensembl chr 7:135,420,050...135,450,513

G

Sp5 transcription factor

decreases expression

ISO

Thalidomide results in decreased expression of SP5 mRNA

NCBI chr 3:75,682,677...75,685,479
Ensembl chr 3:75,682,677...75,685,479

G

sperm autoantigenic protein 17

decreases expression

ISO

Thalidomide results in decreased expression of SPA17 mRNA

NCBI chr 8:37,307,432...37,318,519
Ensembl chr 8:45,496,175...45,507,262

G

sperm associated antigen 5

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA

NCBI chr10:63,693,300...63,714,813
Ensembl chr10:63,696,466...63,714,811

G

SPHK1 interactor, AKAP domain containing

decreases expression

ISO

Thalidomide results in decreased expression of SPHKAP mRNA

NCBI chr 9:84,509,383...84,657,582
Ensembl chr 9:91,957,497...92,105,625

G

SRR1 domain containing

decreases expression

ISO

Thalidomide results in decreased expression of SRRD mRNA

NCBI chr12:49,955,081...49,960,693
Ensembl chr12:49,954,882...49,963,366

G

signal transducer and activator of transcription 3

decreases phosphorylation
multiple interactions

ISO

Thalidomide analog results in decreased phosphorylation of STAT3 protein
[resveratrol co-treated with Thalidomide] results in decreased phosphorylation of STAT3 protein; Thalidomide promotes the reaction [Capsaicin results in decreased phosphorylation of and results in decreased activity of STAT3 protein]

PMID:15858615 PMID:17164350 PMID:17505005

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

stathmin 2

decreases expression

ISO

Thalidomide results in decreased expression of STMN2 mRNA

NCBI chr 2:93,204,690...93,252,011
Ensembl chr 2:95,112,019...95,159,335

G

SWIM-type zinc finger 7 associated protein 1

decreases expression

ISO

Thalidomide results in decreased expression of SWSAP1 mRNA

NCBI chr 8:28,762,753...28,765,281
Ensembl chr 8:28,762,616...28,765,234

G

synaptojanin 2 binding protein

decreases expression

ISO

Thalidomide results in decreased expression of SYNJ2BP mRNA

NCBI chr 6:101,189,714...101,227,400
Ensembl chr 6:106,920,970...106,966,543

G

synaptotagmin 15

decreases expression

ISO

Thalidomide results in decreased expression of SYT15 mRNA

NCBI chr16:9,532,478...9,543,288
Ensembl chr16:9,538,748...9,549,558

G

synaptotagmin 4

increases expression

ISO

Thalidomide results in increased expression of SYT4 mRNA

NCBI chr18:23,311,454...23,320,863
Ensembl chr18:23,312,859...23,320,815

G

tandem C2 domains, nuclear

decreases expression

ISO

Thalidomide results in decreased expression of TC2N mRNA

NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:126,526,009...126,614,215

G

transcription factor 15

decreases expression

ISO

Thalidomide results in decreased expression of TCF15 mRNA

NCBI chr 3:161,099,301...161,105,083
Ensembl chr 3:161,099,301...161,105,083

G

thymine-DNA glycosylase

decreases expression

ISO

Thalidomide results in decreased expression of TDG mRNA

NCBI chr 7:22,965,388...22,990,311
Ensembl chr 7:22,965,388...22,985,100

G

transcription elongation factor, mitochondrial

decreases expression

ISO

Thalidomide results in decreased expression of TEFM mRNA

NCBI chr10:65,617,547...65,622,042
Ensembl chr10:65,617,550...65,622,042

G

TEK receptor tyrosine kinase

decreases expression

ISO

Thalidomide results in decreased expression of TEK mRNA

NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:114,723,006...114,849,991

G

testis expressed gene 16

decreases expression

ISO

Thalidomide results in decreased expression of TEX16 mRNA

NCBI chr X:76,948,823...77,316,809
Ensembl chr X:81,139,575...81,509,047

G

transforming growth factor, beta 1

multiple interactions
decreases expression

ISO
EXP

Thalidomide inhibits the reaction [TGFB1 protein results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of PLAUR protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [TGFB1 protein results in increased transport of NFKBIA protein]
Thalidomide promotes the reaction [SOD1 gene mutant form results in increased expression of TGFB1 mRNA]
Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA]; Thalidomide inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]
Thalidomide results in decreased expression of TGFB1 mRNA; Thalidomide results in decreased expression of TGFB1 protein

PMID:15464241 PMID:16288038 PMID:16510725 PMID:16549389 PMID:16604421 More...

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta induced

decreases expression

ISO

Thalidomide results in decreased expression of TGFBI mRNA

PMID:26006729 PMID:26217789

NCBI chr17:7,960,885...7,990,234
Ensembl chr17:7,960,516...7,990,471

G

transforming growth factor, beta receptor 1

decreases expression

ISO

Thalidomide results in decreased expression of TGFBR1 mRNA; Thalidomide results in decreased expression of TGFBR1 protein

NCBI chr 5:66,449,348...66,506,371
Ensembl chr 5:66,449,293...66,527,260

G

TIMP metallopeptidase inhibitor 1

multiple interactions

EXP

Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TIMP1 mRNA]

PMID:15464241 PMID:17030452

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TIMP metallopeptidase inhibitor 2

multiple interactions

EXP

Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TIMP2 mRNA]

NCBI chr10:104,041,604...104,089,214
Ensembl chr10:104,041,604...104,089,214

G

tubulointerstitial nephritis antigen-like 1

decreases expression

ISO

Thalidomide results in decreased expression of TINAGL1 mRNA

NCBI chr 5:147,797,884...147,807,925
Ensembl chr 5:147,797,892...147,807,871

G

tight junction protein 1

multiple interactions

ISO

Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in decreased expression of TJP1 protein]

NCBI chr 1:128,260,330...128,505,018
Ensembl chr 1:128,260,330...128,505,158

G

TM2 domain containing 3

decreases expression

ISO

Thalidomide results in decreased expression of TM2D3 mRNA

NCBI chr 1:128,677,680...128,687,580
Ensembl chr 1:128,677,629...128,687,580

G

transmembrane protein 138

decreases expression

ISO

Thalidomide results in decreased expression of TMEM138 mRNA

NCBI chr 1:207,219,113...207,226,159

G

transmembrane protein 176A

decreases expression

ISO

Thalidomide results in decreased expression of TMEM176A mRNA

NCBI chr 4:79,101,946...79,109,499
Ensembl chr 4:79,101,857...79,111,175

G

thymopoietin

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA

NCBI chr 7:27,529,977...27,554,980
Ensembl chr 7:27,529,978...27,554,937

G

tumor necrosis factor

multiple interactions
increases expression
decreases expression
increases degradation

ISO
EXP

Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Endotoxins results in increased expression of TNF protein]; Thalidomide inhibits the reaction [lipophosphonoglycan results in increased secretion of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CXCL8 protein]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; Thalidomide inhibits the reaction [TNF protein results in increased transport of RELA protein]
Thalidomide analog inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [[Ethanol co-treated with Hydrochloric Acid] results in increased expression of TNF protein]; Thalidomide inhibits the reaction [dinitrobenzenesulfonic acid results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [SOD1 gene mutant form results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Zymosan results in increased expression of TNF mRNA]; TNF protein affects the reaction [vadimezan affects the metabolism of Thalidomide]
Thalidomide results in increased expression of TNF protein
Thalidomide results in decreased expression of TNF mRNA
HDAC6 protein inhibits the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; MIR141 promotes the reaction [Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]]; Thalidomide inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Dimethylnitrosamine results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Irinotecan results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [Paraquat results in increased expression of TNF protein]; Thalidomide inhibits the reaction [Thioacetamide results in increased expression of TNF mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of CHUK protein]; Thalidomide inhibits the reaction [TNF protein results in increased expression of COL1A2 mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased expression of RELA mRNA]; Thalidomide inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Thalidomide inhibits the reaction [Zymosan results in increased expression of TNF protein]
Thalidomide results in increased expression of TNF mRNA
Thalidomide results in increased degradation of TNF mRNA
Thalidomide results in decreased expression of TNF mRNA; Thalidomide results in decreased expression of TNF protein

PMID:9068814 PMID:9623511 PMID:10496904 PMID:10720640 PMID:11367517 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 10b

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF10A protein

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 1A

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF1A mRNA; Thalidomide results in decreased expression of TNFRSF1A protein

PMID:15618473 PMID:16344495

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF receptor superfamily member 1B

decreases expression

ISO

Thalidomide results in decreased expression of TNFRSF1B mRNA

NCBI chr 5:162,356,250...162,387,411
Ensembl chr 5:162,353,848...162,387,411

G

TNF superfamily member 10

decreases expression

ISO

Thalidomide results in decreased expression of TNFSF10 protein

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 11

multiple interactions

ISO

[Thalidomide co-treated with Dexamethasone] results in decreased expression of TNFSF11 protein

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

troponin C1, slow skeletal and cardiac type

decreases expression

ISO

Thalidomide results in decreased expression of TNNC1 mRNA

PMID:26006729 PMID:26217789

NCBI chr16:6,408,607...6,412,070
Ensembl chr16:6,408,607...6,412,070

G

DNA topoisomerase II alpha

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA

NCBI chr10:84,441,954...84,473,093
Ensembl chr10:84,441,954...84,473,366

G

tumor protein p53

increases expression

ISO

Thalidomide analog results in increased expression of TP53 mRNA

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

translocation associated membrane protein 1-like 1

decreases expression

ISO

Thalidomide results in decreased expression of TRAM1L1 mRNA

NCBI chr 2:215,195,665...215,197,846
Ensembl chr 2:215,195,364...215,198,082

G

trafficking protein particle complex subunit 2L

decreases expression

ISO

Thalidomide results in decreased expression of TRAPPC2L mRNA

NCBI chr19:67,570,954...67,574,722

G

tribbles pseudokinase 3

increases expression

ISO

Thalidomide analog results in increased expression of TRIB3 mRNA

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

tripartite motif-containing 55

decreases expression

ISO

Thalidomide results in decreased expression of TRIM55 mRNA

NCBI chr 2:104,016,361...104,058,302
Ensembl chr 2:104,016,368...104,058,301

G

tetraspanin 33

decreases expression

ISO

Thalidomide results in decreased expression of TSPAN33 mRNA

NCBI chr 4:58,305,378...58,330,013
Ensembl chr 4:59,270,703...59,294,249

G

tetratricopeptide repeat domain 32

decreases expression

ISO

Thalidomide results in decreased expression of TTC32 mRNA

NCBI chr 6:31,834,428...31,841,027
Ensembl chr 6:37,553,628...37,561,821

G

Ttk protein kinase

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA

NCBI chr 8:93,632,678...93,672,664
Ensembl chr 8:93,634,319...93,672,664

G

titin

decreases expression

ISO

Thalidomide results in decreased expression of TTN mRNA

PMID:26006729 PMID:26217789

NCBI chr 3:82,059,648...82,332,130
Ensembl chr 3:82,059,648...82,332,171

G

ubiquitin-conjugating enzyme E2C

multiple interactions

ISO

[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA

NCBI chr 3:173,925,975...173,928,375
Ensembl chr 3:173,925,934...173,932,678

G

UBX domain protein 1

decreases expression

ISO

Thalidomide results in decreased expression of UBXN1 mRNA

NCBI chr 1:215,194,418...215,198,343
Ensembl chr 1:215,174,216...215,198,343

G

ubiquitin C-terminal hydrolase L3

decreases expression

ISO

Thalidomide results in decreased expression of UCHL3 mRNA

NCBI chr15:84,888,847...84,942,095
Ensembl chr15:84,899,806...84,942,095
Ensembl chr 3:84,899,806...84,942,095

G

UNC homeobox

decreases expression

ISO

Thalidomide results in decreased expression of UNCX mRNA

NCBI chr12:20,206,604...20,211,125
Ensembl chr12:20,206,609...20,211,125

G

uridine phosphorylase 1

decreases expression

ISO

Thalidomide results in decreased expression of UPP1 mRNA

NCBI chr14:88,023,155...88,043,036
Ensembl chr14:88,023,351...88,043,034

G

ubiquinol-cytochrome c reductase complex assembly factor 5

decreases expression

ISO

Thalidomide results in decreased expression of UQCC5 mRNA

NCBI chr16:6,316,631...6,320,471
Ensembl chr16:6,292,741...6,326,911

G

vascular cell adhesion molecule 1

decreases expression

EXP

Thalidomide results in decreased expression of VCAM1 mRNA; Thalidomide results in decreased expression of VCAM1 protein

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

vascular endothelial growth factor A

affects expression
affects secretion
decreases secretion
decreases activity
decreases expression
increases expression
multiple interactions

ISO
EXP

Thalidomide affects the expression of VEGFA mRNA; Thalidomide affects the expression of VEGFA protein
Thalidomide affects the secretion of VEGFA protein
Thalidomide analog results in decreased secretion of VEGFA protein
Thalidomide results in decreased activity of VEGFA protein
Thalidomide results in decreased expression of VEGFA mRNA; Thalidomide results in decreased expression of VEGFA protein
Thalidomide results in increased expression of VEGFA protein
[Thalidomide co-treated with Paclitaxel] results in decreased expression of VEGFA mRNA
[temozolomide co-treated with Thalidomide] results in decreased expression of VEGFA protein
[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFA mRNA; FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of and results in decreased secretion of VEGFA protein]; Thalidomide results in decreased expression of and results in decreased secretion of VEGFA protein

PMID:15858615 PMID:15863203 PMID:15939924 PMID:15982930 PMID:16313753 More...

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor B

multiple interactions
decreases expression

ISO

[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFB mRNA
Thalidomide results in decreased expression of VEGFB mRNA

NCBI chr 1:213,601,570...213,607,254
Ensembl chr 1:213,600,966...213,607,152

G

vascular endothelial growth factor C

affects expression

ISO

Thalidomide affects the expression of VEGFC mRNA

NCBI chr16:44,445,293...44,560,887
Ensembl chr16:44,445,293...44,560,887

G

vascular endothelial growth factor D

multiple interactions
decreases expression

ISO

[Arsenic Trioxide co-treated with Thalidomide] results in decreased expression of VEGFD mRNA
Thalidomide results in decreased expression of VEGFD mRNA

NCBI chr X:33,704,582...33,740,305
Ensembl chr X:33,706,055...33,740,167

G

vitronectin

decreases expression

ISO

Thalidomide results in decreased expression of VTN mRNA

NCBI chr10:63,892,782...63,895,862
Ensembl chr10:63,892,766...63,895,860

G

Wnt family member 5B

decreases expression

ISO

Thalidomide results in decreased expression of WNT5B mRNA

NCBI chr 4:154,281,852...154,406,081
Ensembl chr 4:154,281,852...154,405,681

G

Wnt family member 8A

decreases expression

ISO

Thalidomide results in decreased expression of WNT8A mRNA

NCBI chr18:26,137,690...26,143,283
Ensembl chr18:26,411,833...26,417,426

G

X-linked inhibitor of apoptosis

decreases expression

ISO

Thalidomide analog results in decreased expression of XIAP protein

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

YJU2 splicing factor homolog B

decreases expression

ISO

Thalidomide results in decreased expression of YJU2B mRNA

NCBI chr19:40,799,392...40,810,885
Ensembl chr19:40,799,526...40,811,579

G

zinc finger CCHC-type containing 17

increases expression

ISO

Thalidomide results in increased expression of ZCCHC17 mRNA

NCBI chr 5:147,942,789...147,984,596
Ensembl chr 5:147,942,789...147,984,584

G

zinc finger E-box binding homeobox 1

multiple interactions
decreases expression

ISO

FGD5-AS1 inhibits the reaction [Thalidomide results in decreased expression of ZEB1 protein]

NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745

G

zinc finger protein 692

multiple interactions

ISO

Thalidomide results in increased degradation of and results in decreased expression of ZNF692 protein

NCBI chr10:42,484,576...42,496,573
Ensembl chr10:42,988,938...42,997,015

G

zinc finger protein 758

decreases expression

ISO

Thalidomide results in decreased expression of ZFP758 mRNA

NCBI chr 1:61,941,284...61,989,354
Ensembl chr 1:70,614,268...70,662,143

G

zinc finger protein-like 1

decreases expression

ISO

Thalidomide results in decreased expression of ZFPL1 mRNA

NCBI chr 1:212,803,790...212,807,803
Ensembl chr 1:212,803,794...212,807,289

G

zinc finger with KRAB and SCAN domains 5

decreases expression

ISO

Thalidomide results in decreased expression of ZKSCAN5 mRNA

NCBI chr12:14,498,342...14,519,537
Ensembl chr12:14,498,342...14,519,537

G

zinc finger, matrin type 5

decreases expression

ISO

Thalidomide results in decreased expression of ZMAT5 mRNA

NCBI chr14:79,568,644...79,599,595
Ensembl chr14:83,792,262...83,823,095

G

zinc finger protein 780B

decreases expression

ISO

Thalidomide results in decreased expression of ZFP780B mRNA

NCBI chr 1:92,136,761...92,159,076

G

zinc ribbon domain containing 2

decreases expression

ISO

Thalidomide results in decreased expression of ZNRD2 mRNA

NCBI chr 1:212,447,010...212,448,793
Ensembl chr 1:212,447,010...212,448,793

G

zinc finger and SCAN domain containing 12

decreases expression

ISO

Thalidomide results in decreased expression of ZSCAN12 mRNA

NCBI chr17:47,942,976...47,948,930
Ensembl chr17:47,942,977...47,964,605

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20862
chemical entity	20860
atom	20860
nonmetal atom	20766
oxygen atom	20457
oxygen molecular entity	20457
organooxygen compound	19806
piperidones	1528
(1S,3R,7S,8S,8aR)-8-\{2-[(2S,4R)-4-hydroxy-1-\{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl\}-6-oxopiperidin-2-yl]ethyl\}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate	0
(2E,6E,11E,13E)-18-(2,6-dioxopiperidin-4-yl)-9-hydroxy-8-methoxy-10,12,14-trimethyl-15-oxooctadeca-2,6,11,13-tetraenoic acid	0
(2S,3R)-2-[(3S,6R)-3-amino-6-hydroxy-2-oxopiperidinyl]-3-hydroxybutanoic acid	0
(3S)-3-hydroxypiperidin-2-one	0
(3S,4R)-3-hydroxy-2-oxopiperidin-4-yl beta-D-xylopyranoside	0
(3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)piperidin-2-one	0
(4R,5R)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one	0
1-hydroxy-2-piperidinone	0
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione +	475
2-[(2-oxo-2-piperidin-1-ylethyl)sulfanyl]-6-(trifluoromethyl)pyrimidin-4-ol	0
3,5-bis[(4-methylphenyl)methylidene]-4-piperidinone	0
3-aminopiperidine-2-one	0
3-hydroxy-6-methoxy-1-methyl-4,5-diphenyl-2-piperidinone +	0
4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione	0
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione	0
4-ethyl-4-methylpiperidine-2,6-dione	3
4-oxo-TEMPO	0
5-(2,2-diferuloylethen-1-yl)thalidomide	0
5-[2-(feruloyl)ethen-1-yl]thalidomide	0
5-hydroxy-9-methylstreptimidone	0
6-cyclohex-3-enyl-5-nitropiperidin-2-one	0
9-Azabicyclo[3.3.1]nonan-3-one	0
9-methylstreptimidone	0
Epiderstatin	0
Gladiofungin A	0
Gladiofungin B	0
Isocycloheximide	0
Kirrothricin	0
L-glutamimide	0
N-[(1R)-1-(4-carbamimidoylbenzyl)-2-oxo-2-piperidin-1-ylethyl]-N(2)-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-alpha-asparagine	0
Piperidione	0
Secimide	0
Sesbanimide C	0
Sesbanimide D	0
Sesbanimide E	0
Sesbanimide F	0
Triacetonamine	0
Valero-1,5-lactam	0
aminoglutethimide +	54
apixaban	0
atogepant	0
b-AP15	0
buspirone	668
chaetoglocin D	0
cycloheximide	483
dWIZ-2	0
gepirone	0
isotabtoxin	0
lenalidomide	30
migrastatin	0
piperidin-2-one	1
piperidine-2,6-dione +	534
pomalidomide	45
pyroglutamine +	0
Path 2
Term	Annotations
CHEBI ontology	20862
subatomic particle	20860
composite particle	20860
hadron	20860
baryon	20860
nucleon	20860
atomic nucleus	20860
atom	20860
main group element atom	20781
p-block element atom	20781
carbon group element atom	20715
carbon atom	20710
organic molecular entity	20710
organic molecule	20654
organic cyclic compound	20404
organic heterocyclic compound	19388
organic heteromonocyclic compound	18212
piperidines	7814
piperidones	1528
(1S,3R,7S,8S,8aR)-8-\{2-[(2S,4R)-4-hydroxy-1-\{[5-(hydroxymethyl)-6-methoxynaphthalen-2-yl]methyl\}-6-oxopiperidin-2-yl]ethyl\}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate	0
(2E,6E,11E,13E)-18-(2,6-dioxopiperidin-4-yl)-9-hydroxy-8-methoxy-10,12,14-trimethyl-15-oxooctadeca-2,6,11,13-tetraenoic acid	0
(2S,3R)-2-[(3S,6R)-3-amino-6-hydroxy-2-oxopiperidinyl]-3-hydroxybutanoic acid	0
(3S)-3-hydroxypiperidin-2-one	0
(3S,4R)-3-hydroxy-2-oxopiperidin-4-yl beta-D-xylopyranoside	0
(3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)piperidin-2-one	0
(4R,5R)-5-amino-1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-(2,4,5-trifluorophenyl)piperidin-2-one	0
1-hydroxy-2-piperidinone	0
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione +	475
2-[(2-oxo-2-piperidin-1-ylethyl)sulfanyl]-6-(trifluoromethyl)pyrimidin-4-ol	0
3,5-bis[(4-methylphenyl)methylidene]-4-piperidinone	0
3-aminopiperidine-2-one	0
3-hydroxy-6-methoxy-1-methyl-4,5-diphenyl-2-piperidinone +	0
4-[(2R)-2-[(1R,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl]piperidine-2,6-dione	0
4-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]piperidine-2,6-dione	0
4-ethyl-4-methylpiperidine-2,6-dione	3
4-oxo-TEMPO	0
5-(2,2-diferuloylethen-1-yl)thalidomide	0
5-[2-(feruloyl)ethen-1-yl]thalidomide	0
5-hydroxy-9-methylstreptimidone	0
6-cyclohex-3-enyl-5-nitropiperidin-2-one	0
9-Azabicyclo[3.3.1]nonan-3-one	0
9-methylstreptimidone	0
Epiderstatin	0
Gladiofungin A	0
Gladiofungin B	0
Isocycloheximide	0
Kirrothricin	0
L-glutamimide	0
N-[(1R)-1-(4-carbamimidoylbenzyl)-2-oxo-2-piperidin-1-ylethyl]-N(2)-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-alpha-asparagine	0
Piperidione	0
Secimide	0
Sesbanimide C	0
Sesbanimide D	0
Sesbanimide E	0
Sesbanimide F	0
Triacetonamine	0
Valero-1,5-lactam	0
aminoglutethimide +	54
apixaban	0
atogepant	0
b-AP15	0
buspirone	668
chaetoglocin D	0
cycloheximide	483
dWIZ-2	0
gepirone	0
isotabtoxin	0
lenalidomide	30
migrastatin	0
piperidin-2-one	1
piperidine-2,6-dione +	534
pomalidomide	45
pyroglutamine +	0

paths to the root